<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="f">
		<monograph id="1" status="active" ru="yes">
			<mono_name> factor IX complex (human) (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x214">AlphaNine SD</tradename>
					<tradename id="tnidelem4x213">Bebulin</tradename>
					<tradename id="tnidelem4x212">BeneFIX</tradename>
					<tradename id="tnidelem4x211">Mononine</tradename>
					<tradename id="tnidelem4x210">Profilnine SD</tradename>
				</tradenames>
				<class type="func"> Hemostatic</class>
				<class type="chem"> Factors II, VII, IX, X</class>
			</info>
			<section type="uses" id="sidelem4x31">
				<sec_title>Uses:</sec_title>
				<para>Hemophilia B (Christmas disease), factor IX deficiency, anticoagulant reversal, control of bleeding in patients with factor VIII inhibitors, reversal of overdose of anticoagulants in emergencies</para>
			</section>
			<section type="contra" id="sidelem4x36">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to mouse or hamster protein, DIC, mild factor IX deficiency</para>
			</section>
			<section type="doses" id="sidelem4x41">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x44">
					<section type="none" id="sidelem4x45">
						<sec_title>Factor IX complex (human) bleeding in hemophilia B</sec_title>
						<section type="none" id="sidelem4x53">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x53">
									<item>
										<label>•</label>
										<para> establish 25% of normal factor IX or 60-75 units/kg, then 10-20 units/kg/day 1-2×/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x57">
						<sec_title>Prophylaxis for bleeding in hemophilia B (long term)</sec_title>
						<section type="none" id="sidelem4x65">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x65">
									<item>
										<label>•</label>
										<para> 25-40 units/kg 2×/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x69">
						<sec_title>Bleeding in hemophilia A/inhibitors of factor VIII (Proplex T, Konyne 80)</sec_title>
						<section type="none" id="sidelem4x77">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x77">
									<item>
										<label>•</label>
										<para> 75 units/kg, repeat after 12 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x81">
						<sec_title>Oral anticoagulant reversal (factor IX complexer only) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x89">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x89">
									<item>
										<label>•</label>
										<para> 20-50 units/kg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x93">
						<sec_title>Factor VII deficiency (use Proplex T only)</sec_title>
						<section type="none" id="sidelem4x101">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x101">
									<item>
										<label>•</label>
										<para> 0.5 unit/kg × weight (kg) × desired factor IX increase (% of normal); repeat q4-6hr if needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x105">
						<sec_title>Factor IX (human) minor to moderate hemorrhage</sec_title>
						<section type="none" id="sidelem4x114">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x114">
									<item>
										<label>•</label>
										<para> dose to increase factor IX level to 20%-30% in one dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x118">
						<sec_title>Serious hemorrhage</sec_title>
						<section type="none" id="sidelem4x126">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x126">
									<item>
										<label>•</label>
										<para> dose to increase factor IX to 30%-50% as daily infusion</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x130">
						<sec_title>Minor hemorrhage (mononine only)</sec_title>
						<section type="none" id="sidelem4x138">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x138">
									<item>
										<label>•</label>
										<para> dose to increase factor IX to 15%-25% (20-30 units/kg), repeat after 24 hr if needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x142">
						<sec_title>Major hemorrhage</sec_title>
						<section type="none" id="sidelem4x150">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x150">
									<item>
										<label>•</label>
										<para> dose to increase factor IX to 25%-50% (75 units/kg) q18-30hr × ≤10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active" ru="yes">
			<mono_name> factor IX Fc fusion protein, recombinant</mono_name>
			<info>
				<pronunciation>(fak′tor nine′)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x1610">Alprolix</tradename>
				</tradenames>
				<class type="func"> Hemostatic</class>
			</info>
			<section type="uses" id="sidelem4x167">
				<sec_title>Uses:</sec_title>
				<para> Hemophilia B, surgical bleeding</para>
			</section>
			<section type="contra" id="sidelem4x172">
				<sec_title>Contraindications:</sec_title>
				<para> Bleeding disorders</para>
			</section>
			<section type="doses" id="sidelem4x177">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x180">
					<section type="none" id="sidelem4x181">
						<sec_title>Hemophilia B</sec_title>
						<section type="none" id="sidelem4x189">
							<label>•</label>
							<sec_title>
								<route>IV INFUSION</route>
							</sec_title>
							<para>
								<list id="lidelem4x189">
									<item>
										<label>•</label>
										<para>Adults, adolescents, children, infants, and neonates:  infuse dose ≤10 ml/min dose (IU) = body weight (kg) × desired factor IX increase (IU/dl or % of normal) × reciprocal of recovery (IU/kg per IU/dl)  IU/dl (or % of normal) = [total dose (IU)/body weight (kg)] × recovery (IU/dl per IU/kg)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x198">
						<sec_title>Surgical bleeding control, prevention</sec_title>
						<para>
							<list id="lidelem4x202">
								<item>
									<label>•</label>
									<para>Adults, adolescents, children, infants, and neonates: Dose and duration of treatment depend on the severity of the factor IX deficiency, the location and extent of bleeding, and the patient’s clinical condition. Refer to hemophilia B for dosage formula</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x208">
						<sec_title>Routine bleeding prophylaxis to prevent/reduce the frequency of bleeding episodes</sec_title>
						<section type="none" id="sidelem4x216">
							<label>•</label>
							<sec_title>
								<route>IV INFUSION</route>
							</sec_title>
							<para>
								<list id="lidelem4x216">
									<item>
										<label>•</label>
										<para>Adults, adolescents, children, infants, and neonates:  initially, 50 IU/kg every week or 100 IU/kg q10days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>famciclovir (Rx)</mono_name>
			<info>
				<pronunciation>(fam-cy′clo-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x2270">Famvir</tradename>
				</tradenames>
				<class type="func"> Antiviral</class>
				<class type="chem"> Guanosine nucleoside</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x237">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA polymerase and viral DNA synthesis by conversion of this guanosine nucleoside to penciclovir</para>
			</section>
			<section type="uses" id="sidelem4x242">
				<sec_title>Uses:</sec_title>
				<para>Treatment of acute herpes zoster (shingles), genital herpes; recurrent mucocutaneous herpes simplex virus (HSV) in patients with HIV; initial episodes of herpes genitalis; herpes labialis in the immunocompromised, herpes labialis prophylaxis</para>
				<section type="none" id="sidelem4x247">
					<section type="none" id="sidelem4x248">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Bell’s palsy, postherpetic neuralgia prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x253">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, penciclovir, acyclovir, ganciclovir, valacyclovir, valganciclovir</para>
				<section type="none" id="sidelem4x258">
					<section type="none" id="sidelem4x259">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="B">B</preg>), breastfeeding, renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x264">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x267">
					<section type="none" id="sidelem4x268">
						<sec_title>Herpes zoster</sec_title>
						<section type="none" id="sidelem4x276">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x276">
									<item>
										<label>•</label>
										<para> 500 mg q8hr for 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x280">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x288">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 40-59 ml/min, 500 mg q12hr; CCr 20-39 ml/min, 500 mg q24hr; CCr &lt;20 ml/min, 250 mg q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x291">
						<sec_title>Suppression of recurrent herpes simplex virus</sec_title>
						<section type="none" id="sidelem4x299">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x299">
									<item>
										<label>•</label>
										<para> 250 mg q12hr up to 1 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x303">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x311">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 20-39 ml/min, 125 mg q12hr × 5 days; CCr &lt;20 ml/min, 125 mg q24hr × 5 days</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x314">
						<sec_title>Recurrent genital herpes</sec_title>
						<section type="none" id="sidelem4x322">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x322">
									<item>
										<label>•</label>
										<para> 1000 mg bid on a single day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x326">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x334">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 40-59 ml/min, 500 mg q12hr × 1 day; CCr 20-39 ml/min, 500 mg as a single dose; CCr &lt;20ml/min, 250 mg as a single dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x337">
						<sec_title>Suppression of recurrent genital herpes</sec_title>
						<section type="none" id="sidelem4x345">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x345">
									<item>
										<label>•</label>
										<para> 250 mg bid for up to 1 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x349">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x357">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 20-39 ml/min, 125 mg q12hr; CCr &lt;20ml/min, 125 mg q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x360">
						<sec_title>Herpes genitalis initial episodes</sec_title>
						<section type="none" id="sidelem4x368">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x368">
									<item>
										<label>•</label>
										<para> 250 mg tid × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x372">
						<sec_title>Bell’s palsy (unlabeled)</sec_title>
						<section type="none" id="sidelem4x380">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x380">
									<item>
										<label>•</label>
										<para> 750 mg tid × 7 days with predniSONE</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x384">
						<sec_title>Varicella-zoster virus (shingles); chickenpox (unlabeled)</sec_title>
						<section type="none" id="sidelem4x392">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x392">
									<item>
										<label>•</label>
										<para> 500 mg q8hr × 7 days, preferably within 48 hr of onset</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x396">
						<sec_title>Herpes zoster in HIV (unlabeled)</sec_title>
						<section type="none" id="sidelem4x404">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x404">
									<item>
										<label>•</label>
										<para> 500 mg tid × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x408">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 125, 250, 500 mg</para>
					</section>
					<section type="none" id="sidelem4x413">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x417">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>As soon as diagnosed; for herpes zoster within 72 hr</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x428">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x431">
					<section type="none" id="sidelem4x432">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Headache, fatigue, dizziness,</emphasis> paresthesia, somnolence, fever</para>
					</section>
					<section type="none" id="sidelem4x439">
						<sec_title>GI: </sec_title>
						<para>Nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia</para>
					</section>
					<section type="none" id="sidelem4x444">
						<sec_title>GU: </sec_title>
						<para>Decreased sperm count</para>
					</section>
					<section type="none" id="sidelem4x449">
						<sec_title>INTEG: </sec_title>
						<para>
							<emphasis style="italic">Pruritus</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x455">
						<sec_title>MS: </sec_title>
						<para>Back pain, arthralgia</para>
					</section>
					<section type="none" id="sidelem4x460">
						<sec_title>RESP: </sec_title>
						<para>Pharyngitis, sinusitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x465">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability 77%, 20% protein binding, 73% excreted via kidneys, terminal plasma half-life 2-3 hr, peak 1 hr</para>
			</section>
			<section type="interactions" id="sidelem4x470">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of famciclovir—probenecid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of zoster vaccine</para>
			</section>
			<section type="considerations" id="sidelem4x481">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x484">
					<section type="none" id="sidelem4x485">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x493">
							<label>•</label>
							<sec_title>Herpes zoster</sec_title>
							<para>
								<list id="lidelem4x493">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Herpes zoster:</emphasis> number, distribution of lesions; burning, itching, pain, which are early symptoms of herpes infection; assess daily during therapy</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x499">
								<item>
									<label>•</label>
									<para>Renal studies: urine CCr; BUN before and during treatment if decreased renal function; dose may have to be lowered; hepatic studies: LFTs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x504">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; diarrhea may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x509">
								<item>
									<label>•</label>
									<para>Posttherapeutic neuralgia during and after treatment</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x514">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x518">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased size, spread of lesions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x524">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x528">
								<item>
									<label>•</label>
									<para>How to recognize beginning infection</para>
								</item>
								<item>
									<label>•</label>
									<para>How to prevent spread of infection; that this medication does not prevent spread to others; that condoms should be used</para>
								</item>
								<item>
									<label>•</label>
									<para>About the reason for medication, expected results</para>
								</item>
								<item>
									<label>•</label>
									<para>That women with genital herpes should have yearly Pap smears; that cervical cancer is more likely</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>famotidine (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(fa-moe′ti-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x5573"/>
					<tradename id="tnidelem4x5572">Pepcid</tradename>
					<tradename id="tnidelem4x5571">Pepcid AC</tradename>
					<tradename id="tnidelem4x5570"/>
				</tradenames>
				<class type="func"> H-histamine receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x571">
				<sec_title>Action:</sec_title>
				<para>Competitively inhibits histamine at histamine H<emphasis style="inf">2</emphasis>-receptor site, thus decreasing gastric secretion while pepsin remains at a stable level</para>
			</section>
			<section type="uses" id="sidelem4x579">
				<sec_title>Uses:</sec_title>
				<para>Short-term treatment of duodenal ulcer, maintenance therapy for duodenal ulcer, Zollinger-Ellison syndrome, multiple endocrine adenomas, gastric ulcers; gastroesophageal reflux disease, heartburn</para>
				<section type="none" id="sidelem4x584">
					<section type="none" id="sidelem4x585">
						<sec_title>Unlabeled uses: </sec_title>
						<para>GI disorders in those taking NSAIDs; urticaria; prevention of stress ulcers, aspiration pneumonitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x590">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x595">
					<section type="none" id="sidelem4x596">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="B">B</preg>), breastfeeding, children &lt;12 yr, geriatric patients, severe renal/hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x601">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x604">
					<section type="none" id="sidelem4x605">
						<sec_title>Short-term treatment of gastric ulcer</sec_title>
						<section type="none" id="sidelem4x613">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x613">
									<item>
										<label>•</label>
										<para> 40 mg/day at bedtime × 4-8 wk, then 20 mg/day at bedtime if needed (maintenance);  20 mg q12hr if unable to take </para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x625">
							<label>•</label>
							<sec_title>Child 1-16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x625">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg/day in 1-2 divided doses, max 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x629">
						<sec_title>Pathologic hypersecretory conditions</sec_title>
						<section type="none" id="sidelem4x637">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x637">
									<item>
										<label>•</label>
										<para> 20 mg q6hr; may give up to 160 mg q6hr if needed;  20 mg q6hr if unable to take </para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x646">
						<sec_title>GERD</sec_title>
						<section type="none" id="sidelem4x654">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x654">
									<item>
										<label>•</label>
										<para> 20 mg bid ≤6 wk; 40 mg bid ≤2 wk (ulcerative esophagitis)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x658">
						<sec_title>Heartburn relief/prevention</sec_title>
						<section type="none" id="sidelem4x666">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x666">
									<item>
										<label>•</label>
										<para> 10 mg with water or 15 min-1 hr before eating</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x670">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x678">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;50 ml/min, decrease dose by 50% or extend interval to 36-48 hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x681">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 10, 20, 40 mg; powder for oral susp 40 mg/5 ml; inj 10 mg/ml, 20 mg/50 ml</para>
					</section>
					<section type="none" id="sidelem4x686">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x690">
								<item>
									<label>•</label>
									<para>Store in cool environment (oral); IV sol stable for 48 hr at room temperature; do not use discolored sol; discard unused oral sol after 1 mo</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x696">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x700">
									<item>
										<label>•</label>
										<para>After shaking oral suspension</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x706">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x710">
									<item>
										<label>•</label>
										<para>After diluting 2 ml of product (10 mg/ml) in 0.9% NaCl to total volume of 5-10 ml; inject over 2 min to prevent hypotension</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x716">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x720">
									<item>
										<label>•</label>
										<para>After diluting 20 mg (2 ml) of product in 100 ml of LR, 0.9% NaCl, D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">10</emphasis>W; run over 15-30 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x732">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x736">
									<item>
										<label>•</label>
										<para>
											<emphasis style="italic">Adults:</emphasis> Dilute 40 mg of product in 250 ml D<emphasis style="inf">5</emphasis>W, NS; infuse over 24 hr, run at 11 ml/hr, use infusion device</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x748">
						<sec_title>Y-site compatibilities: </sec_title>
						<para>Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B lipid complex, amphotericin B liposome, amsacrine, anakinra, anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, cefonicid, cefotaxime, cefTAZidime, cefuroxime, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, cladribine, clindamycin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, folic acid, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, irinotecan, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, miconazole, midazolam, milrinone, mitoXANtrone, morphine, moxalactam, multiple vitamins injection, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, 0.9% NaCl, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentamidine, pentazocine, PENTobarbital, perphenazine, PHENobarbital, phenylephrine, phytonadione, polymyxin B, potassium chloride/phosphates, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, remifentanil, Ringer’s, ritodrine, riTUXimab, sargramostim, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zoledronic acid</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x753">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x756">
					<section type="none" id="sidelem4x757">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Headache, dizziness,</emphasis> paresthesia, depression, anxiety, somnolence, insomnia, fever, <emphasis style="bold">seizures in renal disease</emphasis></para>
					</section>
					<section type="none" id="sidelem4x766">
						<sec_title>CV: </sec_title>
						<para>
							<emphasis alert="lifethreat">Dysrhythmias, QT prolongation (impaired renal functioning)</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x772">
						<sec_title>EENT: </sec_title>
						<para>Taste change, tinnitus, orbital edema</para>
					</section>
					<section type="none" id="sidelem4x777">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Constipation,</emphasis> nausea, vomiting, anorexia, cramps, abnormal hepatic enzymes, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x784">
						<sec_title>INTEG: </sec_title>
						<para>Rash, <emphasis style="bold">toxic epidermal necrolysis, Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x791">
						<sec_title>MS: </sec_title>
						<para>Myalgia, arthralgia</para>
					</section>
					<section type="none" id="sidelem4x796">
						<sec_title>RESP: </sec_title>
						<para>
							<emphasis alert="lifethreat">Pneumonia</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x802">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Plasma protein binding 15%-20%, metabolized in liver 30% (active metabolites), 70% excreted by kidneys, half-life 2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-3<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr</para>
				<section type="none" id="sidelem4x819">
					<section type="none" id="sidelem4x820">
						<sec_title>PO: </sec_title>
						<para>Onset 60 min, duration 12 hr, peak 1-3 hr, absorption 50%</para>
					</section>
					<section type="none" id="sidelem4x825">
						<sec_title>IV: </sec_title>
						<para>Onset 60 min, peak 1-4 hr, duration 12 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x830">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—ketoconazole, itraconazole, cefpodoxime, cefditoren</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> famotidine absorption—antacids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—atazanavir, delavirdine</para>
			</section>
			<section type="considerations" id="sidelem4x846">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x849">
					<section type="none" id="sidelem4x850">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x858">
							<label>•</label>
							<sec_title>Ulcers</sec_title>
							<para>
								<list id="lidelem4x858">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ulcers:</emphasis> epigastric pain, adominal pain, frank or occult blood in emesis, stools</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x862">
								<item>
									<label>•</label>
									<para>Intragastric pH, serum creatinine/BUN baseline and periodically</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x870">
							<label>•</label>
							<sec_title>
								<route>For bleeding, hematuria, hematuresis, occult blood in stools; abdominal pain</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x873">
								<item>
									<label>•</label>
									<para>Increase in bulk and fluids in diet to prevent constipation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x878">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x882">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased abdominal pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x888">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x892">
								<item>
									<label>•</label>
									<para>That product must be continued for prescribed time in prescribed method to be effective; not to double dose</para>
								</item>
								<item>
									<label>•</label>
									<para>About possibility of decreased libido; that this is reversible after discontinuing therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid irritating foods, alcohol, aspirin, NSAIDs, extreme-temperature foods that may irritate GI system</para>
								</item>
								<item>
									<label>•</label>
									<para>That smoking should be avoided because it diminishes effectiveness of product</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid tasks requiring alertness because dizziness, drowsiness may occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active" ru="yes">
			<mono_name> fat emulsions (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x9235">Intralipid 10%</tradename>
					<tradename id="tnidelem4x9234">Intralipid 20%</tradename>
					<tradename id="tnidelem4x9233">Liposyn II 10%</tradename>
					<tradename id="tnidelem4x9232">Liposyn II 20%</tradename>
					<tradename id="tnidelem4x9231">Liposyn III 10%</tradename>
					<tradename id="tnidelem4x9230">Liposyn III 20%</tradename>
				</tradenames>
				<class type="func"> Caloric</class>
				<class type="chem"> Fatty acid, long chain; nutritional supplement</class>
			</info>
			<section type="uses" id="sidelem4x933">
				<sec_title>Uses:</sec_title>
				<para>Increase calorie intake, fatty acid deficiency, prevention</para>
			</section>
			<section type="contra" id="sidelem4x938">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or eggs, soybeans, legumes; hyperlipemia, lipid necrosis, acute pancreatitis accompanied by hyperlipemia, hyperbilirubinemia of the newborn; renal insufficiency, hepatic damage</para>
			</section>
			<section type="doses" id="sidelem4x943">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x946">
					<section type="none" id="sidelem4x947">
						<sec_title>Deficiency</sec_title>
						<section type="none" id="sidelem4x955">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x955">
									<item>
										<label>•</label>
										<para> 8%-10% of required calorie intake (intralipid)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x959">
						<sec_title>Adjunct to TPN</sec_title>
						<section type="none" id="sidelem4x967">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x967">
									<item>
										<label>•</label>
										<para> 1 ml/min over 15-30 min (10%) or 0.5 ml/min over 15-30 min (20%); may increase to 500 ml over 4-8 hr if no adverse reactions occur; max 2.5 g/kg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x974">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x974">
									<item>
										<label>•</label>
										<para> 0.1 ml/min over 10-15 min (10%) or 0.05 ml/min over 10-15 min (20%); may increase to 1 g/kg over 4 hr if no adverse reactions occur; max 4 g/kg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x978">
						<sec_title>Prevention of deficiency</sec_title>
						<section type="none" id="sidelem4x986">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x986">
									<item>
										<label>•</label>
										<para> 500 ml 2×/wk (10%), given 1 ml/min for 30 min, max 500 ml over 6 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x993">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x993">
									<item>
										<label>•</label>
										<para> 5-10 ml/kg/day (10%), given 0.1 ml/min for 30 min, max 100 ml/hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x997">
						<sec_title>Available forms: </sec_title>
						<para>Inj 10% (50, 100, 200, 250, 500 ml), 20% (50, 100, 200, 250, 500 ml)</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>febuxostat (Rx)</mono_name>
			<info>
				<pronunciation>(feb-ux′oh-stat)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x10070">Uloric</tradename>
				</tradenames>
				<class type="func"> Antigout drug, antihyperuricemic</class>
				<class type="chem"> Xanthene oxidase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x1017">
				<sec_title>Action:</sec_title>
				<para>Inhibits the enzyme xanthine oxidase, thereby reducing uric acid synthesis; more selective for xanthine oxidase than allopurinol</para>
			</section>
			<section type="uses" id="sidelem4x1022">
				<sec_title>Uses:</sec_title>
				<para>Chronic gout, hyperuricemia</para>
			</section>
			<section type="contra" id="sidelem4x1027">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1032">
					<section type="none" id="sidelem4x1033">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breast-feeding, children, renal/hepatic/cardiac/neoplastic disease, stroke, MI, organ transplant, Lesch-Nyhan syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1038">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1046">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1046">
							<item>
								<label>•</label>
								<para> 40 mg daily, may increase to 80 mg daily if uric acid levels are &gt;6 mg/dl after 2 wk of therapy</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1051">
					<section type="none" id="sidelem4x1052">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 40, 80 mg</para>
					</section>
					<section type="none" id="sidelem4x1057">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1060">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1064">
									<item>
										<label>•</label>
										<para>Without regard to meals or antacids; may crush and add to foods or fluids</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1070">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1073">
					<section type="none" id="sidelem4x1074">
						<sec_title>CNS: </sec_title>
						<para>Weakness, flushing</para>
					</section>
					<section type="none" id="sidelem4x1079">
						<sec_title>EENT: </sec_title>
						<para>Retinopathy, cataracts, epistaxis</para>
					</section>
					<section type="none" id="sidelem4x1084">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea, vomiting, anorexia,</emphasis> constipation, diarrhea, dyspepsia, hematemesis, <emphasis style="bold">hepatitis,</emphasis> hepatomegaly, weight gain/loss, cholecystitis, cholelithiasis, melena</para>
					</section>
					<section type="none" id="sidelem4x1094">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Thrombocytopenia, anemia, pancytopenia, leukopenia, bone marrow suppression</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x1100">
						<sec_title>INTEG: </sec_title>
						<para>Rash</para>
					</section>
					<section type="none" id="sidelem4x1105">
						<sec_title>MISC: </sec_title>
						<para>Arthralgia, gout flare</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1110">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-1.5 hr; excreted in feces, urine; half-life 5-8 hr; protein binding 99.2%</para>
			</section>
			<section type="interactions" id="sidelem4x1115">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—azaTHIOprine, didanosine, mercaptopurine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> xanthine nephropathy, calculi—rasburicase, antineoplastics</para>
				<section type="none" id="sidelem4x1126">
					<section type="none" id="sidelem4x1127">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1134">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1137">
					<section type="none" id="sidelem4x1138">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1146">
							<label>•</label>
							<sec_title>Hyperuricemia</sec_title>
							<para>
								<list id="lidelem4x1146">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperuricemia:</emphasis> uric acid levels q2wk; uric acid levels should be ≤6 mg/dl, flares may occur during first 6 wk of treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1150">
								<item>
									<label>•</label>
									<para>Hepatic studies before use, then 2, 4 mo and then periodically; assess for fatigue, anorexia, right upper abdominal discomfort, dark urine, jaundice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1155">
								<item>
									<label>•</label>
									<para>CBC, AST, BUN, creatinine before starting treatment, periodically</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1163">
							<label>•</label>
							<sec_title>Renal disease</sec_title>
							<para>
								<list id="lidelem4x1163">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Renal disease:</emphasis> I&amp;O ratio; increase fluids to 2 L/day to prevent stone formation and toxicity</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1167">
								<item>
									<label>•</label>
									<para>For rash, hypersensitivity reactions; discontinue</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1175">
							<label>•</label>
							<sec_title>Gout</sec_title>
							<para>
								<list id="lidelem4x1175">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Gout:</emphasis> joint pain, swelling; may use with NSAIDs for acute gouty attacks and gout flare (first 6 wk)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1179">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1183">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain in joints, decreased stone formation in kidneys, decreased uric acid levels</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1189">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1194">
								<item>
									<label>•</label>
									<para>That tabs may be crushed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1199">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, to take as soon as remembered; not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1204">
								<item>
									<label>•</label>
									<para>To increase fluid intake to 2 L/day unless contraindicated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1209">
								<item>
									<label>•</label>
									<para>To avoid alcohol, caffeine because they will increase uric acid levels</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1214">
								<item>
									<label>•</label>
									<para>To report cardiovascular events to prescriber immediately</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1222">
							<label>•</label>
							<sec_title>Gout</sec_title>
							<para>
								<list id="lidelem4x1222">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Gout:</emphasis> that flares may occur during first 6 wk of treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>felodipine (Rx)</mono_name>
			<info>
				<pronunciation>(fe-loe′-di-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x12311">Plendil</tradename>
					<tradename id="tnidelem4x12310">
						<country code="CAN">Renedil </country>
					</tradename>
				</tradenames>
				<class type="func"> Antihypertensive, calcium channel blocker, antianginal</class>
				<class type="chem"> Dihydropyridine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1243">
				<para>
					<confusion>
						<tradename id="tnidelem4x12430">Plendil</tradename>
						<drug type="generic" refid="idelem4x12430">pindolol/Pletal/PriLOSEC/Prinivil/Isordil</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1247">
				<sec_title>Action:</sec_title>
				<para>Inhibits calcium ion influx across cell membrane, resulting in the inhibition of the excitation and contraction of vascular smooth muscle</para>
			</section>
			<section type="uses" id="sidelem4x1252">
				<sec_title>Uses:</sec_title>
				<para>Essential hypertension alone or with other antihypertensives</para>
				<section type="none" id="sidelem4x1257">
					<section type="none" id="sidelem4x1258">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Hypertension in adolescents and children, angina pectoris; Prinzmetal’s angina (vasospastic)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1263">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or dihydropyridines, sick sinus syndrome, 2nd- or 3rd-degree heart block, hypotension &lt;90 mm Hg systolic</para>
				<section type="none" id="sidelem4x1268">
					<section type="none" id="sidelem4x1269">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, CHF, hepatic injury, renal disease, coronary artery disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1275">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1283">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1283">
							<item>
								<label>•</label>
								<para> 5 mg/day initially; usual range 2.5-10 mg/day; max 10 mg/day; do not adjust dosage at intervals of &lt;2 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1290">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1290">
							<item>
								<label>•</label>
								<para> 2.5 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1294">
					<section type="none" id="sidelem4x1295">
						<sec_title>Hepatic disease</sec_title>
						<section type="none" id="sidelem4x1303">
							<label>•</label>
							<sec_title>Adult<route> PO 2.5-5 mg, max 10 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1306">
						<sec_title>Hypertension in adolescent/child (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1314">
							<label>•</label>
							<sec_title>Adolescent and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1314">
									<item>
										<label>•</label>
										<para> 2.5 mg initially, titrate upward, max 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1318">
						<sec_title>Available forms: </sec_title>
						<para>Ext rel tabs 2.5, 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x1323">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1326">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1330">
									<item>
										<label>•</label>
										<para>Swallow whole; do not break, crush, or chew ext rel products</para>
									</item>
									<item>
										<label>•</label>
										<para>Once daily with light meal; avoid grapefruit juice</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1341">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1344">
					<section type="none" id="sidelem4x1345">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Headache,</emphasis> fatigue, drowsiness, dizziness, anxiety, depression, nervousness, insomnia, light-headedness, paresthesia, tinnitus, psychosis, somnolence, <emphasis style="bold">flushing</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1354">
						<sec_title>CV: </sec_title>
						<para>
							<emphasis style="bold">Dysrhythmia,</emphasis>
							<emphasis style="italic">edema,</emphasis>
							<emphasis style="bold">CHF,</emphasis> hypotension, palpitations, <emphasis style="bold">MI, pulmonary edema,</emphasis> tachycardia, syncope, AV block, angina</para>
					</section>
					<section type="none" id="sidelem4x1368">
						<sec_title>GI: </sec_title>
						<para>Nausea, vomiting, diarrhea, <emphasis style="bold">gastric upset,</emphasis> constipation, increased LFTs, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x1376">
						<sec_title>GU: </sec_title>
						<para>Nocturia, polyuria, sexual dysfunction, decreased libido</para>
					</section>
					<section type="none" id="sidelem4x1381">
						<sec_title>HEMA: </sec_title>
						<para>Anemia</para>
					</section>
					<section type="none" id="sidelem4x1386">
						<sec_title>INTEG: </sec_title>
						<para>Rash, pruritus, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x1391">
						<sec_title>MISC: </sec_title>
						<para>Flushing, sexual difficulties, cough, nasal congestion, SOB, wheezing, epistaxis, respiratory infection, chest pain, <emphasis style="bold">angioedema,</emphasis> gingival hyperplasia, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1401">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak plasma levels 2.5-5 hr, highly protein bound &gt;99%, metabolized in liver, 0.5% excreted unchanged in urine, elimination half-life 11-16 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1406">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bradycardia, CHF—β-blockers, digoxin, phenytoin, disopyramide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity, hypotension—nitrates, alcohol, quiNIDine, zileuton, miconazole, diltiazem, delavirdine, quinupristin-dalfopristin, conivaptan, cycloSPORINE, cimetidine, clarithromycin, antiretroviral protease inhibitors, other antihypertensives, MAOIs, ketoconazole, erythromycin, itraconazole, propranolol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effects—NSAIDs, carBAMazepine, barbiturates, phenytoin</para>
				<section type="none" id="sidelem4x1421">
					<section type="none" id="sidelem4x1422">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—ginseng, ginkgo, hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra, St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x1433">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> felodipine level—grapefruit juice</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1440">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1443">
					<section type="none" id="sidelem4x1444">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1452">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x1452">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> I&amp;O, weight daily; weight gain, crackles, dyspnea, edema, jugular venous distention</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1456">
								<item>
									<label>•</label>
									<para>Cardiac status: B/P, pulse, respiration; ECG periodically</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1464">
							<label>•</label>
							<sec_title>Angina pain</sec_title>
							<para>
								<list id="lidelem4x1464">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Angina pain:</emphasis> location, duration, intensity; ameliorating, aggravating factors</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1468">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1472">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P, decreased anginal attacks, increased activity tolerance</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1478">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1483">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product, dizziness no longer a problem</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1488">
								<item>
									<label>•</label>
									<para>To avoid OTC products, alcohol unless directed by prescriber; to limit caffeine consumption</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1493">
								<item>
									<label>•</label>
									<para>About the importance of complying with all areas of medical regimen: diet, exercise, stress reduction, product therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1498">
								<item>
									<label>•</label>
									<para>That tablets may appear in stools but are insignificant</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1507">
							<label>•</label>
							<sec_title>
								<route>To report dyspnea, palpitations, irregular heartbeat, swelling of extremities, nausea, vomiting, severe dizziness, severe headache</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1510">
								<item>
									<label>•</label>
									<para>To change positions slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1515">
								<item>
									<label>•</label>
									<para>To obtain correct pulse; to contact prescriber if pulse &lt;50 bpm</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1520">
								<item>
									<label>•</label>
									<para>Use good oral hygiene to prevent gingival hyperplasia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1525">
								<item>
									<label>•</label>
									<para>Do not stop abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1530">
								<item>
									<label>•</label>
									<para>To avoid grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>fenofibrate (Rx)</mono_name>
			<info>
				<pronunciation>(fen-oh-fee′brate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x15456">Antara</tradename>
					<tradename id="tnidelem4x15455">
						<country code="CAN">Fenoglide</country>
					</tradename>
					<tradename id="tnidelem4x15454">
						<country code="CAN">Lipidil EZ</country>
					</tradename>
					<tradename id="tnidelem4x15453">Micro</tradename>
					<tradename id="tnidelem4x15452">Lipidil Supra Lipofen Lofibra</tradename>
					<tradename id="tnidelem4x15451">Tricor</tradename>
					<tradename id="tnidelem4x15450">Triglide</tradename>
				</tradenames>
				<class type="func"> Antilipemic</class>
				<class type="chem"> Fibric acid derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x1564">
				<sec_title>Action:</sec_title>
				<para>Increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase, thereby resulting in changes in triglyceride size and composition of LDL, leading to rapid breakdown of LDL; mobilizes triglycerides from tissue; increases excretion of neutral sterols</para>
			</section>
			<section type="uses" id="sidelem4x1569">
				<sec_title>Uses:</sec_title>
				<para>Hypercholesterolemia; types IV, V hyperlipidemia that do not respond to other treatment and that increase risk for pancreatitis; Fredrickson type IV, V hypertriglyceridemia</para>
			</section>
			<section type="contra" id="sidelem4x1574">
				<sec_title>Contraindications:</sec_title>
				<para>Hypertensivity, severe renal/hepatic disease, primary biliary cirrhosis, preexisting gallbladder disease, breastfeeding</para>
				<section type="none" id="sidelem4x1579">
					<section type="none" id="sidelem4x1580">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), geriatric patients, peptic ulcer, pancreatitis, renal/hepatic disease, diabetes mellitus</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1585">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1588">
					<section type="none" id="sidelem4x1589">
						<sec_title>Hypertriglyceridemia</sec_title>
						<section type="none" id="sidelem4x1597">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1597">
									<item>
										<label>•</label>
										<para> (Antara) 43-130 mg/day; (Lofibra) 67-200 mg/day; (Tricor) 48-145 mg/day; (Triglide) 50-160 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1601">
						<sec_title>Primary hypercholesterolemia/mixed hyperlipidemia</sec_title>
						<section type="none" id="sidelem4x1609">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1609">
									<item>
										<label>•</label>
										<para> (Antara) 130 mg/day; (Lofibra) 200 mg/day; (Tricor) 145 mg/day; (Triglide) 160 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1613">
						<sec_title>Renal dose (geriatric)</sec_title>
						<section type="none" id="sidelem4x1621">
							<label>•</label>
							<sec_title>Adult<route> PO (Tricor) CCr 30-80 ml/min, 48 mg/day; CCr &lt;30 ml/min, contraindicated</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1627">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-80 ml/min, 50 mg/day (Triglide, Liprofen), 30 mg/day (Antara), 40 mg daily (fenoglide), 67 mg/day (Lofibra caps), 54 mg/day (Lofibra tabs); CCr &lt;30 ml/min, contraindicated (Antara, Lipofen, Lofibra, Triglide)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1630">
						<sec_title>Available forms: </sec_title>
						<para>
							<emphasis style="bold">Cap:</emphasis> Antara 30, 90 mg; Lipofen 50, 150 mg; <emphasis style="bold">Tab:</emphasis> Triglide 50, 160 mg; Lofibra 54, 160 mg; Tricor 48, 145 mg; Fenoglide 40, 120 mg</para>
					</section>
					<section type="none" id="sidelem4x1640">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1644">
								<item>
									<label>•</label>
									<para>Product with meals (Lipofen, Lofibra); Triglide, Antara without regard to food; may increase q4-8wk; brands are not interchangeable; therapy should be discontinued if there is not adequate response after 2 mo</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1650">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1653">
					<section type="none" id="sidelem4x1654">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Fatigue, weakness,</emphasis> drowsiness, dizziness, insomnia, depression, vertigo</para>
					</section>
					<section type="none" id="sidelem4x1661">
						<sec_title>CV: </sec_title>
						<para>Angina, hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x1666">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea,</emphasis> vomiting, dyspepsia, increased liver enzymes, flatulence, hepatomegaly, gastritis, <emphasis style="bold">pancreatitis, cholelithiasis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1675">
						<sec_title>GU: </sec_title>
						<para>Dysuria, urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x1680">
						<sec_title>HEMA: </sec_title>
						<para>Anemia, leukopenia, <emphasis style="bold">thrombosis/pulmonary embolism</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1687">
						<sec_title>INTEG: </sec_title>
						<para>
							<emphasis style="italic">Rash,</emphasis> urticaria, pruritus, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x1694">
						<sec_title>MISC: </sec_title>
						<para>Polyphagia, weight gain, infection, flulike syndrome</para>
					</section>
					<section type="none" id="sidelem4x1699">
						<sec_title>MS: </sec_title>
						<para>
							<emphasis style="italic">Myalgias, arthralgias,</emphasis>
							<emphasis alert="lifethreat">myopathy, rhabdomyolysis</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x1707">
						<sec_title>RESP: </sec_title>
						<para>Pharyngitis, bronchitis, cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1712">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 6-8 hr, protein binding 99%, converted to fenofibric acid, metabolized in liver, excreted in urine (60%), feces (25%), half-life 20 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1719">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> myopathy—colchicine</para>
				<section type="none" id="sidelem4x1734">
					<label>•</label>
					<sec_title>
						<route>Avoid use with HMG-CoA reductase inhibitors; rhabdomyolysis may occur</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulant effects—oral anticoagulants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of—antidiabetics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of fenofibrate—bile acid sequestrants</para>
				<section type="none" id="sidelem4x1749">
					<section type="none" id="sidelem4x1750">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect—red yeast rice</para>
					</section>
					<section type="none" id="sidelem4x1757">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> absorption</para>
					</section>
					<section type="none" id="sidelem4x1764">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, BUN, CK, creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, uric acid, Hgb, paradoxical effect in HDL</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1775">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1778">
					<section type="none" id="sidelem4x1779">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1787">
							<label>•</label>
							<sec_title>Diet history</sec_title>
							<para>
								<list id="lidelem4x1787">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Diet history:</emphasis> fat content; lipid levels (triglycerides, LDL, HDL, cholesterol), may cause a paradoxical decrease in HDL, LFTs at baseline, periodically during treatment, CPK if muscle pain occurs, CBC, Hct, Hgb; PT with anticoagulant therapy</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1794">
							<label>•</label>
							<sec_title>
								<route>Pancreatitis, cholelithiasis renal failure, rhabdomyolysis (when combined with HMG Co-A reductase inhibitors), myositis; product should be discontinued</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1797">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1801">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased triglycerides, cholesterol levels</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1807">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1812">
								<item>
									<label>•</label>
									<para>That compliance is needed; not to consume chipped or broken tabs (Triglide)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1817">
								<item>
									<label>•</label>
									<para>That risk factors should be decreased: high-fat diet, smoking, alcohol consumption, absence of exercise</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1822">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is suspected or planned</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1827">
								<item>
									<label>•</label>
									<para>To report GU symptoms: decreased libido, impotence, dysuria, proteinuria, oliguria, hematuria</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1835">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of muscle pain, weakness, fever, fatigue, epigastric pain</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active" ha="yes">
			<mono_name> fentaNYL (Rx)</mono_name>
			<info>
				<pronunciation>(fen′ta-nill)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x18451">
						<country code="CAN">RAN-Fentanyl </country>
					</tradename>
					<tradename id="tnidelem4x18450">Sublimaze</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="10" status="active">
			<mono_name>fentaNYL transdermal (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x18530">Duragesic</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="11" status="active">
			<mono_name>fentaNYL nasal spray (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x18580">Lazanda</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="12" status="active">
			<mono_name>fentaNYL SL spray</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x18630">Subsys</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="13" status="active">
			<mono_name>fentaNYL SL</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x18680">Abstral</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="14" status="active">
			<mono_name>fentaNYL buccal</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x18730">Fentora</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="15" status="active">
			<mono_name>fentaNYL lozenge</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x18780">Actiq</tradename>
				</tradenames>
				<class type="func"> Opioid analgesic</class>
				<class type="chem"> Synthetic phenylpiperidine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x1891">
				<para>
					<confusion>
						<tradename id="tnidelem4x18910">fentaNYL</tradename>
						<drug type="generic" refid="idelem4x18910">Sufenta</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1895">
				<sec_title>Action:</sec_title>
				<para>Inhibits ascending pain pathways in CNS, increases pain threshold, alters pain perception by binding to opiate receptors</para>
			</section>
			<section type="uses" id="sidelem4x1900">
				<sec_title>Uses:</sec_title>
				<para>Controls moderate to severe pain; preoperatively, postoperatively; adjunct to general anesthetic, adjunct to regional anesthesia; <emphasis style="bold">FentaNYL:</emphasis> anesthesia as premedication, conscious sedation; <emphasis style="bold">Actiq:</emphasis> breakthrough cancer pain</para>
			</section>
			<section type="contra" id="sidelem4x1911">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to opiates, myasthenia gravis</para>
				<para>
					<bbw>Headache, migraine (Actiq, ABSTRAL, Fentora, Lazanda, Onsolis); emergency room use (ABSTRAL, Lazanda); outpatient surgeries (Duragesic TD); opioid-naive patients, respiratory depression</bbw>
				</para>
				<section type="none" id="sidelem4x1927">
					<section type="none" id="sidelem4x1928">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, increased intracranial pressure, seizure disorders, severe respiratory disorders, cardiac dysrhythmias</para>
						<para>
							<bbw>Accidental exposure, ambient temperature increase, fever, skin abrasion (TD patch), substance abuse, surgery, requires an experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1943">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1946">
					<sec_title>
						<emphasis style="italic">FentaNYL</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x1950">
						<sec_title>Anesthetic</sec_title>
						<section type="none" id="sidelem4x1958">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1958">
									<item>
										<label>•</label>
										<para> 50-100 mcg/kg over 1-2 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1962">
						<sec_title>Anesthesia supplement</sec_title>
						<section type="none" id="sidelem4x1970">
							<label>•</label>
							<sec_title>Adult and child &gt;12 yr<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x1970">
									<item>
										<label>•</label>
										<para> 2-20 mcg/kg  0.025-0.25 mcg/kg/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1977">
						<sec_title>Induction and maintenance</sec_title>
						<section type="none" id="sidelem4x1985">
							<label>•</label>
							<sec_title>Child 2-12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1985">
									<item>
										<label>•</label>
										<para> 2-3 mcg/kg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1989">
						<sec_title>Preoperatively</sec_title>
						<section type="none" id="sidelem4x1997">
							<label>•</label>
							<sec_title>Adult and child &gt;12 yr<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x1997">
									<item>
										<label>•</label>
										<para> 50-100 mcg q30-60min before surgery</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2001">
						<sec_title>Postoperatively</sec_title>
						<section type="none" id="sidelem4x2009">
							<label>•</label>
							<sec_title>Adult and child &gt;12 yr<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x2009">
									<item>
										<label>•</label>
										<para> 0.05-0.1 mg q1-2hr prn</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2013">
						<sec_title>Moderate/severe pain</sec_title>
						<section type="none" id="sidelem4x2021">
							<label>•</label>
							<sec_title>Adult<route> IV/IM</route></sec_title>
							<para>
								<list id="lidelem4x2021">
									<item>
										<label>•</label>
										<para> 50-100 mcg q1-2hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x2025">
					<sec_title>
						<emphasis style="italic">Actiq</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x2034">
						<label>•</label>
						<sec_title>Adult<route> TRANSMUCOSAL</route></sec_title>
						<para>
							<list id="lidelem4x2034">
								<item>
									<label>•</label>
									<para> 200 mcg; redose if needed 15 min after completion of 1st dose; do not give more than 2 doses during titration period, max 4 doses/day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x2038">
					<sec_title>
						<emphasis style="italic">Fentora</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x2047">
						<label>•</label>
						<sec_title>Adult<route> BUCCAL/SL</route></sec_title>
						<para>
							<list id="lidelem4x2047">
								<item>
									<label>•</label>
									<para> 100 mcg placed above rear molar between upper cheek and gum, a second 100 mcg dose, if needed, may be started 30 min after 1st dose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x2051">
					<sec_title>
						<emphasis style="italic">ABSTRAL</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x2060">
						<label>•</label>
						<sec_title>Adult<route> SL</route></sec_title>
						<para>
							<list id="lidelem4x2060">
								<item>
									<label>•</label>
									<para> 100 mcg; another dose may be taken 30 min after 1st, max 2 doses per episode of breakthrough pain; ≥2 hr must elapse before treating again; titrate stepwise over consecutive episodes</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x2064">
					<sec_title>
						<emphasis style="italic">FentaNYL transdermal</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x2073">
						<label>•</label>
						<sec_title>Adult</sec_title>
						<para>
							<list id="lidelem4x2073">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Adult:</emphasis> 25 mcg/hr; may increase until pain relief occurs; apply patch to flat surface on upper torso and wear for 72 hr; apply new patch on different site; may use 12.5 mcg/hr if &lt;60 mg/day morphine equivalent</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x2077">
					<sec_title>
						<emphasis style="italic">FentaNYL nasal spray</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x2086">
						<label>•</label>
						<sec_title>Adult</sec_title>
						<para>
							<list id="lidelem4x2086">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Adult:</emphasis> 100 mcg (1 spray in 1 nostril), may retreat after ≥2 hr, titrate upward until adequate analgesia; treat a max of 4 episodes daily</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x2090">
					<sec_title>
						<emphasis style="italic">FentaNYL SL spray</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x2099">
						<label>•</label>
						<sec_title>Adult</sec_title>
						<para>
							<list id="lidelem4x2099">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Adult:</emphasis> 100 mcg sprayed under tongue, titrate stepwise carefully</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2103">
						<sec_title>Available forms: </sec_title>
						<para>Inj 0.05 mg/ml; lozenges 100, 200, 300, 400, 600, 800, 1200, 1600 mcg; lozenges on a stick 200, 400, 600, 800, 1200, 1600 mcg; buccal tab 100, 200, 400, 600, 800 mcg; SL tab (ABSTRAL) 100, 200, 300, 400, 600, 800 mcg; transdermal: patch 12, 25, 50, 75, 100 mcg/hr; <emphasis style="italic">SL</emphasis> spray: 100, 200, 400, 600, 800, 1200, 1600 mcg/spray, nasal spray 100, 400 mcg/actuation</para>
					</section>
					<section type="none" id="sidelem4x2111">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2116">
								<item>
									<label>•</label>
									<para>By inj (IM, IV); give slowly to prevent rigidity</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2124">
							<label>•</label>
							<sec_title>
								<route>Overdose has been fatal when confusing products/dose, recheck both before using</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2130">
							<label>•</label>
							<sec_title>
								<route>Must have emergency equipment available, opioid antagonists, O2; to be used only by those appropriately trained; IV products to be used in OR, ER, ICU</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2136">
							<sec_title>Transmucosal route</sec_title>
							<para>
								<list id="lidelem4x2140">
									<item>
										<label>•</label>
										<para>Remove foil just before administration; instruct patient to place product between cheek and lower gum, moving it back and forth and sucking, not chewing (Actiq); place above rear molar (Fentora); place film on the inside of the cheek (Onsolis); all products not used or only partially used should be flushed down the toilet; this product may be used SL</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2147">
							<sec_title>Transdermal route</sec_title>
							<para>
								<list id="lidelem4x2151">
									<item>
										<label>•</label>
										<para>q72hr for continuous pain relief; dosage adjusted after at least 2 applications; apply to clean, dry skin and press firmly</para>
									</item>
									<item>
										<label>•</label>
										<para>Give short-acting analgesics until patch takes effect (8-24 hr); when reducing dosage or switching to alternative IV treatment, withdraw gradually; serum levels drop gradually, give <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> the equianalgesic dose of new analgesic 12-18 hr after removal as ordered</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2168">
							<sec_title>SL spray</sec_title>
							<para>
								<list id="lidelem4x2172">
									<item>
										<label>•</label>
										<para>Open blister package with scissors immediately before use; spray contents of unit under tongue; dispose of each used unit after use by placing it into one of the disposable bags provided; seal bag, discard into a trash container out of reach of children</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2178">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x2182">
									<item>
										<label>•</label>
										<para>IV undiluted by anesthesiologist or diluted with 5 ml or more sterile water or 0.9% NaCl given through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock at 0.1 mg or less/1-2 min. Muscular rigidity may occur with rapid IV administration</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Abciximab, acyclovir, alfentanil, alemtuzumab alprostadil, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B cholesteryl, amphotericin B lipid complex, amphotericin B liposome, anidulafungin, argatroban, ascorbic acid injection, atenolol, atracurium, atropine, azaTHIOprine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, ceFAZolin, cefmetazole, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, ceftobiprole, cefTRIAXone, cefuroxime, cephalothin, chloramphenicol, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, clindamycin, cloNIDine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, doxapram, DOXOrubicin, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, erythromycin, esmolol, etomidate, etoposide, famotidine, fenoldopam, fluconazole, fludarabine, fluorouracil, folic acid, furosemide, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, lansoprazole, levofloxacin, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methicillin, methotrexate, methotrimeprazine, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, mivacurium, morphine, moxalactam, multiple vitamins injection, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, Ringer’s, ritodrine, riTUXimab, rocuronium, sargramostim, scopolamine, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex/C, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2197">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2200">
					<section type="none" id="sidelem4x2201">
						<sec_title>CNS: </sec_title>
						<para>Dizziness, delirium, euphoria, sedation, confusion, weakness, dizziness</para>
					</section>
					<section type="none" id="sidelem4x2206">
						<sec_title>CV: </sec_title>
						<para>
							<emphasis style="bold">Bradycardia, arrest,</emphasis> hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x2213">
						<sec_title>EENT: </sec_title>
						<para>Blurred vision, miosis</para>
					</section>
					<section type="none" id="sidelem4x2218">
						<sec_title>GI: </sec_title>
						<para>Nausea, vomiting, constipation</para>
					</section>
					<section type="none" id="sidelem4x2223">
						<sec_title>GU: </sec_title>
						<para>Urinary retention</para>
					</section>
					<section type="none" id="sidelem4x2228">
						<sec_title>INTEG: </sec_title>
						<para>Rash, diaphoresis</para>
					</section>
					<section type="none" id="sidelem4x2233">
						<sec_title>MS: </sec_title>
						<para>Muscle rigidity</para>
					</section>
					<section type="none" id="sidelem4x2238">
						<sec_title>RESP: </sec_title>
						<para>
							<emphasis alert="lifethreat">Respiratory depression, arrest, laryngospasm</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2244">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted by kidneys, crosses placenta, excreted in breast milk, Half-life: IV: 2-4 hr, Transdermal: 13-22 hr, Transmucosal: 7 hr, Buccal: 4-12 hr, 80% bound to plasma proteins</para>
				<section type="none" id="sidelem4x2249">
					<section type="none" id="sidelem4x2250">
						<sec_title>IM: </sec_title>
						<para>Onset 7-15 min, peak 30 min, duration 1-2 hr</para>
					</section>
					<section type="none" id="sidelem4x2255">
						<sec_title>IV: </sec_title>
						<para>Onset 1 min, peak 3-5 min, duration <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2266">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> fentaNYL effect, fetal respiratory depression: CYP3A4 inhibitors (cycloSPORINE, ketoconazole, itraconazole, cimetidine, conivaptan, fluconazole, nefazodone, ranolazine), zafirlukast, zileuton</bbw>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: fatal reactions—MAOIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—droperidol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CV depression—diazepam</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> fentaNYL effect with other CNS depressants—alcohol, opioids, sedative/hypnotics, antipsychotics, skeletal muscle relaxants, protease inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> fentaNYL effect—CYP3A4 inducers (carBAMazepine, phenytoin, PHENobarbital, rifampin)</para>
				<section type="none" id="sidelem4x2300">
					<section type="none" id="sidelem4x2301">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> action of fentaNYL—St. John’s wort</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect of fentaNYL—echinacea</para>
					</section>
					<section type="none" id="sidelem4x2312">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> amylase, lipase</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2319">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2322">
					<section type="none" id="sidelem4x2323">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2327">
								<item>
									<label>•</label>
									<para>VS after parenteral route; note muscle rigidity, drug history, hepatic/renal function tests</para>
								</item>
								<item>
									<label>•</label>
									<para>CNS changes: dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction</para>
								</item>
								<item>
									<label>•</label>
									<para>Allergic reactions: rash, urticaria</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Respiratory dysfunction: respiratory depression,</emphasis> character, rate, rhythm; notify prescriber if respirations are &lt;10/min</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Headache/migraine:</emphasis> ABSTRAL, Actiq, Fentora, Lazanda, Onsolis not to be used for this condition; ABSTRAL, Lazanda not to be used in ER; Duragesic TD not to be used for outpatient surgery patients</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Apnea, respiratory arrest in opioid-naive patients:</emphasis> do not use ABSTRAL, Actiq, Duragesic, Fentora, Lazanda, Onsolis; opioid-tolerant patients are those using ≥60 mg/day oral morphine, ≥30 mg/day oxyCODONE PO, 8 mg/day HYDROmorphone, 25 mcg TD fentaNYL/hr</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x2379">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2383">
								<item>
									<label>•</label>
									<para>Therapeutic response: induction of anesthesia, relief of breakthrough cancer pain, general pain relief</para>
								</item>
								<item>
									<label>•</label>
									<para>Cancer pain, general pain relief</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2394">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2398">
								<item>
									<label>•</label>
									<para>About CNS changes: physical dependence; not to use with alcohol, other CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Accidental exposure:</emphasis> Discuss the dangers of children or pets ingesting or coming in contact with product</bbw>
						</para>
						<section type="none" id="sidelem4x2416">
							<sec_title>Transdermal route</sec_title>
							<para>
								<bbw>
									<emphasis alert="lifethreat">Ambient temperature:</emphasis> that excessive heat may increase absorption; do not use with heating pads, electric blankets, heat/tanning lamps, saunas, hot tubs, heated waterbeds, when sunbathing</bbw>
							</para>
							<para>
								<list id="lidelem4x2433">
									<item>
										<label>•</label>
										<para>That excessive perspiration may alter adhesiveness</para>
									</item>
									<item>
										<label>•</label>
										<para>To dispose of patch by placing sticky sides together and flushing down toilet</para>
									</item>
									<item>
										<label>•</label>
										<para>That patient may need to clip hair before applying to ensure adhesion</para>
									</item>
									<item>
										<label>•</label>
										<para>May add first aid tape around the edges if there is a problem with adhesion</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active" ru="yes">
			<mono_name> ferric carboxymaltose</mono_name>
			<info>
				<pronunciation>(fer′ik car-box-ee-mal′tose)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x24610">Injectafer</tradename>
				</tradenames>
			</info>
			<section type="uses" id="sidelem4x2467">
				<sec_title>Uses:</sec_title>
				<para>Iron-deficiency anemia in those intolerant or those who have had poor results with other iron supplements</para>
			</section>
			<section type="contra" id="sidelem4x2472">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, iron overload</para>
			</section>
			<section type="doses" id="sidelem4x2477">
				<sec_title>Dosage and routes</sec_title>
				<para>
					<emphasis style="bold">Adults ≥50 kg: IV</emphasis> Give 2 doses of 750 mg/dose separated by ≥7 days, max 1500 mg of iron per course, may repeat if iron deficiency anemia recurs</para>
				<para>
					<emphasis style="bold">Adults &lt;50 kg: IV</emphasis> Give 2 doses of 15 mg/kg/dose separated by ≥7 days, max 1500 mg of iron per course, may repeat if iron-deficiency anemia recurs</para>
				<section type="none" id="sidelem4x2488">
					<section type="none" id="sidelem4x2489">
						<sec_title>Available forms: </sec_title>
						<para>750 mg/15 ml solution for injection</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active">
			<mono_name>ferrous fumarate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x24975">Femiron</tradename>
					<tradename id="tnidelem4x24974">Feostat</tradename>
					<tradename id="tnidelem4x24973">Ferrate</tradename>
					<tradename id="tnidelem4x24972">Ferretts</tradename>
					<tradename id="tnidelem4x24971">Ferrocite Hemocyte</tradename>
					<tradename id="tnidelem4x24970">
						<country code="CAN">Palafer </country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="18" status="active">
			<mono_name>ferrous gluconate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x25040">Fergon</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="19" status="active">
			<mono_name>ferrous sulfate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x25093">Feosol</tradename>
					<tradename id="tnidelem4x25092">Fer-Gen-Sol</tradename>
					<tradename id="tnidelem4x25091">Fer-In-Sol</tradename>
					<tradename id="tnidelem4x25090">FeroSul</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="20" status="active">
			<mono_name>ferrous sulfate, dried (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x25143">Feosol</tradename>
					<tradename id="tnidelem4x25142">Feratab</tradename>
					<tradename id="tnidelem4x25141">Slow Fe</tradename>
					<tradename id="tnidelem4x25140">slow-release Iron</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="21" status="active">
			<mono_name>carbonyl iron (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(kar′bo-nil)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x25241">ICAR Pediatric</tradename>
					<tradename id="tnidelem4x25240">Iron Chews</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="22" status="active">
			<mono_name>iron polysaccharide (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x25322">iFerex</tradename>
					<tradename id="tnidelem4x25321">Niferex</tradename>
					<tradename id="tnidelem4x25320">Nu-Iron</tradename>
				</tradenames>
				<class type="func"> Hematinic</class>
				<class type="chem"> Iron preparation</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x2542">
				<sec_title>Action:</sec_title>
				<para>Replaces iron stores needed for red blood cell development as well as energy and O<emphasis style="inf">2</emphasis> transport and use; fumarate contains 33% elemental iron; gluconate, 12%; sulfate, 20%; iron, 30%; ferrous sulfate exsiccated</para>
			</section>
			<section type="uses" id="sidelem4x2550">
				<sec_title>Uses:</sec_title>
				<para>Iron deficiency anemia, prophylaxis for iron deficiency in pregnancy, nutritional supplementation</para>
			</section>
			<section type="contra" id="sidelem4x2555">
				<sec_title>Contraindications:</sec_title>
				<para>Sideroblastic anemia, thalassemia, hemosiderosis/hemochromatosis</para>
				<section type="none" id="sidelem4x2560">
					<section type="none" id="sidelem4x2561">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="B">B</preg>) (ferric gluconate complex), (C) (iron dextran, oral products), anemia (long term), ulcerative colitis/regional enteritis, peptic ulcer disease, hemolytic anemia, cirrhosis, sulfite sensitivity</para>
						<para>
							<bbw>Accidental exposure</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2577">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2580">
					<section type="none" id="sidelem4x2581">
						<sec_title>Fumarate</sec_title>
						<section type="none" id="sidelem4x2589">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2589">
									<item>
										<label>•</label>
										<para> 200-325 mg tid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2596">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2596">
									<item>
										<label>•</label>
										<para> 3 mg/kg/day (elemental iron) tid-qid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2603">
							<label>•</label>
							<sec_title>Infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2603">
									<item>
										<label>•</label>
										<para> 10-25 mg/day (elemental iron) in 3-4 divided doses, max 15 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2607">
						<sec_title>Gluconate</sec_title>
						<section type="none" id="sidelem4x2615">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2615">
									<item>
										<label>•</label>
										<para> 50-100 mg elemental iron tid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2622">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2622">
									<item>
										<label>•</label>
										<para> 3 mg/kg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2626">
						<sec_title>Sulfate</sec_title>
						<section type="none" id="sidelem4x2634">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2634">
									<item>
										<label>•</label>
										<para> 0.75-1.5 g/day in divided doses tid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2641">
							<label>•</label>
							<sec_title>Child 6-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2641">
									<item>
										<label>•</label>
										<para> 3 mg/kg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2645">
						<sec_title>Pregnancy</sec_title>
						<section type="none" id="sidelem4x2653">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2653">
									<item>
										<label>•</label>
										<para> 300-600 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2657">
						<sec_title>Iron polysaccharide</sec_title>
						<section type="none" id="sidelem4x2665">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2665">
									<item>
										<label>•</label>
										<para> 100-200 mg tid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2672">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2672">
									<item>
										<label>•</label>
										<para> 4-6 mg/kg/day in 3 divided doses (severe iron deficiency)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2676">
						<sec_title>Available forms: </sec_title>
						<para>
							<emphasis style="bold">Fumarate:</emphasis> tabs 90, 150, 200, 300, 324, 325 mg; chewable tabs 100 mg; ext rel tabs 18 mg; <emphasis style="bold">gluconate:</emphasis> tabs 225, 240, 324, 325 mg; <emphasis style="bold">sulfate:</emphasis> tabs 195, 300, 325 mg; elixir 220 mg/5 ml; <emphasis style="bold">dried:</emphasis> tabs 200 mg; ext rel tabs 160 mg; ext rel caps 160 mg; <emphasis style="bold">iron polysaccharide:</emphasis> tabs 50 mg; caps 150 mg; sol 100 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x2695">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2698">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x2703">
									<item>
										<label>•</label>
										<para>Swallow tabs whole; do not break, crush, or chew unless labeled as chewable</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2708">
									<item>
										<label>•</label>
										<para>Between meals for best absorption; may give with juice; do not give with antacids or milk, delay at least 1 hr; if GI symptoms occur, give after meals even if absorption is decreased; eggs, milk products, chocolate, caffeine interfere with absorption</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2713">
									<item>
										<label>•</label>
										<para>Store in tight, light-resistant container</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x2721">
								<label>•</label>
								<sec_title>
									<route>Liquid</route>
								</sec_title>
								<para>
									<list id="lidelem4x2721">
										<item>
											<label>•</label>
											<para> through plastic straw to avoid discoloration of tooth enamel; dilute thoroughly</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x2725">
									<item>
										<label>•</label>
										<para>At least 1 hr before bedtime; corrosion may occur in stomach; ferrous gluconate is less irritating to GI tract than ferrous sulfate</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2730">
									<item>
										<label>•</label>
										<para>For &lt;6 mo for anemia</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2735">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2738">
					<section type="none" id="sidelem4x2739">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea, constipation, epigastric pain, black and red tarry stools,</emphasis> vomiting, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x2746">
						<sec_title>INTEG: </sec_title>
						<para>Temporarily discolored tooth enamel and eyes</para>
					</section>
					<section type="none" id="sidelem4x2751">
						<sec_title>SYST: </sec_title>
						<para>
							<emphasis alert="lifethreat">Hypersensitivity reactions (Ferrlecit)</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2757">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2760">
					<section type="none" id="sidelem4x2761">
						<sec_title>PO: </sec_title>
						<para>Excreted in feces, urine, skin, breast milk; enters bloodstream; bound to transferrin; crosses placenta</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2766">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of iron preparation—ascorbic acid, chloramphenicol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of penicillamine, levodopa, methyldopa, fluoroquinolones, <emphasis style="smallcaps">l</emphasis>-thyroxine, tetracycline</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of iron preparations—antacids, H<emphasis style="inf">2</emphasis>-antagonists, proton pump inhibitors, cholestyramine, vit E</para>
				<section type="none" id="sidelem4x2787">
					<section type="none" id="sidelem4x2788">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption—dairy products, caffeine, eggs</para>
					</section>
					<section type="none" id="sidelem4x2795">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False positive:</emphasis> occult blood</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2802">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2805">
					<section type="none" id="sidelem4x2806">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2811">
								<item>
									<label>•</label>
									<para>Blood studies: Hct, Hgb, reticulocytes, bilirubin before treatment, at least monthly; iron studies (iron, TIBC, ferritin)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2817">
								<item>
									<para>
										<emphasis alert="nurse">Toxicity: nausea, vomiting, diarrhea (green then tarry stools), hematemesis, pallor, cyanosis, shock, coma</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2822">
								<item>
									<label>•</label>
									<para>Elimination: if constipation occurs, increase water, bulk, activity</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2830">
							<label>•</label>
							<sec_title>Nutrition</sec_title>
							<para>
								<list id="lidelem4x2830">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Nutrition:</emphasis> amount of iron in diet (meat, dark green leafy vegetables, dried beans, dried fruits, eggs)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2835">
								<item>
									<label>•</label>
									<para>Cause of iron loss or anemia, including salicylates, sulfonamides, antimalarials, quiNIDine</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2840">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2844">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in Hct, Hgb, reticulocytes; decreased fatigue, weakness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2850">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2855">
								<item>
									<label>•</label>
									<para>That iron will turn stools black or dark green, stain teeth</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2863">
							<label>•</label>
							<sec_title>Accidental exposure<route> to keep out of reach of children, pets; iron poisoning may occur if increased beyond recommended level</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2869">
							<label>•</label>
							<sec_title>
								<route>Not to substitute 1 iron salt for another; that elemental iron content differs (e.g., 300 mg ferrous fumarate contains about 100 mg elemental iron; 300 mg ferrous gluconate contains only about 30 mg elemental iron)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2875">
							<label>•</label>
							<sec_title>
								<route>To avoid reclining position for 15-30 min after taking product to avoid esophageal corrosion</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2878">
								<item>
									<label>•</label>
									<para>To follow a diet high in iron; to avoid taking iron, dairy products, calcium supplements, and vit C together because they compete for absorption</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="23" status="active">
			<mono_name>fesoterodine (Rx)</mono_name>
			<info>
				<pronunciation>(fess′oh-ter-oh-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x28930">Toviaz</tradename>
				</tradenames>
				<class type="func"> Overactive bladder product</class>
				<class type="chem"> Muscarinic receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2903">
				<sec_title>Action:</sec_title>
				<para>Relaxes smooth muscles in urinary tract by inhibiting acetylcholine at postganglionic sites</para>
			</section>
			<section type="uses" id="sidelem4x2908">
				<sec_title>Uses:</sec_title>
				<para>Overactive bladder (urinary frequency, urgency), urinary incontinence</para>
			</section>
			<section type="contra" id="sidelem4x2913">
				<sec_title>Contraindications:</sec_title>
				<para>GI obstruction, ileus, pyloric stenosis, urinary retention, gastric retention, hypersensitivity, closed-angle glaucoma</para>
				<section type="none" id="sidelem4x2918">
					<section type="none" id="sidelem4x2919">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, renal/hepatic disease, urinary tract obstruction, ambient temperature increase, autonomic neuropathy, constipation, contact lenses, hazardous activity, GERD, gastroparesis, myasthenia gravis, prostatic hypertrophy, toxic megacolon, ulcerative colitis, possible cross-sensitivity with tolterodine</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2924">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2932">
					<label>•</label>
					<sec_title>Adult and geriatric<route> PO EXT REL</route></sec_title>
					<para>
						<list id="lidelem4x2932">
							<item>
								<label>•</label>
								<para> 4 mg/day, may increase to 8 mg/day based on response, max 4 mg/day in those taking potent CYP3A4 inhibitors</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2936">
					<section type="none" id="sidelem4x2937">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x2945">
							<label>•</label>
							<sec_title>Adult<route> PO EXT REL CCr &lt;30 ml/min, max 4 mg/day in severe renal impairment</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2948">
						<sec_title>Available forms: </sec_title>
						<para>
							<emphasis style="bold">EXT REL TABS</emphasis> 4, 8 mg</para>
					</section>
					<section type="none" id="sidelem4x2955">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2959">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew ext rel product</para>
								</item>
								<item>
									<label>•</label>
									<para>Give without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature; protect from moisture</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2975">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2978">
					<section type="none" id="sidelem4x2979">
						<sec_title>CNS: </sec_title>
						<para>Insomnia</para>
					</section>
					<section type="none" id="sidelem4x2984">
						<sec_title>CV: </sec_title>
						<para>Chest pain, angina, <emphasis style="bold">QT prolongation</emphasis>, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x2992">
						<sec_title>EENT: </sec_title>
						<para>Xerophthalmia</para>
					</section>
					<section type="none" id="sidelem4x2997">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea, vomiting,</emphasis> abdominal pain, constipation, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x3004">
						<sec_title>GU: </sec_title>
						<para>Dysuria, urinary retention, UTI</para>
					</section>
					<section type="none" id="sidelem4x3009">
						<sec_title>INTEG: </sec_title>
						<para>Rash, <emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3016">
						<sec_title>MISC: </sec_title>
						<para>Peripheral edema, insomnia</para>
					</section>
					<section type="none" id="sidelem4x3021">
						<sec_title>MS: </sec_title>
						<para>Back pain</para>
					</section>
					<section type="none" id="sidelem4x3026">
						<sec_title>RESP: </sec_title>
						<para>Cough, URI</para>
					</section>
					<section type="none" id="sidelem4x3031">
						<sec_title>SYST: </sec_title>
						<para>Infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3036">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 5 hr, rapidly absorbed, protein binding 50%, excreted in urine/feces, half-life 7 hr</para>
			</section>
			<section type="interactions" id="sidelem4x3041">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of fesoterodine—CYP3A4 inhibitors (antiretroviral protease inhibitors, macrolide antiinfectives, azole antifungals)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic effect—antimuscarinics, anticholinergics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> urinary frequency—diuretics</para>
				<section type="none" id="sidelem4x3058">
					<section type="none" id="sidelem4x3059">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> fesoterodine—caffeine, green tea, guarana</para>
					</section>
					<section type="none" id="sidelem4x3066">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> fesoterodine level—grapefruit juice</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> fesoterodine level—cola, coffee, tea</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3077">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3080">
					<section type="none" id="sidelem4x3081">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3089">
							<label>•</label>
							<sec_title>Urinary patterns</sec_title>
							<para>
								<list id="lidelem4x3089">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Urinary patterns:</emphasis> distention, nocturia, frequency, urgency, incontinence</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3096">
							<label>•</label>
							<sec_title>Allergic reactions</sec_title>
							<para>
								<list id="lidelem4x3096">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reactions:</emphasis> rash; if this occurs, product should be discontinued</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3100">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3104">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of urinary frequency, urgency, incontinence</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3110">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3114">
								<item>
									<label>•</label>
									<para>Not to drink liquids before bedtime</para>
								</item>
								<item>
									<label>•</label>
									<para>About the importance of bladder maintenance</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use new meds, herbs without prescriber approval</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="24" status="active">
			<mono_name>fexofenadine (Rx, otc)</mono_name>
			<info>
				<pronunciation>(fex-oh-fi′na-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x31350">Allegra</tradename>
				</tradenames>
				<class type="func"> Antihistamine—2nd generation</class>
				<class type="chem"> Piperidine, peripherally selective</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3145">
				<para>
					<confusion>
						<tradename id="tnidelem4x31450">Allegra</tradename>
						<drug type="generic" refid="idelem4x31450">Viagra</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3149">
				<sec_title>Action:</sec_title>
				<para>Acts on blood vessels, GI, respiratory system by competing with histamine for H<emphasis style="inf">1</emphasis>-receptor site; decreases allergic response by blocking pharmacologic effects of histamine, less sedating</para>
			</section>
			<section type="uses" id="sidelem4x3157">
				<sec_title>Uses:</sec_title>
				<para>Rhinitis, allergy symptoms, chronic idiopathic urticaria</para>
			</section>
			<section type="contra" id="sidelem4x3162">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, newborn or premature infants, hypersensitivity</para>
				<section type="none" id="sidelem4x3167">
					<section type="none" id="sidelem4x3168">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), children, geriatric patients, respiratory disease, closed-angle glaucoma, prostatic hypertrophy, bladder neck obstruction, asthma, renal failure</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3173">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3181">
					<label>•</label>
					<sec_title>Adult and child &gt;12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3181">
							<item>
								<label>•</label>
								<para> Rx only, 60 mg bid or 180 mg/day; PO OTC only, 60 mg bid or 180 mg/day (self-treatment of allergic rhinitis)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3188">
					<label>•</label>
					<sec_title>Child 2-11 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3188">
							<item>
								<label>•</label>
								<para> 30 mg bid; <emphasis style="bold">ORALLY DISINTEGRATING TAB Child 6-11 yr:</emphasis> 30 mg bid dissolved on tongue</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3195">
					<section type="none" id="sidelem4x3196">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x3204">
							<label>•</label>
							<sec_title>Adult and child ≥12 yr<route> PO CCr &lt;80 ml/min, 60 mg/day</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3210">
							<label>•</label>
							<sec_title>Child 2-11 yr<route> PO CCr &lt;80 ml/min, 30 mg daily</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3216">
							<label>•</label>
							<sec_title>Child &lt;2 yr<route> PO CCr &lt;80 ml/min, 15 mg daily</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3219">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 30, 60, 180 mg; oral susp 6 mg/ml, orally disintegrating tab 30 mg</para>
					</section>
					<section type="none" id="sidelem4x3224">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3229">
								<item>
									<label>•</label>
									<para>Without regard to meals; caps/tabs should not be given with or right before grapefruit, orange, or apple juice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3234">
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3242">
							<label>•</label>
							<sec_title>Orally disintegrating tab</sec_title>
							<para>
								<list id="lidelem4x3242">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Orally disintegrating tab:</emphasis> allow to dissolve, swallow; do not remove from blister pack until time of administration</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3249">
							<label>•</label>
							<sec_title>Oral susp</sec_title>
							<para>
								<list id="lidelem4x3249">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral susp:</emphasis> shake well; use calibrated measuring device</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3253">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3256">
					<section type="none" id="sidelem4x3257">
						<sec_title>CNS: </sec_title>
						<para>Headache, stimulation, drowsiness, sedation, fatigue, confusion, blurred vision, tinnitus, restlessness, tremors, paradoxical excitation in children or geriatric patients</para>
					</section>
					<section type="none" id="sidelem4x3262">
						<sec_title>CV: </sec_title>
						<para>Hypotension, palpitations, bradycardia, tachycardia, <emphasis style="bold">dysrhythmias</emphasis> (rare)</para>
					</section>
					<section type="none" id="sidelem4x3270">
						<sec_title>GI: </sec_title>
						<para>Nausea, diarrhea, abdominal pain, vomiting, constipation</para>
					</section>
					<section type="none" id="sidelem4x3276">
						<sec_title>GU: </sec_title>
						<para>Frequency, dysuria, urinary retention, impotence</para>
					</section>
					<section type="none" id="sidelem4x3281">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Hemolytic anemia, thrombocytopenia, leukopenia, agranulocytosis, pancytopenia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x3287">
						<sec_title>INTEG: </sec_title>
						<para>Rash, eczema, photosensitivity, urticaria</para>
					</section>
					<section type="none" id="sidelem4x3292">
						<sec_title>RESP: </sec_title>
						<para>Thickening of bronchial secretions, dry nose, throat</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3297">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed; onset 1 hr; peak 2-3 hr; duration 12-24 hr; 80% excreted in urine; half-life 14.5 hr, increased in renal disease</para>
			</section>
			<section type="interactions" id="sidelem4x3302">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> fexofenadine effect—erythromycin, ketoconazole</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> fexofenadine effect—rifampin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect—magnesium-aluminum-containing antacids</para>
				<section type="none" id="sidelem4x3317">
					<section type="none" id="sidelem4x3318">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption of product—apple, orange, grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x3325">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False negative:</emphasis> skin allergy tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3332">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3335">
					<section type="none" id="sidelem4x3336">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3344">
							<label>•</label>
							<sec_title>Allergy</sec_title>
							<para>
								<list id="lidelem4x3344">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergy:</emphasis> itchy, runny, watery eyes; congested nose; before and during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3348">
								<item>
									<label>•</label>
									<para>I&amp;O ratio: be alert for urinary retention, frequency, dysuria, especially among geriatric patients; product should be discontinued if these occur; serum creatinine/BUN at baseline and periodically during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3353">
								<item>
									<label>•</label>
									<para>Bronchial secretions, lung sounds, increase fluids to 2000 ml/day unless contraindicated to decrease thickness of secretions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3358">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3362">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of running or congested nose or rashes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3368">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3373">
								<item>
									<label>•</label>
									<para>About all aspects of product use; to notify prescriber if confusion, sedation, hypotension occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3378">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activity if drowsiness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3383">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3391">
							<label>•</label>
							<sec_title>
								<route>Not to exceed recommended dose; that dysrhythmias may occur</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="25" status="active">
			<mono_name>fidaxomicin</mono_name>
			<info>
				<pronunciation>(fye-dax′oh-mye′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x34040">Dificid</tradename>
				</tradenames>
				<class type="func"> Antiinfective-macrolide</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x3410">
				<sec_title>Action:</sec_title>
				<para>Bactericidal against <emphasis style="italic">Clostridium difficile;</emphasis> is a fermentation product obtained from <emphasis style="italic">Dactylosporangium aurantiacum;</emphasis> inhibits RNA synthesis by inhibiting transcription of bacterial RNA polymerases; may act at the early stages of transcription</para>
			</section>
			<section type="uses" id="sidelem4x3421">
				<sec_title>Uses:</sec_title>
				<para>Pseudomembraneous colitis <emphasis style="italic">Clostridium difficile</emphasis>-associated diarrhea</para>
			</section>
			<section type="contra" id="sidelem4x3429">
				<sec_title>Contraindications:</sec_title>
				<para>Hyper-sensitivity</para>
				<section type="none" id="sidelem4x3434">
					<section type="none" id="sidelem4x3435">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="B">B</preg>), breastfeeding, children</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3440">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3448">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3448">
							<item>
								<label>•</label>
								<para> 200 mg bid × 10 days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3452">
					<section type="none" id="sidelem4x3453">
						<sec_title>Available forms: </sec_title>
						<para>Tab 200 mg</para>
					</section>
					<section type="none" id="sidelem4x3458">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3462">
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3473">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3476">
					<section type="none" id="sidelem4x3477">
						<sec_title>GI: </sec_title>
						<para>Nausea, vomiting, abdominal pain, <emphasis style="bold">GI bleeding</emphasis>, intestinal obstruction</para>
					</section>
					<section type="none" id="sidelem4x3485">
						<sec_title>HEMA: </sec_title>
						<para>Anemia, <emphasis style="bold">neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3492">
						<sec_title>INTEG: </sec_title>
						<para>Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x3497">
						<sec_title>META: </sec_title>
						<para>
							<emphasis style="bold">Metabolic acidosis,</emphasis> hyperglycemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3504">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 12 hr, onset &lt;1 hr, peak 1-5 hr, excreted in feces 92%, minimal absorption, substrate of PGP efflux transporter</para>
			</section>
			<section type="interactions" id="sidelem4x3511">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> fidaxomicin action—cycloSPORINE</para>
				<section type="none" id="sidelem4x3518">
					<section type="none" id="sidelem4x3519">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> glucose, LFTs, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> sodium bicarbonate, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3530">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3533">
					<section type="none" id="sidelem4x3534">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3542">
							<label>•</label>
							<sec_title>Pseudomembraneous colitis<route> for diarrhea, abdominal pain, fever, fatigue, anorexia, anemia, elevated WBC and low serum albumin; product may be used in place of vancomycin; monitor CBC with differential and stool culture (</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3550">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3554">
								<item>
									<label>•</label>
									<para>Positive therapeutic response: resolution of <emphasis style="italic">Clostridium difficile</emphasis>, decreased diarrhea</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3563">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3567">
								<item>
									<label>•</label>
									<para>To report GI bleeding, severe abdominal pain</para>
								</item>
								<item>
									<label>•</label>
									<para>To report if pregnancy is planned or suspected or if breastfeeding</para>
								</item>
								<item>
									<label>•</label>
									<para>May take without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="26" status="active" ha="yes">
			<mono_name> filgrastim (Rx)</mono_name>
			<info>
				<pronunciation>(fill-grass′stim)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x35902">G-CSF</tradename>
					<tradename id="tnidelem4x35901">granulocyte colony stimulator</tradename>
					<tradename id="tnidelem4x35900">Neupogen</tradename>
				</tradenames>
				<class type="func"> Biologic modifier</class>
				<class type="chem"> Granulocyte colony-stimulating factor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3600">
				<sec_title>Action:</sec_title>
				<para>Stimulates proliferation and differentiation of neutrophils</para>
			</section>
			<section type="uses" id="sidelem4x3605">
				<sec_title>Uses:</sec_title>
				<para>To decrease infection in patients receiving antineoplastics that are myelosuppressive; to increase WBC in patients with product-induced neutropenia; bone marrow transplantation, acute radiation exposure</para>
				<section type="none" id="sidelem4x3610">
					<section type="none" id="sidelem4x3611">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Neutropenia with HIV infection, aplastic anemia, ganciclovir-induced neutropenia, zidovudine-induced neutropenia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3616">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to proteins of <emphasis style="italic">Escherichia coli</emphasis></para>
				<section type="none" id="sidelem4x3623">
					<section type="none" id="sidelem4x3624">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, myeloid malignancies, radiation therapy, sepsis, sickle cell disease, chemotherapy, respiratory disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3629">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3632">
					<section type="none" id="sidelem4x3633">
						<sec_title>After myelosuppressive chemotherapy</sec_title>
						<section type="none" id="sidelem4x3641">
							<label>•</label>
							<sec_title>Adult and child<route> IV/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3641">
									<item>
										<label>•</label>
										<para> 5 mcg/kg/day in a single dose × up to 14 days; may increase by 5 mcg/kg with each cycle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3645">
						<sec_title>After myelosuppressive doses of radiation</sec_title>
						<section type="none" id="sidelem4x3653">
							<label>•</label>
							<sec_title>Adult and child &gt;7 mo<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3653">
									<item>
										<label>•</label>
										<para> 10 mcg/kg/day, start as soon as possible after receiving ≥2 Gy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3657">
						<sec_title>After bone marrow transplantation</sec_title>
						<section type="none" id="sidelem4x3665">
							<label>•</label>
							<sec_title>Adult<route> IV/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3665">
									<item>
										<label>•</label>
										<para> 10 mcg/kg/day as  over 4 hr or 24 hr, begin 24 hr after chemotherapy and 24 hr after bone marrow transplantation</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3672">
						<sec_title>Peripheral blood progenitor cell collection/therapy</sec_title>
						<section type="none" id="sidelem4x3680">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x3680">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 10 mcg/kg/day as bolus or  × ≥4 days before leukapheresis, continue to last leukapheresis; may alter dose if WBC &gt;100,000 cells/mm<emphasis style="sup">3</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3689">
						<sec_title>Severe neutropenia (chronic), idiopathic/cyclical</sec_title>
						<section type="none" id="sidelem4x3697">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3697">
									<item>
										<label>•</label>
										<para> 5 mcg/kg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3701">
						<sec_title>Available forms: </sec_title>
						<para>Inj 300 mcg/ml, 480 mcg/1.6 ml, 480 mcg/0.8 ml</para>
					</section>
					<section type="none" id="sidelem4x3706">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3710">
								<item>
									<label>•</label>
									<para>Given by subcut inj, short IV infusion, or continuous SC or IV infusion</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid use within 24 hr before or after chemotherapy</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not shake commercial single-dose vials before withdrawing the dose; if the vial is shaken and froth or bubbles form, allow the vial to stand undisturbed for a few minutes until the froth or bubbles dissipate</para>
								</item>
								<item>
									<label>•</label>
									<para>Before injection, filgrastim may be allowed to reach room temperature for a maximum of 24 hr; any vial or syringe exposed to room temperature for more than 24 hr should be discarded</para>
								</item>
								<item>
									<label>•</label>
									<para>Visually inspect for particulate matter and discoloration before use</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in refrigerator; do not freeze; may store at room temperature up to 24 hr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3743">
							<sec_title>SUBCUT route</sec_title>
							<section type="none" id="sidelem4x3751">
								<label>•</label>
								<sec_title>Subcut inj</sec_title>
								<para>
									<list id="lidelem4x3751">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Subcut inj:</emphasis> no dilution is necessary; inject by rapid subcut inj, taking care not to inject intradermally</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x3758">
								<label>•</label>
								<sec_title>Subcut continuous infusion</sec_title>
								<para>
									<list id="lidelem4x3758">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Subcut continuous infusion:</emphasis> infuse subcut at a rate not to exceed 2 ml/hr</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x3762">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x3767">
									<item>
										<label>•</label>
										<para>May be diluted with 5% dextrose; do not dilute with NS; product can precipitate</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x3772">
									<item>
										<label>•</label>
										<para>May be diluted to concentrations 5-15 mcg/ml; should be protected from adsorption to plastic by the addition of albumin to a final albumin concentration of 2 mg/ml; do not dilute filgrastim to a concentration &lt;5 mcg/ml</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x3780">
								<label>•</label>
								<sec_title>IV infusion</sec_title>
								<para>
									<list id="lidelem4x3780">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">IV infusion:</emphasis> infuse IV over 15-30 min or as a continuous infusion over 24 hr</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, allopurinol, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, CARBOplatin, carmustine, ceFAZolin, cefoTEtan, cefTAZidime, chlorproMAZINE, cimetidine, CISplatin, cyclophosphamide, cytarabine, dacarbazine, DAUNOrubicin, dexamethasone, diphenhydrAMINE, DOXOrubicin, doxycycline, droperidol, enalaprilat, famotidine, floxuridine, fluconazole, fludarabine, gallium, ganciclovir, granisetron, haloperidol, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, leucovorin, LORazepam, mechlorethamine, melphalan, meperidine, mesna, methotrexate, metoclopramide, miconazole, minocycline, mitoXANtrone, morphine, nalbuphine, netilmicin, ondansetron, plicamycin, potassium chloride, promethazine, ranitidine, sodium bicarbonate, streptozocin, ticarcillin, ticarcillin/clavulanate, tobramycin, trimethoprim-sulfamethoxazole, vancomycin, vinBLAStine, vinCRIStine, vinorelbine, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3788">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3791">
					<section type="none" id="sidelem4x3792">
						<sec_title>CNS: </sec_title>
						<para>Fever, headache</para>
					</section>
					<section type="none" id="sidelem4x3797">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, mucositis, anorexia</para>
					</section>
					<section type="none" id="sidelem4x3804">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis style="bold">Thrombocytopenia,</emphasis> excessive leukocytosis</para>
					</section>
					<section type="none" id="sidelem4x3811">
						<sec_title>INTEG: </sec_title>
						<para>Alopecia, exacerbation of skin conditions, urticaria, cutaneous vasculitis, <emphasis style="bold">allergic reactions</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3818">
						<sec_title>MS: </sec_title>
						<para>Osteoporosis, skeletal pain</para>
					</section>
					<section type="none" id="sidelem4x3823">
						<sec_title>OTHER: </sec_title>
						<para>Chest pain, hypotension</para>
					</section>
					<section type="none" id="sidelem4x3828">
						<sec_title>RESP: </sec_title>
						<para>
							<emphasis style="bold">Acute respiratory distress syndrome,</emphasis> wheezing, <emphasis style="bold">alveolar hemorrhage</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3837">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x3840">
					<section type="none" id="sidelem4x3841">
						<sec_title>SUBCUT: </sec_title>
						<para>Onset 5-60 min, peak 2-8 hr, duration up to 1 wk</para>
					</section>
					<section type="none" id="sidelem4x3846">
						<sec_title>IV: </sec_title>
						<para>Onset 5-60 min, peak 24 hr, duration up to 1 wk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x3851">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions—do not use this product concomitantly with antineoplastics, lithium</para>
				<section type="none" id="sidelem4x3858">
					<section type="none" id="sidelem4x3859">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid, LDH, alk phos, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3866">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3869">
					<section type="none" id="sidelem4x3870">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3875">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, platelet count before treatment and twice weekly; neutrophil counts drop by 50% if filgrastim is discontinued the next day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3880">
								<item>
									<label>•</label>
									<para>B/P, respirations, pulse before and during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3885">
								<item>
									<label>•</label>
									<para>Bone pain; give mild analgesics</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3890">
								<item>
									<label>•</label>
									<para>CBC with differential, platelets</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3899">
							<label>•</label>
							<sec_title>Respiratory distress syndrome<route> fever, dyspnea; withhold product if these occur</route></sec_title>
						</section>
						<section type="none" id="sidelem4x3905">
							<label>•</label>
							<sec_title>Allergic reactions<route> rash, wheezing, facial edema, dyspnea, may occur within 30 min of use, give antihistamines, bronchodilators and epinephrine if needed</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3908">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3912">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3918">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3922">
								<item>
									<label>•</label>
									<para>About the technique for self-administration: dose, side effects, disposal of containers and needles; provide instruction sheet</para>
								</item>
								<item>
									<label>•</label>
									<para>That bone pain is common</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="27" status="active">
			<mono_name>finasteride (Rx)</mono_name>
			<info>
				<pronunciation>(fin-ass′te-ride)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x39381">Propecia</tradename>
					<tradename id="tnidelem4x39380">Proscar</tradename>
				</tradenames>
				<class type="func"> Hormone, androgen inhibitor, hair stimulant</class>
				<class type="chem"> 5-α-Reductase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3948">
				<para>
					<confusion>
						<tradename id="tnidelem4x39480">finasteride</tradename>
						<drug type="generic" refid="idelem4x39480">furosemide</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3955">
				<sec_title>Action:</sec_title>
				<para>Inhibits 5-α-reductase and reduction in DHT; DHT induces androgenic effects by binding to androgen receptors in the cell nuclei of the prostate gland, liver, skin; prevents development of BHP</para>
			</section>
			<section type="uses" id="sidelem4x3960">
				<sec_title>Uses:</sec_title>
				<para>Symptomatic benign prostatic hyperplasia (Proscar); male-pattern baldness (Propecia)</para>
				<section type="none" id="sidelem4x3965">
					<section type="none" id="sidelem4x3966">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Hirsutism, prostate cancer prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3971">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, children, women who are pregnant or who may become pregnant should not handle tabs, hypersensitivity</para>
				<section type="none" id="sidelem4x3976">
					<section type="none" id="sidelem4x3977">
						<sec_title>Precautions: </sec_title>
						<para>Large residual urinary volume, severely diminished urinary flow, hepatic function abnormalities</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3982">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3985">
					<section type="none" id="sidelem4x3986">
						<sec_title>BPH</sec_title>
						<section type="none" id="sidelem4x3994">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3994">
									<item>
										<label>•</label>
										<para> 5 mg/day × 6-12 mo (Proscar)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3998">
						<sec_title>Male-pattern baldness</sec_title>
						<section type="none" id="sidelem4x4006">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4006">
									<item>
										<label>•</label>
										<para> 1 mg/day for 3 mo or more for results (Propecia)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4010">
						<sec_title>Hirsutism (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4018">
							<label>•</label>
							<sec_title>Adult (nonpregnant)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4018">
									<item>
										<label>•</label>
										<para> 5 mg/day alone or in combination with oral contraceptives</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4022">
						<sec_title>Available forms: </sec_title>
						<para>Tabs (Propecia) 1 mg, (Proscar) 5 mg</para>
					</section>
					<section type="none" id="sidelem4x4027">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4031">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>For a minimum of 6 mo; not all patients will respond</para>
								</item>
								<item>
									<label>•</label>
									<para>Store &lt;86° F (30° C); protect from light; keep container tightly closed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4047">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4050">
					<section type="none" id="sidelem4x4051">
						<sec_title>GU: </sec_title>
						<para>Impotence, decreased libido, decreased volume of ejaculate, sexual dysfunction</para>
					</section>
					<section type="none" id="sidelem4x4056">
						<sec_title>INTEG: </sec_title>
						<para>Rash</para>
					</section>
					<section type="none" id="sidelem4x4061">
						<sec_title>MISC: </sec_title>
						<para>Breast tenderness, <emphasis style="bold">secondary malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4068">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability 63%; readily absorbed from GI tract; plasma protein binding 90%; metabolized in the liver; excreted in urine (metabolites) 39%, feces (57%); crosses blood-brain barrier; peak 1-2 hr; duration 24 hr</para>
			</section>
			<section type="interactions" id="sidelem4x4073">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x4076">
					<section type="none" id="sidelem4x4077">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> PSA levels</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4084">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4087">
					<section type="none" id="sidelem4x4088">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4096">
							<label>•</label>
							<sec_title>BPH</sec_title>
							<para>
								<list id="lidelem4x4096">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">BPH:</emphasis> urinary patterns, residual urinary volume, severely diminished urinary flow</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4100">
								<item>
									<label>•</label>
									<para>PSA levels and digital rectal exam before initiating therapy and periodically thereafter, PSA levels may be altered by this product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4105">
								<item>
									<label>•</label>
									<para>Hepatic studies before treatment; extensively metabolized in liver</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4110">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4114">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased urinary flow; decreased postvoiding dribbling, frequency, nocturia or hair growth within 3-6 mo; regression of prostate size</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4121">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4127">
								<item>
									<para>
										<emphasis alert="nurse">That pregnant women or women who may become pregnant should not touch crushed tabs or come into contact with the semen of a patient taking this product; that product may adversely affect developing male fetus</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4132">
								<item>
									<label>•</label>
									<para>That volume of ejaculate may be decreased during treatment; that impotence and decreased libido may also occur and may continue after discontinuing treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4137">
								<item>
									<label>•</label>
									<para>That Propecia results may not occur for 3 mo</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4142">
								<item>
									<label>•</label>
									<para>That Proscar results may not occur for 6-12 mo</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="28" status="active">
			<mono_name>fingolimod (Rx)</mono_name>
			<info>
				<pronunciation>(fin-gol′i-mod)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x41520">Gilenya</tradename>
				</tradenames>
				<class type="func"> Biologic response modifier</class>
				<class type="chem"> Sphingosine 1-phosphate receptor modulator</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4162">
				<sec_title>Action:</sec_title>
				<para>Binds with high affinity to sphingosine 1-phosphate receptors; blocks lymphocyte egress to lymph nodes, thereby reducing the number of peripheral blood lymphocytes; may reduce lymphocyte migration into the CNS</para>
			</section>
			<section type="uses" id="sidelem4x4167">
				<sec_title>Uses:</sec_title>
				<para>To reduce frequency of exacerbation, to delay physical disability of relapsing forms of MS</para>
			</section>
			<section type="contra" id="sidelem4x4172">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x4177">
					<section type="none" id="sidelem4x4178">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, neonates/infants/children, AIDS, asthma, AV block, bradycardia, cardiac disease, COPD, diabetes mellitus, dysrhythmias, heart failure, hepatic disease, HIV, hypertension, immunosuppression, leukemia, lymphoma, QT prolongation, respiratory insufficiency, sick sinus syndrome, syncope, uveitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4183">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4191">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4191">
							<item>
								<label>•</label>
								<para> 0.5 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4195">
					<section type="none" id="sidelem4x4196">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x4204">
							<label>•</label>
							<sec_title>Adult<route> PO Child-Pugh C, total score &gt;10</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4207">
						<sec_title>Available forms: </sec_title>
						<para>Caps 0.5 mg</para>
					</section>
					<section type="none" id="sidelem4x4212">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4215">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x4219">
									<item>
										<label>•</label>
										<para>Watch patient for 6 hr after initial dose or if product not given for &gt;2 wk for development of bradycardia</para>
									</item>
									<item>
										<label>•</label>
										<para>Give without regard to food</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature, protect from moisture</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4235">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4238">
					<section type="none" id="sidelem4x4239">
						<sec_title>CNS: </sec_title>
						<para>Asthenia, depression, fatigue, headache, dizziness, <emphasis style="bold">progressive multifocal leukoencephalopathy,</emphasis> migraine, paresthesias, <emphasis style="bold">stroke</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4249">
						<sec_title>CV: </sec_title>
						<para>
							<emphasis style="bold">AV block, bradycardia</emphasis>, chest pain, hypertension, palpitations, <emphasis style="bold">QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4258">
						<sec_title>EENT: </sec_title>
						<para>Blurred vision, vision impairment, ocular pain, macular edema</para>
					</section>
					<section type="none" id="sidelem4x4263">
						<sec_title>GI: </sec_title>
						<para>Abdominal pain, anorexia, diarrhea, jaundice, vomiting, weight loss</para>
					</section>
					<section type="none" id="sidelem4x4268">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Leukopenia, lymphopenia, neutropenia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x4274">
						<sec_title>INTEG: </sec_title>
						<para>Alopecia, pruritus</para>
					</section>
					<section type="none" id="sidelem4x4279">
						<sec_title>MS: </sec_title>
						<para>Back pain</para>
					</section>
					<section type="none" id="sidelem4x4284">
						<sec_title>RESP: </sec_title>
						<para>Dyspnea, cough</para>
					</section>
					<section type="none" id="sidelem4x4289">
						<sec_title>SYST: </sec_title>
						<para>Infection, influenza, <emphasis style="bold">secondary malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4296">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding (99.7%), distributed to RBCs (86%), steady state 1-2 mo, metabolized by CYP4F2 and CYP2D6 to a lesser extent, terminal half-life 6-9 days, excreted in urine (81% inactive metabolites), peak 12-16 hr</para>
			</section>
			<section type="interactions" id="sidelem4x4301">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> risk of heart block, serious bradycardia—β-blockers, calcium channel blockers, digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> immunosuppression—antineoplastics, immunosuppressants, immune-modulating therapies</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> fingolimod effect—ketoconazole</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> infection risk—live vaccines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—inactive vaccines, toxoids</para>
				<para>
					<emphasis alert="lifethreat">Increase: risk of torsades de pointes—Class Ia/III antidysrhythmics</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x4328">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4331">
					<section type="none" id="sidelem4x4332">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4340">
							<label>•</label>
							<sec_title>Multiple sclerosis</sec_title>
							<para>
								<list id="lidelem4x4340">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Multiple sclerosis:</emphasis> improving paresthesia, muscle weakness, clonus, muscle spasms, difficulty with moving, difficulty with coordination of balance, speech, swallowing, vision problems, fatigue; prevention of increasing disability</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4347">
							<label>•</label>
							<sec_title>Laboratory monitoring<route> obtain before initial dose; CBC, LFTs, serum bilirubin, ophthalmologic exam, antibodies to VZV; if there is no history of chickenpox or no vaccination, may give VZV vaccination to antibody-negative patient before giving product, postpone for 1 mo after vaccination; obtain ECG for evidence of bradycardia, AV block</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4353">
							<label>•</label>
							<sec_title>Progressive multifocal leukoencephalopathy (PML)<route> confusion, apathy, dizziness, unstable gait; may be fatal, discontinue product, contact prescriber</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4359">
							<label>•</label>
							<sec_title>Bradycardia<route> monitor for ≥6 hr after beginning dose, ECG before and after 1st dose, if heart rate &lt;45 bpm or new heart block (2nd degree) occurs, do not use until resolved</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4365">
							<label>•</label>
							<sec_title>
								<route>Monitor for QT prolongation</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4368">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4372">
								<item>
									<label>•</label>
									<para>Therapeutic response: improved symptoms of multiple sclerosis and prevention of increasing disability</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4378">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4382">
								<item>
									<label>•</label>
									<para>About use of product and expected results; provide med guide to patient</para>
								</item>
								<item>
									<label>•</label>
									<para>That continuing follow-up exams and laboratory tests will be required on a regular basis</para>
								</item>
								<item>
									<label>•</label>
									<para>To use contraception during and for 2 mo after conclusion of treatment</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis alert="lifethreat">Liver dysfunction: report jaundice, nausea, vomiting, anorexia, abdominal pain, fatigue, dark urine red</emphasis>
						</para>
						<para>
							<emphasis alert="lifethreat">Cardiac changes: chest pain, palpitations</emphasis>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="29" status="active">
			<mono_name>flecainide (Rx)</mono_name>
			<info>
				<pronunciation>(flek-ay′nide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x44090"/>
				</tradenames>
				<class type="func"> Antidysrhythmic (Class IC)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4417">
				<sec_title>Action:</sec_title>
				<para>Decreases conduction in all parts of the heart, with greatest effect on the His-Purkinje system, which stabilizes cardiac membrane</para>
			</section>
			<section type="uses" id="sidelem4x4422">
				<sec_title>Uses:</sec_title>
				<para>Life-threatening ventricular dysrhythmias, sustained ventricular tachycardia, supraventricular tachydysrhythmias, paroxysmal atrial fibrillation/flutter associated with disabling symptoms</para>
				<section type="none" id="sidelem4x4427">
					<section type="none" id="sidelem4x4428">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Atrial fibrillation, single dose</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4433">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, AV bundle branch block, cardiogenic shock</para>
				<section type="none" id="sidelem4x4438">
					<section type="none" id="sidelem4x4439">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, renal/hepatic disease, CHF, respiratory depression, myasthenia gravis, electrolyte abnormalities, atrial fibrillation, sick sinus syndrome, torsades de pointes, MI, bundle branch block, QT prolongation</para>
						<para>
							<bbw>Cardiac arrhythmias, atrial fibrillation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4454">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4457">
					<section type="none" id="sidelem4x4458">
						<sec_title>PSVT/PAT</sec_title>
						<section type="none" id="sidelem4x4466">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4466">
									<item>
										<label>•</label>
										<para> 50 mg q12hr; may increase q4days by 50 mg q12hr to desired response, max 300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4470">
						<sec_title>Life-threatening ventricular dysrhythmias</sec_title>
						<section type="none" id="sidelem4x4478">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4478">
									<item>
										<label>•</label>
										<para> 100 mg q12hr; may increase by 50 mg q12hr q4days, max 400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4482">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x4490">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;35 ml/min, 100 mg daily or 50 mg bid initially</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4493">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 50, 100, 150 mg</para>
					</section>
					<section type="none" id="sidelem4x4499">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4502">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x4506">
									<item>
										<label>•</label>
										<para>Reduced dosage as soon as dysrhythmia is controlled</para>
									</item>
									<item>
										<label>•</label>
										<para>May give with meals for GI upset</para>
									</item>
									<item>
										<label>•</label>
										<para>May adjust dose q4days</para>
									</item>
									<item>
										<label>•</label>
										<para>Therapeutic trough serum concentrations for adults range from 200 to 1000 ng/ml (average, 500 ng/ml); toxicity is more common with trough serum concentrations &gt;1000 ng/mL; usual therapeutic range in children is 200-500 ng/mL; in some cases, up to 800 ng/mL is required</para>
									</item>
									<item>
										<label>•</label>
										<para>Adjust dosage at intervals of ≥4 days (approximate plateau effects) following dosage adjustments; however, longer intervals are needed in patients with renal or hepatic impairment</para>
									</item>
									<item>
										<label>•</label>
										<para>Frequent serum drug concentration monitoring is required for patients with severe renal (CrCl &lt;35 ml/min) or hepatic disease and may also be helpful in patients with CHF or in patients with moderate renal disease</para>
									</item>
									<item>
										<label>•</label>
										<para>Monitoring of flecainide serum concentrations is strongly recommended in patients receiving amiodarone therapy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4542">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4545">
					<section type="none" id="sidelem4x4546">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Headache, dizziness,</emphasis> involuntary movement, confusion, psychosis, restlessness, irritability, paresthesias, ataxia, flushing, somnolence, depression, anxiety, malaise, fatigue, asthenia, tremors</para>
					</section>
					<section type="none" id="sidelem4x4553">
						<sec_title>CV: </sec_title>
						<para>
							<emphasis style="italic">Hypotension, bradycardia,</emphasis> angina, PVCs, <emphasis style="bold">heart block, cardiovascular collapse, arrest,</emphasis> dysrhythmias, <emphasis style="bold">CHF, fatal ventricular tachycardia,</emphasis> palpitations, <emphasis style="bold">QT prolongation, torsades de pointes</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4568">
						<sec_title>EENT: </sec_title>
						<para>Tinnitus, <emphasis style="italic">blurred vision,</emphasis> hearing loss, corneal deposits, dry eyes</para>
					</section>
					<section type="none" id="sidelem4x4576">
						<sec_title>GI: </sec_title>
						<para>Nausea, vomiting, anorexia, constipation, abdominal pain, flatulence, change in taste, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x4581">
						<sec_title>GU: </sec_title>
						<para>Impotence, decreased libido, polyuria, urinary retention</para>
					</section>
					<section type="none" id="sidelem4x4586">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Leukopenia, thrombocytopenia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x4592">
						<sec_title>INTEG: </sec_title>
						<para>Rash, urticaria, edema, swelling</para>
					</section>
					<section type="none" id="sidelem4x4597">
						<sec_title>RESP: </sec_title>
						<para>Dyspnea, <emphasis style="bold">respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4604">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 3 hr, half-life 12-27 hr, metabolized by liver, excreted unchanged by kidneys (10%), excreted in breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x4609">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl; CYP3A4 substrates (methadone, pimozide, quetiapine, quinidine, risperidone, ziprasidone)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> of both products—propranolol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CV depressant action—β-blockers, disopyramide, verapamil</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> flecainide level—amiodarone, cimetidine, ritonavir</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> digoxin level—digoxin</para>
				<para>
					<emphasis style="bold">Increase or decrease:</emphasis> effect—urinary, alkalinizing agents, acidifying agents</para>
				<section type="none" id="sidelem4x4635">
					<section type="none" id="sidelem4x4636">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x4640">
								<item>
									<label>•</label>
									<para>Do not use with hawthorn</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4646">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CPK</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4653">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4656">
					<section type="none" id="sidelem4x4657">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">CHF, cardiogenic shock:</emphasis> should not be used in these conditions</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Atrial fibrillation:</emphasis> avoid use, risk of ventricular dysrhythmias</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Cardiac dysrhythmias:</emphasis> discontinue in those with prolonged QRS &gt;180 ms or prolonged PR &gt;300 ms, monitor for QT prolongation, monitor ECG before and during treatment</bbw>
						</para>
						<section type="none" id="sidelem4x4701">
							<label>•</label>
							<sec_title>Electrolyte imbalances</sec_title>
							<para>
								<list id="lidelem4x4701">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Electrolyte imbalances:</emphasis> hypo/hyperkalemia before administration; correct electrolytes before use</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4705">
								<item>
									<label>•</label>
									<para>CNS effects: dizziness, confusion, psychosis, paresthesias, seizures; product should be discontinued</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4714">
							<label>•</label>
							<sec_title>Flecainide level</sec_title>
							<para>
								<list id="lidelem4x4714">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Flecainide level:</emphasis> Monitor level in those with CHF or renal failure; peak, trough</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4718">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4722">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased dysrhythmias</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4728">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4732">
								<item>
									<label>•</label>
									<para>To change position slowly from lying or sitting to standing to minimize orthostatic hypotension</para>
								</item>
								<item>
									<label>•</label>
									<para>To take as prescribed; not to skip or double dose, take missed dose as soon as remembered (within 6 hr) of next dose</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities that require alertness until response is known</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID with disorder, medications taken</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify all health care providers of treatment, that follow-up will be needed</para>
								</item>
								<item>
									<label>•</label>
									<para>To report new or worsening cardiac symptoms (chest pain, trouble breathing, sweating)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="30" status="active">
			<mono_name>fluconazole (Rx)</mono_name>
			<info>
				<pronunciation>(floo-kon′a-zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x47760">Diflucan</tradename>
				</tradenames>
				<class type="func"> Antifungal, systemic; azole</class>
			</info>
			<section type="confusion" id="sidelem4x4786">
				<para>
					<confusion>
						<tradename id="tnidelem4x47860">Diflucan</tradename>
						<drug type="generic" refid="idelem4x47860">Diprivan</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4790">
				<sec_title>Action:</sec_title>
				<para>Inhibits ergosterol biosynthesis, causes direct damage to fungal membrane phospholipids</para>
			</section>
			<section type="uses" id="sidelem4x4795">
				<sec_title>Uses:</sec_title>
				<para>Oropharyngeal candidiasis, chronic mucocutaneous candidiasis; systemic, vaginal, urinary candidiasis; cryptococcal meningitis; prevention of candidiasis in bone marrow transplant in those who receive chemotherapy and/or radiation therapy; cystitis, fungal prophylaxis, peritonitis, pneumonia, pyelonephritis</para>
				<section type="none" id="sidelem4x4800">
					<section type="none" id="sidelem4x4801">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Prophylaxis, systemic candidiasis in very-low-birthweight premature infants, blastomycosis, chemotherapy-induced neutropenia, coccidioidomycosis cryptococcosis prophylaxis, endocarditis, endophthalmitis, histoplasmosis infectious arthritis, myocarditis, osteomyelitis, pericarditis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4806">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or azoles, pregnancy (D)</para>
				<section type="none" id="sidelem4x4811">
					<section type="none" id="sidelem4x4812">
						<sec_title>Precautions: </sec_title>
						<para>Breastfeeding, renal/hepatic disease, torsades de pointes</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4817">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4820">
					<section type="none" id="sidelem4x4821">
						<sec_title>Vulvovaginal candidiasis</sec_title>
						<section type="none" id="sidelem4x4829">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4829">
									<item>
										<label>•</label>
										<para> 150 mg as a single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4833">
						<sec_title>Serious fungal infections</sec_title>
						<section type="none" id="sidelem4x4841">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x4841">
									<item>
										<label>•</label>
										<para> 50-400 mg initially, then 200 mg/day for 4 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4848">
							<label>•</label>
							<sec_title>Child</sec_title>
							<para>
								<list id="lidelem4x4848">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child:</emphasis> 6-12 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4852">
						<sec_title>Oropharyngeal candidiasis</sec_title>
						<section type="none" id="sidelem4x4860">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x4860">
									<item>
										<label>•</label>
										<para> 200 mg initially, then 100 mg/day for ≥2 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4867">
							<label>•</label>
							<sec_title>Child<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x4867">
									<item>
										<label>•</label>
										<para> 6 mg/kg initially, then 3 mg/kg/day for ≥2 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4871">
						<sec_title>Esophageal candidiasis</sec_title>
						<section type="none" id="sidelem4x4879">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x4879">
									<item>
										<label>•</label>
										<para> 200 mg on 1st day, then 100 mg daily × ≥3 wk and for ≥2 wk after resolution of symptoms</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4886">
							<label>•</label>
							<sec_title>Child<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x4886">
									<item>
										<label>•</label>
										<para> 6 mg/kg on 1st day, then 3 mg/kg × ≥3 wk and for ≥2 wk after resolution of symptoms</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4890">
						<sec_title>Cryptococcal meningitis</sec_title>
						<section type="none" id="sidelem4x4898">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x4898">
									<item>
										<label>•</label>
										<para> 400 mg on 1st day, then 200 mg daily × 10-12 wk after CSF culture negative</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4905">
							<label>•</label>
							<sec_title>Child/infants/neonates ≥14 days<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x4905">
									<item>
										<label>•</label>
										<para> 12 mg/kg on 1st day, then 6-12 mg/kg daily × 10-12 wk after CSF culture negative, max 600 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4912">
							<label>•</label>
							<sec_title>Neonates 0-14 days<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x4912">
									<item>
										<label>•</label>
										<para> 12 mg/kg on 1st day, then 6-12 mg/kg q72hr × 10-12 wk after CSF culture negative</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4916">
						<sec_title>Prevention of candidiasis in bone marrow transplant</sec_title>
						<section type="none" id="sidelem4x4924">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x4924">
									<item>
										<label>•</label>
										<para> 400 mg/day, those anticipated to have neutrophils &lt;500/mm<emphasis style="sup">3</emphasis>, start several days before anticipated onset of neutropenia and continue for 7 days after rise of neutrophils &gt;1000/mm<emphasis style="sup">3</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4934">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x4942">
							<label>•</label>
							<sec_title>Adult<route> PO/IV CCr ≤50 ml/min, after loading dose, give 50% of usual dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4945">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 50, 100, 150, 200 mg; inj 2 mg/ml; powder for oral susp 10 mg/ml, 40 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x4950">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4953">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x4957">
									<item>
										<label>•</label>
										<para>Tap bottle to loosen powder, add water in 2 portions, review manufacturer reconstitution instructions</para>
									</item>
									<item>
										<label>•</label>
										<para>Shake oral susp before each use, use within 2 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4968">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x4972">
									<item>
										<label>•</label>
										<para>After diluting according to package directions; run at ≤200 mg/hr; do not use plastic containers in connections; check for bag leaks</para>
									</item>
									<item>
										<label>•</label>
										<para>Use infusion pump; check for extravasation and necrosis q2hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use if cloudy or precipitated</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not admix; do not refrigerate</para>
									</item>
									<item>
										<label>•</label>
										<para>Store protected from moisture and light; diluted sol stable 24 hr; do not freeze</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, aldesleukin, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, anidulafungin, ascorbic acid injection, atenolol, atracurium, atropine, azaTHIOprine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride, CARBOplatin, caspofungin, ceFAZolin, cefepime, cefmetazole, cefonicid, cefoTEtan, cefOXitin, cefpirome, cefTAZidime, ceftizoxime, ceftobiprole, cephalothin, cephapirin, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, diltiazem, dimenhyDRINATE, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, drotrecogin alfa, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fludarabine, fluorouracil, folic acid, foscarnet, gallium, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, IV immune globulin, inamrinone, indomethacin, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, lansoprazole, leucovorin, levofloxacin, lidocaine, linezolid, LORazepam, LR, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, multiple vitamins injection, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, phenytoin, phytonadione, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, Ringer’s, ritodrine, riTUXimab, rocuronium, sargramostim, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, temocillin, teniposide, theophylline, thiotepa, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5003">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5006">
					<section type="none" id="sidelem4x5007">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Headache,</emphasis>
							<emphasis alert="lifethreat">seizures</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x5015">
						<sec_title>CV: </sec_title>
						<para>
							<emphasis alert="lifethreat">QT prolongation, torsades de pointes</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x5021">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea, vomiting,</emphasis> diarrhea, cramping, flatus, increased AST, ALT, <emphasis style="bold">hepatotoxicity</emphasis>, abdominal pain, cholestasis</para>
					</section>
					<section type="none" id="sidelem4x5031">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Agranulocytosis, eosinophilia, leukopenia, neutropenia, thrombocytopenia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x5037">
						<sec_title>INTEG: </sec_title>
						<para>
							<emphasis alert="lifethreat">Stevens-Johnson syndrome, angioedema, anaphylaxis, exfoliative dermatitis, toxic epidermal necrolysis</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5043">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-2 hr, bioavailability (PO) &gt;90%, excreted unchanged in urine 80%, metabolized by CYP3A enzyme system at dose &gt;200 mg/day, elimination half-life 30 hr</para>
			</section>
			<section type="interactions" id="sidelem4x5048">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—oral sulfonyl/ureas (glipiZIDE)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulation—warfarin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentrations—cycloSPORINE, phenytoin, theophylline, rifabutin, tacrolimus, sirolimus, zidovudine, zolpidem</para>
				<para>
					<emphasis alert="lifethreat">Increase: myopathy, rhabdomyolysis risk—HMG-CoA reductase inhibitors: lovastatin, simvastatin</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of zidovudine, methadone, SUFentanil, alfentanil, buprenorphine, saquinavir, fentaNYL, ergots</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of oral contraceptives, calcium channel blockers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> fluconazole effect—proton pump inhibitors</para>
				<section type="none" id="sidelem4x5078">
					<section type="none" id="sidelem4x5079">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> alk phos, LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5090">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5093">
					<section type="none" id="sidelem4x5094">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5102">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x5102">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> clearing of CSF and other culture during treatment, obtain C&amp;S baseline and throughout treatment, product may be started as soon as culture is taken</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5107">
								<item>
									<para>
										<emphasis alert="nurse">Hepatotoxicity: increasing AST, ALT, periodically alk phos, bilirubin; for renal status: BUN, creatinine</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5115">
							<label>•</label>
							<sec_title>Skin symptoms<route> color, lesions, inj-site reactions; if lesions progress, stop product</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5118">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5122">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing oral candidiasis, fever, malaise, rash; negative C&amp;S for infection organism</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5128">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5133">
								<item>
									<label>•</label>
									<para>That long-term therapy may be needed to clear infection, not to add new meds, herbs without prescriber approval</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5138">
								<item>
									<label>•</label>
									<para>That medication may be taken with food to reduce GI effects</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5146">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of nausea, vomiting, diarrhea, jaundice, anorexia, clay-colored stools, dark urine, skin rash, abdominal pain, fever, bruising, bleeding</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x5152">
							<label>•</label>
							<sec_title>
								<route>To use alternative method of contraception while taking this product, pregnancy (D)</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active" ha="yes">
			<mono_name> fludarabine (Rx)</mono_name>
			<info>
				<pronunciation>(floo-dar′a-been)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x51621">Fludara</tradename>
					<tradename id="tnidelem4x51620">Oforta</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, antimetabolite</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="uses" id="sidelem4x5168">
				<sec_title>Uses:</sec_title>
				<para>Chronic lymphocytic leukemia</para>
			</section>
			<section type="contra" id="sidelem4x5173">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity</para>
				<para>
					<bbw>Hemolytic anemia, bone marrow suppression, coma, seizures, visual disturbances</bbw>
				</para>
			</section>
			<section type="doses" id="sidelem4x5188">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5196">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x5196">
							<item>
								<label>•</label>
								<para> 25 mg/m<emphasis style="sup">2</emphasis> over 30 min × 5 days, may repeat q28days; reconstitute with 2 ml of sterile water for inj; dissolution should occur in &lt;15 sec, adjust dose based on toxicity;  40 mg/m<emphasis style="sup">2</emphasis> × 5 days q28days</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="32" status="active">
			<mono_name>fludrocortisone (Rx)</mono_name>
			<info>
				<pronunciation>(floo-droe-kor′ti-sone)</pronunciation>
				<class type="func"> Corticosteroid, synthetic</class>
				<class type="chem"> Mineralocorticoid</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="uses" id="sidelem4x5223">
				<sec_title>Uses:</sec_title>
				<para>Adrenal insufficiency, salt-losing adrenogenital syndrome, Addison’s disease</para>
				<section type="none" id="sidelem4x5228">
					<section type="none" id="sidelem4x5229">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Renal tubular acidosis (type IV), idiopathic orthostatic hypotension</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5234">
				<sec_title>Contraindications:</sec_title>
				<para>Children &lt;2 yr, hypersensitivity</para>
				<section type="none" id="sidelem4x5239">
					<section type="none" id="sidelem4x5240">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &gt;2 yr, osteoporosis, CHF, hypertension, diabetes, acute glomerulonephritis, amebiasis, psychoses, Cushing syndrome, fungal infections</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5245">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5253">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5253">
							<item>
								<label>•</label>
								<para> 100-200 mcg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5260">
					<label>•</label>
					<sec_title>Child<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5260">
							<item>
								<label>•</label>
								<para> 50-100 mcg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5264">
					<section type="none" id="sidelem4x5265">
						<sec_title>Idiopathic hypotension (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5273">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5273">
									<item>
										<label>•</label>
										<para> 50-200 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5277">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 100 mcg (0.1 mg)</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5282">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5285">
					<section type="none" id="sidelem4x5286">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Flushing, sweating,</emphasis> headache, paralysis, dizziness, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5295">
						<sec_title>CV: </sec_title>
						<para>
							<emphasis style="italic">Hypertension,</emphasis>
							<emphasis style="bold">circulatory collapse, thrombophlebitis, embolism,</emphasis> tachycardia, <emphasis style="bold">CHF,</emphasis><emphasis style="italic">edema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5308">
						<sec_title>ENDO: </sec_title>
						<para>Weight gain, adrenal suppression, hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x5313">
						<sec_title>META: </sec_title>
						<para>
							<emphasis style="italic">Hypokalemia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x5319">
						<sec_title>MISC: </sec_title>
						<para>Hypersensitivity, cataracts, GI ulcers, <emphasis style="bold">anaphylaxis</emphasis>, infection</para>
					</section>
					<section type="none" id="sidelem4x5327">
						<sec_title>MS: </sec_title>
						<para>Fractures, osteoporosis, weakness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5332">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1.5 hr, half-life 18-36 hr, metabolized by liver, excreted in urine</para>
			</section>
			<section type="interactions" id="sidelem4x5337">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> B/P—sodium-containing food or medication</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> fludrocortisone action—barbiturates, rifampin, phenytoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> potassium levels—thiazides, potassium-wasting products, loop diuretics, amphotericin B, piperacillin, mezlocillin</para>
				<section type="none" id="sidelem4x5352">
					<section type="none" id="sidelem4x5353">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hypokalemia—aloe, buckthorn, cascara sagrada, Chinese rhubarb, senna</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> corticosteroid effect—aloe, licorice, perilla</para>
					</section>
					<section type="none" id="sidelem4x5364">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> potassium, sodium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5371">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5374">
					<section type="none" id="sidelem4x5375">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5379">
								<item>
									<label>•</label>
									<para>Weight daily; notify prescriber of weekly gain &gt;5 lb</para>
								</item>
								<item>
									<label>•</label>
									<para>I&amp;O ratio; be alert for decreasing urinary output, increasing edema</para>
								</item>
								<item>
									<label>•</label>
									<para>B/P q4hr, pulse; notify prescriber if chest pain occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>Potassium depletion: paresthesias, fatigue, nausea, vomiting, depression, polyuria, dysrhythmias, weakness</para>
								</item>
								<item>
									<label>•</label>
									<para>Electrolytes: sodium, potassium, chloride, hypokalemia is common</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5405">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5409">
								<item>
									<label>•</label>
									<para>Titrated dose; use lowest effective dose</para>
								</item>
								<item>
									<label>•</label>
									<para>With food or milk to decrease GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Assistance with ambulation in patient with bone tissue disease to prevent fractures</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5425">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5429">
								<item>
									<label>•</label>
									<para>Therapeutic response: correction of adrenal insufficiency</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5435">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5440">
								<item>
									<label>•</label>
									<para>That emergency ID as steroid user should be carried</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5445">
								<item>
									<label>•</label>
									<para>Not to discontinue this medication abruptly</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5453">
							<label>•</label>
							<sec_title>
								<route>To notify health care provider of muscle cramps, weight gain, edema, nausea, infection, trauma, stress</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x5459">
							<label>•</label>
							<sec_title>
								<route>Not to breastfeed while taking this medication</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x5462">
								<item>
									<label>•</label>
									<para>Avoid exposure to disease, trauma</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="33" status="active">
			<mono_name>flumazenil (Rx)</mono_name>
			<info>
				<pronunciation>(flu-maz′e-nill)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x54731">
						<country code="CAN">Anexate </country>
					</tradename>
					<tradename id="tnidelem4x54730">Romazicon</tradename>
				</tradenames>
				<class type="func"> Antidote: benzodiazepine receptor antagonist</class>
				<class type="chem"> Imidazobenzodiazepine derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x5486">
				<sec_title>Action:</sec_title>
				<para>Antagonizes actions of benzodiazepines on CNS, competitively inhibits activity at benzodiazepine recognition site on GABA/benzodiazepine receptor complex</para>
			</section>
			<section type="uses" id="sidelem4x5491">
				<sec_title>Uses:</sec_title>
				<para>Reversal of sedative effects of benzodiazepines</para>
			</section>
			<section type="contra" id="sidelem4x5496">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or benzodiazepines, serious cyclic antidepressant overdose, patients given benzodiazepine for control of life-threatening conditions</para>
				<section type="none" id="sidelem4x5501">
					<section type="none" id="sidelem4x5502">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, status epilepticus, head injury, labor/delivery, renal/hepatic disease, hypoventilation, panic disorder, drug and alcohol dependency, ambulatory patients</para>
						<para>
							<bbw>Benzodiazepine dependence, seizures</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5517">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5520">
					<section type="none" id="sidelem4x5521">
						<sec_title>Reversal of conscious sedation or general anesthesia</sec_title>
						<section type="none" id="sidelem4x5529">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5529">
									<item>
										<label>•</label>
										<para> 0.2 mg given over 15 sec; wait 45 sec, then give 0.2 mg if consciousness does not occur; may be repeated at 60-sec intervals prn (max 3 mg/hr) or 1 mg/5 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5536">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5536">
									<item>
										<label>•</label>
										<para> 10 mcg (0.01 mg)/kg; cumulative dose of 1 mg or less</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5540">
						<sec_title>Management of suspected benzodiazepine overdose</sec_title>
						<section type="none" id="sidelem4x5548">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5548">
									<item>
										<label>•</label>
										<para> 0.2 mg given over 30 sec; wait 30 sec, then give 0.3 mg over 30 sec if consciousness does not occur; further doses of 0.5 mg can be given over 30 sec at intervals of 1 min up to cumulative dose of 3 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5555">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5555">
									<item>
										<label>•</label>
										<para> 10 mcg (0.01 mg/kg), cumulative dose of &lt;1 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5559">
						<sec_title>Available forms: </sec_title>
						<para>Inj 0.1 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x5564">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5568">
								<item>
									<label>•</label>
									<para>Check airway and IV access before administration</para>
								</item>
								<item>
									<label>•</label>
									<para>Use large vein</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5579">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x5583">
									<item>
										<label>•</label>
										<para>Give undiluted or diluted with 0.9% NaCl, D<emphasis style="inf">5</emphasis>W, LR; give over 15-30 sec into running IV, check for extravasation</para>
									</item>
									<item>
										<label>•</label>
										<para>Stable for 24 hr if drawn into a syringe or mixed with other solutions</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5597">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5600">
					<section type="none" id="sidelem4x5601">
						<sec_title>CNS: </sec_title>
						<para>Dizziness, agitation, emotional lability, confusion, <emphasis style="bold">seizures,</emphasis> somnolence, panic attacks</para>
					</section>
					<section type="none" id="sidelem4x5609">
						<sec_title>CV: </sec_title>
						<para>Hypertension, palpitations, cutaneous vasodilation, <emphasis style="bold">dysrhythmias,</emphasis> bradycardia, tachycardia, chest pain</para>
					</section>
					<section type="none" id="sidelem4x5617">
						<sec_title>EENT: </sec_title>
						<para>Abnormal vision, blurred vision, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x5622">
						<sec_title>GI: </sec_title>
						<para>Nausea, vomiting, hiccups</para>
					</section>
					<section type="none" id="sidelem4x5627">
						<sec_title>SYST: </sec_title>
						<para>Headache, inj site pain, increased sweating, fatigue, rigors</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5632">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Terminal half-life 41-79 min, metabolized in liver, onset 1-2 min</para>
			</section>
			<section type="interactions" id="sidelem4x5637">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x5641">
						<item>
							<label>•</label>
							<para>Toxicity: mixed product overdosage</para>
						</item>
						<item>
							<label>•</label>
							<para>Antagonize action of benzodiazepines, zaleplon, zolpidem</para>
						</item>
					</list>
				</para>
			</section>
			<section type="considerations" id="sidelem4x5652">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5655">
					<section type="none" id="sidelem4x5656">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5661">
								<item>
									<label>•</label>
									<para>Cardiac status using continuous monitoring
<bbw>For seizures; protect patient from injury; most likely among those who are withdrawing from benzodiazepines; flumazenil can precipitate benzodiazepine withdrawal and onset of seizures, seizures are increased in head trauma</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5676">
								<item>
									<label>•</label>
									<para>GI symptoms: nausea, vomiting; place patient in side-lying position to prevent aspiration</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5684">
							<label>•</label>
							<sec_title>Allergic reactions</sec_title>
							<para>
								<list id="lidelem4x5684">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reactions:</emphasis> flushing, rash, urticaria, pruritus
<bbw>
												<emphasis alert="lifethreat">Seizures/benzodiazepine dependence:</emphasis> do not use in those who have used these products for status epilepticus; use in intensive care setting cautiously, there may be unrecognized benzodiazepine dependence</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="34" status="active">
			<mono_name>flunisolide nasal agent</mono_name>
			<section type="none" id="sidelem4x5702">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="35" status="active">
			<mono_name>fluocinolone topical</mono_name>
			<section type="none" id="sidelem4x5709">
				<para>See<see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="36" status="active">
			<mono_name>fluorometholone ophthalmic</mono_name>
			<section type="none" id="sidelem4x5716">
				<para>See<see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="37" status="active" ha="yes">
			<mono_name> fluorouracil (Rx)</mono_name>
			<info>
				<pronunciation>(flure-oh-yoor′a-sil)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x57274">Carac</tradename>
					<tradename id="tnidelem4x57273">Efudex</tradename>
					<tradename id="tnidelem4x57272">Fluoroplex</tradename>
					<tradename id="tnidelem4x57271">5-FU</tradename>
					<tradename id="tnidelem4x57270">Tolak</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, antimetabolite</class>
				<class type="chem"> Pyrimidine analog</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5737">
				<para>
					<confusion>
						<tradename id="tnidelem4x57370">fluorouracil</tradename>
						<drug type="generic" refid="idelem4x57370">flucytosine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5744">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA, RNA synthesis; interferes with cell replication by competitively inhibiting thymidylate production, specific for S phase of cell cycle</para>
			</section>
			<section type="uses" id="sidelem4x5749">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="bold">Systemic:</emphasis> cancer of breast, colon, rectum, stomach, pancreas; <emphasis style="bold">topical:</emphasis> multiple actinic keratoses, superficial basal cell carcinomas</para>
				<section type="none" id="sidelem4x5759">
					<section type="none" id="sidelem4x5760">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Anal, biliary tract, cervical, head and neck, hepatocellular, ovarian cancer</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5765">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity, poor nutritional status, serious infections, dihydropyrimidine</para>
				<para>
					<bbw>Bone marrow suppression</bbw>
				</para>
				<section type="none" id="sidelem4x5780">
					<section type="none" id="sidelem4x5781">
						<sec_title>Precautions: </sec_title>
						<para>Children, renal/hepatic disease, angina, stomatitis, diarrhea, sunlight exposure, vaccination, occlusive dressing</para>
						<para>
							<bbw>GI bleeding</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5796">
				<sec_title>Dosage and routes</sec_title>
				<para>Doses vary widely, based on actual body weight unless obese, then based on lean body weight</para>
				<section type="none" id="sidelem4x5801">
					<section type="none" id="sidelem4x5802">
						<sec_title>Advanced colorectal cancer</sec_title>
						<section type="none" id="sidelem4x5810">
							<label>•</label>
							<sec_title>Adult<route> IV bolus</route></sec_title>
							<para>
								<list id="lidelem4x5810">
									<item>
										<label>•</label>
										<para> 300-500 mg/m<emphasis style="sup">2</emphasis>/day × 4-5 days q28days or 600-1500 mg/m<emphasis style="sup">2</emphasis> weekly or every other wk; continuous IV infusion: 300-1000 mg/m<emphasis style="sup">2</emphasis>/day × 4-5 days q4wk or 300 mg/m<emphasis style="sup">2</emphasis>/day indefinitely, high dose 3000-3400 mg/m<emphasis style="sup">2</emphasis> over 24-72 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5829">
						<sec_title>Breast cancer</sec_title>
						<section type="none" id="sidelem4x5837">
							<label>•</label>
							<sec_title>Adult<route> IV bolus</route></sec_title>
							<para>
								<list id="lidelem4x5837">
									<item>
										<label>•</label>
										<para> 400-600 mg/m<emphasis style="sup">2</emphasis> on days 1 and 8 of every cycle with cyclophosphamide and methotrexate or 600 mg/m<emphasis style="sup">2</emphasis> day 1 with cyclophosphamide and methotrexate q21-28days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5847">
						<sec_title>Pancreatic cancer</sec_title>
						<section type="none" id="sidelem4x5855">
							<label>•</label>
							<sec_title>Adult<route> IV bolus</route></sec_title>
							<para>
								<list id="lidelem4x5855">
									<item>
										<label>•</label>
										<para> 600 mg/m<emphasis style="sup">2</emphasis> on days 1, 8, 29, 36 with DOXOrubicin and mitoMYcin q8wk or 600 mg/m<emphasis style="sup">2</emphasis> bolus on days 1, 8, 29, 36 with streptozocin</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5866">
						<sec_title>Actinic/solar keratoses</sec_title>
						<section type="none" id="sidelem4x5874">
							<label>•</label>
							<sec_title>Adult<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x5874">
									<item>
										<label>•</label>
										<para> 1% cream/sol bid or 2-5% sol for hands</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5878">
						<sec_title>Superficial basal cell carcinoma</sec_title>
						<section type="none" id="sidelem4x5886">
							<label>•</label>
							<sec_title>Adult<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x5886">
									<item>
										<label>•</label>
										<para> 5% sol or cream 2×/day × 3-12 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5890">
						<sec_title>Available forms: </sec_title>
						<para>Inj 50 mg/ml; cream 0.5%, 1%, 4%, 5%; sol 2%, 5%</para>
					</section>
					<section type="none" id="sidelem4x5895">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5899">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product to prevent vomiting, for several days thereafter</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5905">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x5909">
									<item>
										<label>•</label>
										<para>The 1% strength is used on face; higher strengths are used on other parts of the body</para>
									</item>
									<item>
										<label>•</label>
										<para>Wear gloves when applying; may use with a loose dressing; use plastic or wooden applicator, do not use occlusive dressings, may use gauze dressing</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5920">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x5925">
									<item>
										<label>•</label>
										<para>Prepared in biologic cabinet using gloves, gown, mask; use cytotoxic handling procedures</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5933">
								<para>
									<list id="lidelem4x5933">
										<item>
											<label>•</label>
											<para>Undiluted; may inject through <emphasis style="sans-serif">
													<emphasis style="bold">Y</emphasis>
												</emphasis>-tube or 3-way stopcock; give over 1-3 min; may be diluted in NS, D<emphasis style="inf">5</emphasis>W; given as a continuous infusion in plastic containers; given over 2-8 hr; do not refrigerate/freeze; protect from light, discard unused portion, stable for 24 hr at room temperature, do not use discolored, cloudy solution; solution is pale yellow, for crystals, dissolve by warming slowly and shaking, cool to body temperature before use</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alatrofloxacin, alfentanil, allopurinol, amifostine, amikacin, amphotericin B lipid complex, amphotericin B liposome, ampicillin, ampicillin-sulbactam, anidulafungin, argatroban, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, butorphanol, calcium gluconate, CARBOplatin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cimetidine, cisatracurium, CISplatin, clindamycin, codeine, cyclophosphamide, cycloSPORINE, DAPTOmycin, dexamethasone, digoxin, DOCEtaxel, DOPamine, doripenem, DOXOrubicin liposomal, enalaprilat, ePHEDrine, ertapenem, erythromycin, esmolol, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, foscarnet, fosphenytoin, furosemide, ganciclovir, gatifloxacin, gemcitabine, gentamicin, granisetron, heparin, hydrocortisone, HYDROmorphone, ifosfamide, imipenem-cilastatin, inamrinone, isoproterenol, ketorolac, labetalol, leucovorin, levorphanol, lidocaine, linezolid, magnesium sulfate, mannitol, melphalan, meperidine, meropenem, mesna, methohexital, methotrexate, methylPREDNISolone, metoprolol, metroNIDAZOLE, milrinone, mitoMYcin, mitoXANtrone, morphine sulfate, nalbuphine, naloxone, nesiritide, nitroglycerin, nitroprusside, octreotide, ofloxacin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, PEMEtrexed, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, potassium chloride/phosphates, procainamide, propofol, propranolol, ranitidine, remifentanil, riTUXimab, sargramostim, sodium acetate/bicarbonate/phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, trastuzumab, vasopressin, vecuronium, vinBLAStine, vinCRIStine, vitamin B complex/C, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5946">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5949">
					<sec_title>
						<emphasis style="italic">Systemic use</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x5953">
						<sec_title>CNS: </sec_title>
						<para>Lethargy, malaise, weakness, acute cerebellar dysfunction</para>
					</section>
					<section type="none" id="sidelem4x5958">
						<sec_title>CV: </sec_title>
						<para>
							<emphasis style="bold">Myocardial ischemia,</emphasis> angina</para>
					</section>
					<section type="none" id="sidelem4x5965">
						<sec_title>EENT: </sec_title>
						<para>Light intolerance, lacrimation</para>
					</section>
					<section type="none" id="sidelem4x5970">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Anorexia, stomatitis,</emphasis> diarrhea, nausea, vomiting, <emphasis style="bold">hemorrhage,</emphasis> enteritis, glossitis</para>
					</section>
					<section type="none" id="sidelem4x5980">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Thrombocytopenia, leukopenia, myelosuppression, anemia, agranulocytosis</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x5986">
						<sec_title>INTEG: </sec_title>
						<para>
							<emphasis style="italic">Rash,</emphasis> fever, photosensitivity, <emphasis style="bold">anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5996">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 16 min (IV): metabolized in liver; excreted in urine; crosses blood-brain barrier</para>
			</section>
			<section type="interactions" id="sidelem4x6001">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—anticoagulants, NSAIDs, platelet inhibitors, thrombolytics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—metroNIDAZOLE, irinotecan</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity, bone marrow depression—radiation or other antineoplastics, leucovorin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live virus vaccines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of phenytoin</para>
				<section type="none" id="sidelem4x6024">
					<section type="none" id="sidelem4x6025">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, LDH, serum bilirubin, Hct, Hgb, WBC, platelets, 5-HIAA</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> albumin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6036">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6039">
					<section type="none" id="sidelem4x6040">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Bone marrow suppression monitor daily during IV treatment: CBC, differential, platelet count daily (IV); withhold product if WBC is &lt;3500/mm3 or platelet count is &lt;100,000/mm3; notify prescriber of results; product should be discontinued; nadir of leukopenia within 2 wk, recovery 1 mo, if pretreatment of WBC &lt;2,000/mm3 or platelets &lt;100,000/mm3, delay until recovery of counts above this level; nadir usually 9-14 days, recovery 30 days</bbw>
						</para>
						<section type="none" id="sidelem4x6070">
							<label>•</label>
							<sec_title>Palmer-planter erythrodysesthesia</sec_title>
							<para>
								<list id="lidelem4x6070">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Palmer-planter erythrodysesthesia:</emphasis> hand/foot tingling changing to pain, redness</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6077">
							<label>•</label>
							<sec_title>Infiltration</sec_title>
							<para>
								<list id="lidelem4x6077">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infiltration:</emphasis> monitor frequently for pain, redness, inflammation at site, if present, stop infusion and start at new site, may use ice at site</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6081">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr, electrolytes before, during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6086">
								<item>
									<label>•</label>
									<para>Hepatic studies before, during therapy: bilirubin, alk phos, AST, ALT, LDH before, during therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6094">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x6094">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> hematuria, guaiac, bruising, petechiae, mucosa or orifices q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6098">
								<item>
									<label>•</label>
									<para>Inflammation of mucosa, breaks in skin; buccal cavity q8hr for dryness, sores or ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6106">
							<label>•</label>
							<sec_title>Infection<route> those with current infections should be treated before receiving 5-FU, the dose reduced or discontinued if infection occurs</route></sec_title>
						</section>
						<section type="none" id="sidelem4x6112">
							<label>•</label>
							<sec_title>Toxicity<route> hemorrhage, severe vomiting, severe diarrhea, stomatitis, WBC &lt;3500/mm3, platelets &lt;100,000 notify prescriber</route></sec_title>
						</section>
						<section type="none" id="sidelem4x6121">
							<label>•</label>
							<sec_title>Acute cerebellar dysfunction<route> dizziness, weakness</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6124">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6128">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6134">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6139">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with known infection</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6144">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture if stomatitis is present; to drink adequate fluids</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6149">
								<item>
									<label>•</label>
									<para>To report stomatitis: any bleeding, white spots, ulcerations in mouth; that patient should examine mouth daily, report symptoms; viscous lidocaine may be used; rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicator for stomatitis; use unwaxed dental floss, give ice chips for mucositis</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6157">
							<label>•</label>
							<sec_title>To report signs of infection<route> fever, sore throat, flulike symptoms</route></sec_title>
						</section>
						<section type="none" id="sidelem4x6163">
							<label>•</label>
							<sec_title>anemia</sec_title>
							<para>
								<list id="lidelem4x6163">
									<item>
										<label>•</label>
										<para>To report signs of <emphasis style="bold">anemia:</emphasis> fatigue, headache, faintness, shortness of breath, irritability</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6171">
							<label>•</label>
							<sec_title>bleeding</sec_title>
							<para>
								<list id="lidelem4x6171">
									<item>
										<label>•</label>
										<para>To report <emphasis style="bold">bleeding:</emphasis> to avoid razors, commercial mouthwash, IM inj if counts are low</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6176">
								<item>
									<label>•</label>
									<para>Not to use aspirin products or NSAIDs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6184">
							<label>•</label>
							<sec_title>
								<route>To use contraception during therapy (men and women), pregnancy (X); to avoid breastfeeding (topical use)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6187">
								<item>
									<label>•</label>
									<para>Not to receive vaccinations during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6192">
								<item>
									<label>•</label>
									<para>To use sunscreen or stay out of the sun to prevent photosensitivity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6197">
								<item>
									<label>•</label>
									<para>About hair loss; to explore use of wigs or other products until hair regrowth occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6202">
								<item>
									<label>•</label>
									<para>Topical: To apply only to affected areas, being careful around mouth, nose, eyes</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="38" status="active">
			<mono_name>FLUoxetine (Rx)</mono_name>
			<info>
				<pronunciation>(floo-ox′eh-teen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x62132">PROzac</tradename>
					<tradename id="tnidelem4x62131">PROzac Weekly</tradename>
					<tradename id="tnidelem4x62130">Sarafem</tradename>
				</tradenames>
				<class type="func"> Antidepressant, SSRI (selective serotonin reuptake inhibitor)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6219">
				<para>
					<confusion>
						<tradename id="tnidelem4x62190">PROzac</tradename>
						<drug type="generic" refid="idelem4x62190">Proscar/ProSom/PriLOSEC</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6226">
				<sec_title>Action:</sec_title>
				<para>Inhibits CNS neuron uptake of serotonin but not of norepinephrine</para>
			</section>
			<section type="uses" id="sidelem4x6231">
				<sec_title>Uses:</sec_title>
				<para>Major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa, premenstrual dysphoric disorder (PMDD), panic disorder</para>
				<section type="none" id="sidelem4x6236">
					<section type="none" id="sidelem4x6237">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Alcoholism, anorexia nervosa, borderline personality disorder, obesity, posttraumatic stress disorder, autism, fibromyalgia, orthostatic hypotension, premature ejaculation, social phobia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6242">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x6247">
					<section type="none" id="sidelem4x6248">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, diabetes mellitus, narrow-angle glaucoma, cardiac malformations in infants (exposed to FLUoxetine in utero), osteoporosis, QT prolongation</para>
						<para>
							<bbw>Children, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6263">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6266">
					<section type="none" id="sidelem4x6267">
						<sec_title>Depression/obsessive-compulsive disorder</sec_title>
						<section type="none" id="sidelem4x6275">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6275">
									<item>
										<label>•</label>
										<para> 20 mg/day in <emphasis style="smallcaps">am</emphasis>; after 4 wk, if no clinical improvement is noted, dose may be increased to 20 mg bid in <emphasis style="smallcaps">am</emphasis>, <emphasis style="smallcaps">pm</emphasis>, max 80 mg/day;  90 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6294">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6294">
									<item>
										<label>•</label>
										<para> 10 mg/day, increase as needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6301">
							<label>•</label>
							<sec_title>Child 7-17 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6301">
									<item>
										<label>•</label>
										<para> 10 mg/day, max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6305">
						<sec_title>Premenstrual dysphoric disorder (Sarafem)</sec_title>
						<section type="none" id="sidelem4x6313">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6313">
									<item>
										<label>•</label>
										<para> 20 mg/day, may be taken daily 14 days before menses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6317">
						<sec_title>Alcoholism (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6325">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6325">
									<item>
										<label>•</label>
										<para> 20-80 mg/day, give in divided doses if &gt;40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6329">
						<sec_title>Anorexia nervosa (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6337">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6337">
									<item>
										<label>•</label>
										<para> 10 mg daily, max 60 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6341">
						<sec_title>Borderline personality disorder/fibromyalgia/autism/orthostatic hypotension/premature ejaculation/hot flashes (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6349">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6349">
									<item>
										<label>•</label>
										<para> 20 mg/day, max 80 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6353">
						<sec_title>Obesity (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6361">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6361">
									<item>
										<label>•</label>
										<para> 60 mg/day after titration</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6365">
						<sec_title>Posttraumatic stress disorder (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6373">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6373">
									<item>
										<label>•</label>
										<para> 10-80 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6377">
						<sec_title>Available forms: </sec_title>
						<para>Caps 10, 20, 40 mg; tabs 10, 20, 60 mg; oral sol 20 mg/5 ml; del rel caps (PROzac Weekly) 90 mg</para>
					</section>
					<section type="none" id="sidelem4x6382">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6387">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6392">
								<item>
									<label>•</label>
									<para>Crushed if patient is unable to swallow medication whole (tab only)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6397">
								<item>
									<label>•</label>
									<para>Gum, hard candy, frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6402">
								<item>
									<label>•</label>
									<para>Store at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6410">
							<label>•</label>
							<sec_title>
								<route>PROzac Weekly</route>
							</sec_title>
							<para>
								<list id="lidelem4x6410">
									<item>
										<label>•</label>
										<para> on the same day each wk, swallow whole; do not crush, cut, chew</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6417">
							<label>•</label>
							<sec_title>Oral sol</sec_title>
							<para>
								<list id="lidelem4x6417">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral sol:</emphasis> use oral syringe or calibrated measuring device</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6421">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6424">
					<section type="none" id="sidelem4x6425">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Headache, nervousness, insomnia, drowsiness, anxiety, tremor, dizziness, fatigue, sedation, poor concentrations, abnormal dreams, agitation,</emphasis>
							<emphasis style="bold">seizures,</emphasis> apathy, euphoria, hallucinations, delusions, psychosis, <emphasis style="bold">suicidal ideation, neuroleptic malignant syndrome–like reactions</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6436">
						<sec_title>CV: </sec_title>
						<para>
							<emphasis style="italic">Hot flashes, palpitations,</emphasis> angina pectoris, hypertension, <emphasis style="bold">tachycardia, 1st-degree AV block, bradycardia, MI, thrombophlebitis,</emphasis> generalized edema, <emphasis style="bold">torsades de pointes</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6448">
						<sec_title>EENT: </sec_title>
						<para>Visual changes, ear/eye pain, photophobia, tinnitus, increased intraocular pressure</para>
					</section>
					<section type="none" id="sidelem4x6454">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea, diarrhea, dry mouth, anorexia, dyspepsia, constipation,</emphasis>taste changes, flatulence, decreased appetite</para>
					</section>
					<section type="none" id="sidelem4x6461">
						<sec_title>GU: </sec_title>
						<para>
							<emphasis style="italic">Dysmenorrhea, decreased libido, urinary frequency, UTI,</emphasis> amenorrhea, cystitis, impotence, urine retention</para>
					</section>
					<section type="none" id="sidelem4x6468">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Hemorrhage</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x6474">
						<sec_title>INTEG: </sec_title>
						<para>
							<emphasis style="italic">Sweating, rash, pruritus,</emphasis> acne, alopecia, urticaria, <emphasis style="bold">angioedema, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6483">
						<sec_title>META: </sec_title>
						<para>Hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x6488">
						<sec_title>MS: </sec_title>
						<para>
							<emphasis style="italic">Pain,</emphasis> arthritis, twitching</para>
					</section>
					<section type="none" id="sidelem4x6495">
						<sec_title>RESP: </sec_title>
						<para>
							<emphasis style="italic">Pharyngitis, cough, dyspnea, bronchitis,</emphasis> asthma, hyperventilation, pneumonia</para>
					</section>
					<section type="none" id="sidelem4x6502">
						<sec_title>SYST: </sec_title>
						<para>
							<emphasis style="italic">Asthenia,</emphasis>
							<emphasis style="bold">serotonin syndrome,</emphasis> flu-like symptoms, <emphasis style="bold">neonatal abstinence syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6513">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x6516">
					<section type="none" id="sidelem4x6517">
						<sec_title>PO: </sec_title>
						<para>Peak 6-8 hr, metabolized in liver, excreted in urine, terminal half-life 2-3 days, norfluoxetine active metabolite half-life 4-16 days, steady state 28-35 days, protein binding 94%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6522">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—SSRIs, SNRIs, serotonin-receptor agonists, selegiline, busPIRone, tryptophan, phenothiazines, haloperidol, loxapine, thiothixene, tricyclics; do not use concurrently</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—platelet inhibitors, thrombolytics, NSAIDs, salicylates, anticoagulants</para>
				<para>
					<emphasis alert="nurse">Do not use MAOIs with or 14 days before FLUoxetine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels or toxicity of carBAMazepine, lithium, digoxin, warfarin, phenytoin, diazepam, vinBLAStine, donepezil, antidiabetics, dorifenacin, paricalcitrol, budesonide, bosentan, thioridazine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, antidepressants, opioids, sedatives</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> FLUoxetine effect—cyproheptadine</para>
				<section type="none" id="sidelem4x6549">
					<section type="none" id="sidelem4x6550">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="nurse">Do not use together; increased risk of serotonin syndrome: St. John’s wort, SAM-e</emphasis>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS effect—hops, kava, lavender, valerian</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6562">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6565">
					<section type="none" id="sidelem4x6566">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Mental status: mood, sensorium, affect, suicidal tendencies (child/young adult), increase in psychiatric symptoms, depression, panic; monitor for seizures, seizure potential increased, sarafem is not approved for children</bbw>
						</para>
						<section type="none" id="sidelem4x6584">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> symptoms can occur anytime after first dose, nausea/vomiting, sedation, dizziness, diaphoresis, mental changes, elevated B/P; if these occur product should be stopped, notify prescriber</route></sec_title>
						</section>
						<section type="none" id="sidelem4x6590">
							<label>•</label>
							<sec_title>Bulimia nervosa</sec_title>
							<para>
								<list id="lidelem4x6590">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bulimia nervosa:</emphasis> appetite, weight daily, increase nutritious foods in diet, watch for bingeing and vomiting</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6595">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions/serious skin reactions: angioedema, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, itching, rash, urticaria; product should be discontinued, may need to give antihistamine</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6600">
								<item>
									<label>•</label>
									<para>B/P (lying/standing), pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; ECG for flattening of T wave, bundle branch, AV block, dysrhythmias in cardiac patients</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6608">
							<label>•</label>
							<sec_title>Blood studies</sec_title>
							<para>
								<list id="lidelem4x6608">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Blood studies:</emphasis> CBC, leukocytes, differential, cardiac enzymes if patient is receiving long-term therapy; check platelets; bleeding can occur, thyroid function, growth rate (children), weight</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6615">
							<label>•</label>
							<sec_title>Hepatic studies</sec_title>
							<para>
								<list id="lidelem4x6615">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hepatic studies:</emphasis> AST, ALT, bilirubin, creatinine, weight weekly; appetite may decrease with product</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6619">
								<item>
									<label>•</label>
									<para>Safety measures, primarily for geriatric patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6624">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6628">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression, symptoms of OCD</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6634">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6639">
								<item>
									<label>•</label>
									<para>That therapeutic effect may take 1-4 wk, not to discontinue abruptly, that follow-up will be required</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6645">
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities requiring alertness because of drowsiness, dizziness, blurred vision</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6650">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6655">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnant, planning to become pregnant, or breastfeeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6660">
								<item>
									<label>•</label>
									<para>To change positions slowly because orthostatic hypotension may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6665">
								<item>
									<label>•</label>
									<para>To avoid all OTC products unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6670">
								<item>
									<label>•</label>
									<para>To notify prescriber if allergic reactions occur (rash, trouble breathing, itching)
<bbw>That suicidal thoughts/behaviors may occur in young adults, children, usually during early treatment</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6684">
								<item>
									<label>•</label>
									<para>To notify prescriber of worsening symptoms, or if insomnia, anxiety, or depression continues</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6692">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> fever, sweating, diarrhea, poor coordination, nausea/vomiting, sedation, flushing, mental changes</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="39" status="active">
			<mono_name>fluPHENAZine decanoate (Rx)</mono_name>
			<info>
				<pronunciation>(floo-fen′a-zeen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x67000">
						<country code="CAN">Modecate </country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="40" status="active">
			<mono_name>fluPHENAZine hydrochloride (Rx)</mono_name>
			<info>
				<class type="func"> Antipsychotic</class>
				<class type="chem"> Phenothiazine, piperazine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6715">
				<para>
					<confusion>
						<tradename id="tnidelem4x67150">Prolixin</tradename>
						<drug type="generic" refid="idelem4x67150">Proloid</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6719">
				<sec_title>Action:</sec_title>
				<para>Depresses cerebral cortex, hypothalamus, limbic system, which control activity and aggression; blocks neurotransmission produced by DOPamine at synapse; exhibits strong α-adrenergic and anticholinergic blocking action; mechanism for antipsychotic effects is unclear</para>
			</section>
			<section type="uses" id="sidelem4x6724">
				<sec_title>Uses:</sec_title>
				<para>Schizophrenia</para>
				<section type="none" id="sidelem4x6729">
					<section type="none" id="sidelem4x6730">
						<sec_title>Unlabeled use: </sec_title>
						<para>Agitation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6735">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, blood dyscrasias, coma, bone marrow depression</para>
				<section type="none" id="sidelem4x6740">
					<section type="none" id="sidelem4x6741">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;12 yr, geriatric patients, seizure disorders, hypertension, cardiac/hepatic disease, abrupt discontinuation; accidental exposure, agranulocytosis, ambient temperature increase, angina, hypersensitivity to benzyl alcohol/parabens/sesame oil/tartrazine dye, QT prolongation, suicidal ideation, renal failure, Parkinson’s disease, hypocalcemia, head trauma, prostatic hypertrophy, pulmonary disease, infection, ileus, chemotherapy, breast cancer</para>
						<para>
							<bbw>Increased mortality in elderly patients with dementia-related psychosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6756">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6759">
					<sec_title>
						<emphasis style="italic">Decanoate</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x6768">
						<label>•</label>
						<sec_title>Adult and child &gt;12 yr<route> IM/SUBCUT</route></sec_title>
						<para>
							<list id="lidelem4x6768">
								<item>
									<label>•</label>
									<para> 12.5-25 mg q1-3wk, may increase slowly, max 100 mg/dose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x6772">
					<sec_title>
						<emphasis style="italic">HCl</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x6781">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x6781">
								<item>
									<label>•</label>
									<para> 2.5-10 mg in divided doses q6-8hr, max 40 mg/day;  initially 1.25 mg, then 2.5-10 mg in divided doses q6-8hr</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6788">
						<sec_title>Available forms: </sec_title>
						<para>
							<emphasis style="italic">Decanoate:</emphasis> inj 25, 100 <country code="CAN">FIX_STRUCTUREinj 25, 100</country> mg/ml; <emphasis style="italic">HCl:</emphasis> tabs 1, 2.5, 5, 10 mg; inj 2.5 mg/ml; elixir 2.5 mg/5 ml; oral solution 5 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x6801">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6804">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x6809">
									<item>
										<label>•</label>
										<para>Give with food, milk, or a full glass of water to minimize gastric irritation</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x6817">
								<label>•</label>
								<sec_title>Oral concentrate</sec_title>
								<para>
									<list id="lidelem4x6817">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral concentrate:</emphasis> Give using a calibrated measuring device; dilute just before use with 120-240 ml of water, saline, milk, 7-Up, carbonated orange beverage, or apricot, orange, pineapple, prune, tomato, or V-8 juice; do not mix with beverages containing caffeine (coffee, cola), tannics (tea), or pectinates (apple juice) or with other liquid medications; avoid spilling the solution on the skin and clothing</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x6825">
								<label>•</label>
								<sec_title>Oral elixir</sec_title>
								<para>
									<list id="lidelem4x6825">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral elixir:</emphasis> Give using a calibrated measuring device; avoid spilling the solution on the skin and clothing</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x6829">
							<sec_title>Injectable routes</sec_title>
							<para>
								<list id="lidelem4x6833">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter and discoloration before use, slight yellow to amber color does not alter potency, markedly discolored solutions should be discarded, protect from light</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6839">
							<sec_title>IM route (fluPHENAZine HCl only)</sec_title>
							<para>
								<list id="lidelem4x6843">
									<item>
										<label>•</label>
										<para>No dilution necessary; if irritation occurs, subsequent IM doses may be diluted with NS for injection or 2% procaine</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject slowly and deeply into the upper outer quadrant of the gluteal muscle using a dry syringe and needle, aspirate before injection</para>
									</item>
									<item>
										<label>•</label>
										<para>Keep patient in a recumbent position ≥30 min following injection to minimize hypotensive effects</para>
									</item>
									<item>
										<label>•</label>
										<para>Rotate the site of injection to avoid irritation or sterile abscess formation with repeat use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6864">
							<sec_title>IM injection (fluPHENAZine decanoate)</sec_title>
							<para>
								<list id="lidelem4x6868">
									<item>
										<label>•</label>
										<para>Use a dry syringe and needle of at least 21-G, do not dilute</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject slowly and deeply into the upper outer quadrant of the gluteal muscle, aspirate</para>
									</item>
									<item>
										<label>•</label>
										<para>Keep patient in a recumbent position for at least 30 min following the initial injection to minimize hypotensive effects; rotate the site of injection to avoid irritation or sterile abscess formation with repeat administration</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6884">
							<sec_title>Subcut injection route (fluPHENAZine decanoate)</sec_title>
							<para>
								<list id="lidelem4x6888">
									<item>
										<label>•</label>
										<para>Use a dry syringe and a needle of at least 21-G, do not dilute</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject subcut, taking care not to inject intradermally</para>
									</item>
									<item>
										<label>•</label>
										<para>Keep patient in a recumbent position for at least 30 min following the initial injection to minimize hypotensive effects. rotate the injection sites</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6904">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6907">
					<section type="none" id="sidelem4x6908">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">EPS: pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia, drowsiness, headache,</emphasis>
							<emphasis alert="lifethreat">seizures, neuroleptic malignant syndrome</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x6916">
						<sec_title>CV: </sec_title>
						<para>
							<emphasis style="italic">Orthostatic hypotension,</emphasis> hypertension, <emphasis style="bold">cardiac arrest,</emphasis> ECG changes, <emphasis style="bold">tachycardia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6928">
						<sec_title>EENT: </sec_title>
						<para>Blurred vision, glaucoma, dry eyes, nasal congestion</para>
					</section>
					<section type="none" id="sidelem4x6933">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Dry mouth, nausea, vomiting, anorexia, constipation,</emphasis> diarrhea, jaundice, weight gain, <emphasis style="bold">paralytic ileus, hepatitis,</emphasis> cholecystic jaundice</para>
					</section>
					<section type="none" id="sidelem4x6943">
						<sec_title>GU: </sec_title>
						<para>Urinary retention, urinary frequency, enuresis, impotence, amenorrhea, gynecomastia</para>
					</section>
					<section type="none" id="sidelem4x6948">
						<sec_title>HEMA: </sec_title>
						<para>Anemia, <emphasis style="bold">leukopenia, leukocytosis, agranulocytosis, aplastic anemia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6955">
						<sec_title>INTEG: </sec_title>
						<para>
							<emphasis style="italic">Rash,</emphasis> photosensitivity, dermatitis, hyperpigmentation (long-term use)</para>
					</section>
					<section type="none" id="sidelem4x6962">
						<sec_title>RESP: </sec_title>
						<para>
							<emphasis style="bold">Laryngospasm,</emphasis> dyspnea, <emphasis style="bold">respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6971">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted in urine (metabolites), crosses placenta, enters breast milk, protein binding &gt;90%, not dialyzable</para>
				<section type="none" id="sidelem4x6976">
					<section type="none" id="sidelem4x6977">
						<sec_title>PO/IM (HCl): </sec_title>
						<para>Onset 1 hr, peak 90-120 min, duration 6-8 hr, half-life 15 hr</para>
					</section>
					<section type="none" id="sidelem4x6982">
						<sec_title>IM/SUBCUT (decanoate): </sec_title>
						<para>Onset 1-3 days; peak 1-2 days, duration over 4 wk, single-dose half-life 7-10 days, multiple dose 14.3 days</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6987">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation, torsades de pointes (at higher doses)—amiodarone, arsenic trioxide, astemizole, dasatinib, disopyramide, dofetilide, droperidol, erythromycin, flecainide, gatifloxacin, ibutilide, levomethadyl, ondansetron, paliperidone, palonosetron, some antidepressants, vorinostat, ziprasidone, haloperidol, phenothiazines, ARIPiprazole, lurasidone</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—other CNS depressants, alcohol, barbiturate anesthetics, haloperidol, metyrosine, risperiDONE</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—EPINEPHrine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic effects—anticholinergics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of levodopa, lithium</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> fluPHENAZine effects—smoking, barbiturates</para>
				<section type="none" id="sidelem4x7014">
					<section type="none" id="sidelem4x7015">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, cardiac enzymes, cholesterol, blood glucose, prolactin, bilirubin, cholinesterase</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> hormones (blood and urine)</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> pregnancy tests, PKU urinary steroids, 17-OHCS</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7030">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7033">
					<section type="none" id="sidelem4x7034">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Increased mortality in elderly patients with dementia-related psychosis</bbw>
						</para>
						<para>
							<list id="lidelem4x7049">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation, torsades de pointes: ECG for changes</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7054">
								<item>
									<label>•</label>
									<para>Bilirubin, CBC, LFTs monthly; ophthalmic exams periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7059">
								<item>
									<label>•</label>
									<para>Urinalysis recommended before and during prolonged therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7064">
								<item>
									<label>•</label>
									<para>Affect, orientation, LOC, reflexes, gait, coordination, sleep pattern disturbances</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7069">
								<item>
									<label>•</label>
									<para>B/P standing and lying; pulse and respirations q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7074">
								<item>
									<label>•</label>
									<para>Dizziness, faintness, palpitations, tachycardia on rising</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7082">
							<label>•</label>
							<sec_title>
								<route>EPS</route>
							</sec_title>
							<para>
								<list id="lidelem4x7082">
									<item>
										<label>•</label>
										<para> including akathisia (inability to sit still, no pattern to movements), tardive dyskinesia (bizarre movements of jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7086">
								<item>
									<label>•</label>
									<para>Constipation, urinary retention daily; if these occur, increase bulk, water in diet</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7091">
								<item>
									<label>•</label>
									<para>Supervised ambulation until stabilized on medication; do not involve patient in strenuous exercise; fainting possible; patient should not stand still for long periods</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7096">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7100">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in emotional excitement, hallucinations, delusions, paranoia, reorganization of patterns of thought, speech</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7106">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7111">
								<item>
									<label>•</label>
									<para>That orthostatic hypotension occurs often; to rise from sitting or lying position gradually; to avoid hazardous activities until stabilized on medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7116">
								<item>
									<label>•</label>
									<para>To avoid hot tubs, hot showers, tub baths because hypotension may occur; that in hot weather, heat stroke may occur; to take extra precautions to stay cool</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7122">
								<item>
									<para>
										<emphasis alert="nurse">To avoid abrupt withdrawal of this product or EPS may result; that product should be withdrawn slowly</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7127">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (cough, hay fever, cold) unless approved by prescriber; that serious product interactions may occur; to avoid use with alcohol, CNS depressants; that increased drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7132">
								<item>
									<label>•</label>
									<para>To use a sunscreen to prevent burns</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7137">
								<item>
									<label>•</label>
									<para>About the importance of compliance with product regimen, follow-up, lab, ophthalmic exams</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7142">
								<item>
									<label>•</label>
									<para>About EPS and the need for meticulous oral hygiene because oral candidiasis may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7147">
								<item>
									<label>•</label>
									<para>To report sore throat, malaise, fever, bleeding, mouth sores; if these occur, CBC should be drawn, product discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7152">
								<item>
									<label>•</label>
									<para>That urine may turn pink to reddish brown</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="41" status="active">
			<mono_name>flurandrenolide topical</mono_name>
			<section type="none" id="sidelem4x7167">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="42" status="active">
			<mono_name>flurbiprofen ophthalmic</mono_name>
			<section type="none" id="sidelem4x7174">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="43" status="active" ha="yes">
			<mono_name> flutamide (Rx)</mono_name>
			<info>
				<pronunciation>(floo′ta-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x71850">
						<country code="CAN">Euflex </country>
					</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, hormone</class>
				<class type="chem"> Antiandrogen</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x7197">
				<sec_title>Action:</sec_title>
				<para>Interferes with androgen uptake in the nucleus or androgen activity in target tissues; arrests tumor growth in androgen-sensitive tissue (i.e., prostate gland)</para>
			</section>
			<section type="uses" id="sidelem4x7203">
				<sec_title>Uses:</sec_title>
				<para>Metastatic prostatic carcinoma, stage D<emphasis style="inf">2</emphasis> in combination with LHRH agonistic analogs (leuprolide), B<emphasis style="inf">2</emphasis>-C in combination with goserelin and radiation</para>
			</section>
			<section type="contra" id="sidelem4x7214">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity</para>
				<para>
					<bbw>Severe hepatic disease</bbw>
				</para>
				<section type="none" id="sidelem4x7229">
					<section type="none" id="sidelem4x7230">
						<sec_title>Precautions: </sec_title>
						<para>G6PD deficiency, hemoglobinopathy, lactase deficiency, polycystic ovary syndrome, tobacco smoking</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7235">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7243">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7243">
							<item>
								<label>•</label>
								<para> 250 mg q8hr for a daily dosage of 750 mg</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7247">
					<section type="none" id="sidelem4x7248">
						<sec_title>Available forms: </sec_title>
						<para>Caps 125, 250 <country code="CAN">FIX_STRUCTURECaps 125, 250 </country> mg</para>
					</section>
					<section type="none" id="sidelem4x7256">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7260">
								<item>
									<label>•</label>
									<para>Do not break, crush, chew caps</para>
								</item>
								<item>
									<label>•</label>
									<para>Give without regard to food with a full glass of water</para>
								</item>
								<item>
									<label>•</label>
									<para>Use cytotoxic handling procedures</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7276">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7279">
					<section type="none" id="sidelem4x7280">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Hot flashes,</emphasis> drowsiness, confusion, depression, anxiety, paresthesia</para>
					</section>
					<section type="none" id="sidelem4x7287">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Diarrhea, nausea, vomiting,</emphasis> increased levels in hepatic studies, <emphasis style="bold">hepatitis,</emphasis> anorexia, <emphasis style="bold">hepatotoxicity, abdominal pain, cholestasis, hepatic necrosis/failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7299">
						<sec_title>GU: </sec_title>
						<para>
							<emphasis style="italic">Decreased libido, impotence, gynecomastia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x7305">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Hemolytic anemia, leukopenia, thrombocytopenia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x7311">
						<sec_title>INTEG: </sec_title>
						<para>Irritation at site, rash, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x7316">
						<sec_title>MISC: </sec_title>
						<para>Edema, neuromuscular and pulmonary symptoms, hypertension, secondary malignancy</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7321">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly and completely absorbed; excreted in urine and feces as metabolites; half-life 6 hr, geriatric half-life 8 hr; 94% protein binding, peak 2 hr</para>
			</section>
			<section type="interactions" id="sidelem4x7326">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> PT—warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> flutamide action—LHRH analog (leuprolide)</para>
				<section type="none" id="sidelem4x7337">
					<section type="none" id="sidelem4x7338">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, BUN, creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7349">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7352">
					<section type="none" id="sidelem4x7353">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Severe hepatic disease:</emphasis> Monitor before start of therapy and monthly × 4 mo, AST, ALT, alk phos, which may be elevated; if LFTs elevated, product may need to be discontinued; monitor CBC, bilirubin, creatinine periodically</bbw>
						</para>
						<para>
							<list id="lidelem4x7368">
								<item>
									<label>•</label>
									<para>CNS symptoms, including drowsiness, confusion, depression, anxiety</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7374">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7378">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in prostatic tumor size, decrease in spread of cancer</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7384">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x7392">
							<para>
								<list id="lidelem4x7392">
									<item>
										<label>•</label>
										<para>To report side effects: decreased libido, impotence, breast enlargement, hot flashes, diarrhea
<bbw>
												<emphasis alert="lifethreat">Hepatotoxicity:</emphasis> to report nausea, vomiting, yellow eyes or skin, dark urine, clay-colored stools; hepatotoxicity may be the cause</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7405">
								<item>
									<label>•</label>
									<para>Notify of yellow, green urine discoloration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7410">
								<item>
									<label>•</label>
									<para>Avoid sun exposure, tanning beds</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7418">
							<label>•</label>
							<sec_title>
								<route>To use contraception during treatment; pregnancy category (D)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7421">
								<item>
									<label>•</label>
									<para>To use with full glass of water, without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="44" status="active">
			<mono_name>fluticasone (Rx)</mono_name>
			<info>
				<pronunciation>(floo-tic′a-sone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x74313">Flonase</tradename>
					<tradename id="tnidelem4x74312">Flovent HFA</tradename>
					<tradename id="tnidelem4x74311">Flovent Diskus</tradename>
					<tradename id="tnidelem4x74310">Veramyst (nasal spray)</tradename>
				</tradenames>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x7437">
				<sec_title>Action:</sec_title>
				<para>Decreases inflammation by inhibiting mast cells, macrophages, and leukotrienes; antiinflammatory and vasoconstrictor properties</para>
			</section>
			<section type="uses" id="sidelem4x7444">
				<sec_title>Uses:</sec_title>
				<para>Prevention of chronic asthma during maintenance treatment in those requiring oral corticosteroids; nasal symptoms of seasonal/perennial, allergic/nonallergic rhinitis</para>
				<section type="none" id="sidelem4x7449">
					<section type="none" id="sidelem4x7450">
						<sec_title>Unlabeled uses: </sec_title>
						<para>COPD</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x7455">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or milk protein, primary treatment in status asthmaticus, acute bronchospasm</para>
				<section type="none" id="sidelem4x7460">
					<section type="none" id="sidelem4x7461">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, active infections, glaucoma, diabetes, immunocompromised patients, Cushing syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7466">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7469">
					<section type="none" id="sidelem4x7470">
						<sec_title>Prevention of chronic asthma during maintenance treatment in those requiring oral corticosteroids</sec_title>
						<para/>
					</section>
				</section>
				<section type="none" id="sidelem4x7474">
					<sec_title>
						<emphasis style="italic">Flovent HFA</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x7483">
						<label>•</label>
						<sec_title>Adult and child ≥12 yr<route> INH</route></sec_title>
						<para>
							<list id="lidelem4x7483">
								<item>
									<label>•</label>
									<para> 88-440 mcg bid (in those previously taking bronchodilators alone);  88-220 mcg bid, max 440 mcg bid (in those previously taking inhaled corticosteroids);  440 mcg bid, max 880 mcg bid (in those previously taking oral corticosteroids)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7496">
						<label>•</label>
						<sec_title>Child 4-11 yr<route> INH</route></sec_title>
						<para>
							<list id="lidelem4x7496">
								<item>
									<label>•</label>
									<para> 88 mcg bid</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x7500">
					<sec_title>
						<emphasis style="italic">Flovent Diskus</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x7509">
						<label>•</label>
						<sec_title>Adult and child ≥12 yr<route> INH</route></sec_title>
						<para>
							<list id="lidelem4x7509">
								<item>
									<label>•</label>
									<para> 100 mcg bid, max 500 mcg bid (in those previously taking bronchodilators alone);  100-250 mcg bid, max 500 mcg bid (in those previously taking inhaled corticosteroids);  500-1000 mcg bid, max 1000 mcg bid (in those previously taking oral corticosteroids)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7522">
						<label>•</label>
						<sec_title>Child 4-11 yr<route> INH</route></sec_title>
						<para>
							<list id="lidelem4x7522">
								<item>
									<label>•</label>
									<para> Initially 50 mcg bid, max 100 mcg bid (in those previously taking bronchodilators alone or inhaled corticosteroids)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7526">
						<sec_title>Nasal symptoms of seasonal, perennial allergic, nonallergic rhinitis</sec_title>
						<para/>
					</section>
				</section>
				<section type="none" id="sidelem4x7530">
					<sec_title>
						<emphasis style="italic">Flonase</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x7539">
						<label>•</label>
						<sec_title>Adult</sec_title>
						<para>
							<list id="lidelem4x7539">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Adult:</emphasis> nasal 2 sprays initially, in each nostril daily or 1 spray bid, when controlled, lower to 1 spray in each nostril daily</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7546">
						<label>•</label>
						<sec_title>Adolescent/child &gt;4 yr</sec_title>
						<para>
							<list id="lidelem4x7546">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Adolescent/child &gt;4 yr:</emphasis> nasal 1 spray in each nostril daily, may increase to 2 sprays in each nostril daily, when controlled lower to 1 spray in each nostril daily</para>
								</item>
							</list>
						</para>
					</section>
				</section>
				<section type="none" id="sidelem4x7550">
					<sec_title>
						<emphasis style="italic">Veramyst</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x7559">
						<label>•</label>
						<sec_title>Adult/child ≥12 yr</sec_title>
						<para>
							<list id="lidelem4x7559">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Adult/child ≥12 yr:</emphasis> nasal 2 sprays in each nostril daily</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7566">
						<label>•</label>
						<sec_title>Child 2-11 yr</sec_title>
						<para>
							<list id="lidelem4x7566">
								<item>
									<label>•</label>
									<para>
										<emphasis style="bold">Child 2-11 yr:</emphasis> nasal 1 spray in each nostril daily</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7570">
						<sec_title>Available forms: </sec_title>
						<para>Oral inhalation aerosol 44, 110, 220 mcg; oral inhalation powder 50, 100, 250 mcg; nasal spray (Veramyst) 27.5 mcg/actuation, (propionate) 50 mcg/actuation, 27.5 mcg/spray (furoate)</para>
					</section>
					<section type="none" id="sidelem4x7575">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7579">
								<item>
									<label>•</label>
									<para>Give at 1-min intervals; if a bronchodilator aerosol spray is used, use bronchodilator first, wait 5-15 min, then use fluticasone</para>
								</item>
								<item>
									<label>•</label>
									<para>Decrease dose to lowest effective dose after desired effect; decrease dose at 2-4 wk intervals</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7590">
							<sec_title>Inhalation route (aerosol)</sec_title>
							<para>
								<list id="lidelem4x7594">
									<item>
										<label>•</label>
										<para>Shake well, prime before 1st use, release 4 sprays into air away from face, prime using 1 spray if not used for ≥7 days; when the counter reads 000, discard; clean mouthpiece daily in warm water, dry; do not share inhaler with others</para>
									</item>
									<item>
										<label>•</label>
										<para>Child &lt;4 yr requires a face mask with spacer/VHC device for delivery; allow 3-5 INH per actuation; do not use spacer with Flovent Diskus</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7605">
							<sec_title>Inhalation route: Powder for oral inhalation (Flovent Diskus)</sec_title>
							<para>
								<list id="lidelem4x7609">
									<item>
										<label>•</label>
										<para>Fill in the “Pouch opened” and “Use by” dates in the blank lines on the label; the “Use by” date for Flovent Diskus 50 mcg is 6 wk from the date the pouch is opened; the “Use by” date for Diskus 100 mcg and 250 mcg is 2 mo from the date the pouch is opened</para>
									</item>
									<item>
										<label>•</label>
										<para>Open the diskus by holding in one hand and using the thumb of the other to push the thumb grip away as far as it will go until the mouthpiece shows and snaps into place</para>
									</item>
									<item>
										<label>•</label>
										<para>Slide the lever away from the patient as far as it will go until it clicks; the number on the dose counter will count down from 1; the diskus is now ready to use</para>
									</item>
									<item>
										<label>•</label>
										<para>Before inhaling the dose, have patient breathe out, hold the diskus level and away from mouth, do not breathe out into the mouthpiece</para>
									</item>
									<item>
										<label>•</label>
										<para>Instruct the patient to put the mouthpiece to the lips and breathe in through the mouth quickly and deeply through the diskus; remove the diskus from the mouth, hold breath for about 10 sec, and breathe out slowly</para>
									</item>
									<item>
										<label>•</label>
										<para>After taking a dose, close the diskus by sliding the thumb grip back as far as it will go; the diskus will click shut; the lever automatically returns to its original position</para>
									</item>
									<item>
										<label>•</label>
										<para>The counter displays how many doses are left; the counter number counts down each time the patient uses the diskus; after 55 doses (23 doses from the sample pack), numbers 5 to 0 are red to warn that there are only a few doses left</para>
									</item>
									<item>
										<label>•</label>
										<para>After use, patient should rinse mouth with water and spit out the water, not swallow it</para>
									</item>
									<item>
										<label>•</label>
										<para>To avoid the spread of infection, do not use the inhaler for more than one person</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7657">
							<sec_title>Intranasal</sec_title>
							<para>
								<list id="lidelem4x7661">
									<item>
										<label>•</label>
										<para>Prime before first use</para>
									</item>
									<item>
										<label>•</label>
										<para>Shake bottle gently before each use</para>
									</item>
									<item>
										<label>•</label>
										<para>Rinse tip after use, dry with tissue</para>
									</item>
									<item>
										<label>•</label>
										<para>Blow nose before use</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7682">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7685">
					<section type="none" id="sidelem4x7686">
						<sec_title>CNS: </sec_title>
						<para>Fatigue, fever, headache, nervousness, dizziness, migraines</para>
					</section>
					<section type="none" id="sidelem4x7691">
						<sec_title>EENT: </sec_title>
						<para>
							<emphasis style="italic">Pharyngitis</emphasis>, sinusitis, rhinitis, laryngitis, hoarseness, dry eyes, cataracts, nasal discharge, epistaxis, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x7698">
						<sec_title>GI: </sec_title>
						<para>Diarrhea, abdominal pain, nausea, vomiting, <emphasis style="italic">oral candidiasis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7705">
						<sec_title>INTEG: </sec_title>
						<para>Urticaria, dermatitis</para>
					</section>
					<section type="none" id="sidelem4x7710">
						<sec_title>META: </sec_title>
						<para>Hyperglycemia, growth retardation in children, cushingoid features</para>
					</section>
					<section type="none" id="sidelem4x7715">
						<sec_title>MISC: </sec_title>
						<para>Influenza, <emphasis style="bold">eosinophilic conditions, angioedema, Churg-Strauss syndrome, anaphylaxis, adrenal insufficiency (high doses),</emphasis> bone mineral density reduction</para>
					</section>
					<section type="none" id="sidelem4x7723">
						<sec_title>MS: </sec_title>
						<para>Osteoporosis, muscle soreness, joint pain, arthralgia</para>
					</section>
					<section type="none" id="sidelem4x7728">
						<sec_title>RESP: </sec_title>
						<para>
							<emphasis style="italic">Upper respiratory infection,</emphasis> dyspnea, cough, bronchitis, <emphasis style="bold">bronchospasm</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7737">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption 30% aerosol, 13.5% powder; protein binding 91%; metabolized in liver after absorption in lung; half-life 7.8 hr; &lt;5% excreted in urine and feces</para>
				<section type="none" id="sidelem4x7742">
					<section type="none" id="sidelem4x7743">
						<sec_title>Oral INH: </sec_title>
						<para>Onset 24 hr, peak several days, duration 1-2 wk</para>
					</section>
					<section type="none" id="sidelem4x7748">
						<sec_title>Intranasal: </sec_title>
						<para>Onset 12 hr, peak several days</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7753">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> fluticasone levels—CYP3A4 inhibitors (ketoconazole, itraconazole), darunavir, nelfinavir, ritonavir, amprenavir, fosamprenavir, atazanavir, delavirdine, saquinavir</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> cardiac toxicity—isoproterenol (asthma patients)</para>
			</section>
			<section type="considerations" id="sidelem4x7764">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7767">
					<section type="none" id="sidelem4x7768">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7776">
							<label>•</label>
							<sec_title>Respiratory status</sec_title>
							<para>
								<list id="lidelem4x7776">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory status:</emphasis> lung sounds, pulmonary function tests during, for several mo after change from systemic to inhalation corticosteroids</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7780">
								<item>
									<label>•</label>
									<para>Withdrawal symptoms from oral corticosteroids: depression, pain in joints, fatigue</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7786">
								<item>
									<para>
										<emphasis alert="nurse">Adrenal insufficiency: nausea, weakness, fatigue, hypotension, hypoglycemia, anorexia; may occur when changing from systemic to inhalation corticosteroids; may be life-threatening; adrenal function tests periodically: hypothalamic–pituitary–adrenal axis suppression in long-term treatment</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7791">
								<item>
									<label>•</label>
									<para>Growth rate in children; blood glucose, serum potassium for all patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7796">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7800">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased severity of asthma, COPD, allergies</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7806">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7811">
								<item>
									<label>•</label>
									<para>To use bronchodilator 1st, before using inhalation, if taking both</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7817">
								<item>
									<label>•</label>
									<para>Not to use for acute asthmatic attack; acute asthma may require oral corticosteroids</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7822">
								<item>
									<label>•</label>
									<para>To avoid smoking, smoke-filled rooms, those with URIs, those not immunized against chickenpox or measles</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7827">
								<item>
									<label>•</label>
									<para>To rinse mouth after inhaled product to decrease risk of oral candidiasis</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7835">
							<label>•</label>
							<sec_title>To report immediately cushingoid symptoms<route> no appetite, nausea, weakness, fatigue, decreased B/P</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7838">
								<item>
									<label>•</label>
									<para>How to use, and when it may be empty</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7843">
								<item>
									<label>•</label>
									<para>To use medical ID identifying corticosteroid use</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="45" status="active">
			<mono_name>fluticasone (topical)</mono_name>
			<info>
				<pronunciation>(floo-tic′a-sone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x78530">Cutivate</tradename>
				</tradenames>
				<class type="func"> Corticosteroid, topical</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7859">
				<para>
					<confusion>
						<tradename id="tnidelem4x78590">fluticasone</tradename>
						<drug type="generic" refid="idelem4x78590">mometasone/fludrocortisone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7863">
				<sec_title>Action:</sec_title>
				<para>Crosses cell membrane to attach to receptors to decrease inflammation, itching; inhibits multiple inflammatory cytokines</para>
			</section>
			<section type="uses" id="sidelem4x7868">
				<sec_title>Uses:</sec_title>
				<para>Inflammation/itching of corticosteroid-responsive dermatoses on the skin</para>
			</section>
			<section type="contra" id="sidelem4x7873">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or milk protein, status asthmaticus, monotherapy in primary infections, Cushing syndrome, rosacea, perioral dermatits, diabetes mellitus</para>
				<section type="none" id="sidelem4x7878">
					<section type="none" id="sidelem4x7879">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), children, breastfeeding, skin infections, skin atrophy</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7884">
				<sec_title>Dosage and routes</sec_title>
				<para>
					<list id="lidelem4x7888">
						<item>
							<label>•</label>
							<para>Adult: Apply to affected areas bid (cream/ointment) or daily (lotion) × 4 wk</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x7894">
					<section type="none" id="sidelem4x7895">
						<sec_title>Available forms: </sec_title>
						<para>Lotion, cream 0.05%, ointment 0.005%</para>
					</section>
					<section type="none" id="sidelem4x7900">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7903">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x7909">
									<item>
										<para>
											<emphasis alert="nurse">Do not use with occlusive dressings</emphasis>
										</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x7917">
								<label>•</label>
								<sec_title>Cream/Ointment/Lotion</sec_title>
								<para>
									<list id="lidelem4x7917">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream/Ointment/Lotion:</emphasis> Apply sparingly in a thin film and rub gently into the cleansed, affected area, wash hands, use gloves, avoid use on face, groin, underarms</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x7921">
									<item>
										<label>•</label>
										<para>Reassess treatment after 2 uses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7926">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7929">
					<section type="none" id="sidelem4x7930">
						<sec_title>INTEG: </sec_title>
						<para>Burning, pruritus, dermatitis, hypertrichosis, hives, rash, xerosis, irritation, hyperpigmentation, miliaria</para>
					</section>
					<section type="none" id="sidelem4x7935">
						<sec_title>META: </sec_title>
						<para>Hyperglycemia, glycosuria</para>
					</section>
					<section type="none" id="sidelem4x7940">
						<sec_title>MISC: </sec_title>
						<para>HPA axis suppression, Cushing syndrome</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7945">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption 5% but variable; half life 7 hr</para>
			</section>
			<section type="interactions" id="sidelem4x7950">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x7953">
					<section type="none" id="sidelem4x7954">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> Blood glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7961">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7964">
					<section type="none" id="sidelem4x7965">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7969">
								<item>
									<label>•</label>
									<para>Skin reactions: burning, pruritus, dermatitis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7975">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7979">
								<item>
									<label>•</label>
									<para>Decreasing itching, inflammation on the skin</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7985">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x7988">
							<sec_title>Topical route:</sec_title>
							<para>
								<list id="lidelem4x7994">
									<item>
										<para>
											<emphasis alert="nurse">Not to use with occlusive dressings</emphasis>
										</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x8002">
								<label>•</label>
								<sec_title>Cream/Ointment/Lotion</sec_title>
								<para>
									<list id="lidelem4x8002">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream/Ointment/Lotion:</emphasis> To apply sparingly in a thin film and rub gently into the cleansed, affected area; avoid use on face, groin, underarms; wash hands; use gloves</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x8006">
									<item>
										<label>•</label>
										<para>To reassess treatment after each use</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="46" status="active">
			<mono_name>fluticasone/salmeterol</mono_name>
			<info>
				<pronunciation>(floo-tic′a-sone) (sal-mee′ter-ol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x80161">Advair Diskus</tradename>
					<tradename id="tnidelem4x80160">Advair HFA</tradename>
				</tradenames>
				<class type="func"> Corticosteroid, long-acting/β-adrenergic agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x8025">
				<sec_title>Action:</sec_title>
				<para>Decreased inflammation in inhibiting mast cells, macrophages and leukotrienes; anti-inflammatory and vasoconstrictor properties relax bronchial smooth muscles</para>
			</section>
			<section type="uses" id="sidelem4x8032">
				<sec_title>Uses:</sec_title>
				<para>Maintenance of asthma (long term), COPD</para>
			</section>
			<section type="contra" id="sidelem4x8037">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, acute asthma/COPD episodes, severe hypersensitivity to milk proteins</para>
				<para>
					<bbw>Asthma-related deaths</bbw>
				</para>
				<section type="none" id="sidelem4x8052">
					<section type="none" id="sidelem4x8053">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, active infections, diabetes mellitus, glaucoma, immunosuppression, hyperthyroidism, Cushing syndrome, hypertension, QT prolongation, pheochromocytoma, seizures, MAOIs, other long-acting B<emphasis style="inf">2</emphasis> agonists, inhaled corticosteroid</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8061">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8064">
					<section type="none" id="sidelem4x8065">
						<sec_title>Asthma maintenance</sec_title>
						<section type="none" id="sidelem4x8073">
							<label>•</label>
							<sec_title>Adult/adolescent ≥12 yr<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x8073">
									<item>
										<label>•</label>
										<para> 1 inhalation of Advair diskus q12hr, or 2 inhalations of Advair HFA q12hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8080">
							<label>•</label>
							<sec_title>Child 4-11 yr<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x8080">
									<item>
										<label>•</label>
										<para> 1 inhalation of fluticasone 100 mcg/salmeterol 50 mcg (Advair Diskus) q12hr, must be 12 hr apart</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8084">
						<sec_title>COPD</sec_title>
						<section type="none" id="sidelem4x8092">
							<label>•</label>
							<sec_title>Adult<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x8092">
									<item>
										<label>•</label>
										<para> 1 inhalation of Advair 250/50 diskus q12hr, must be 12 hr apart</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8096">
						<sec_title>Available forms: </sec_title>
						<para>Inhalation 100/50, 250/50, 500/50 mcg fluticasone/salmeterol; aerosol spray 45/21, 115/21, 230/21 mcg fluticasone/salmeterol</para>
					</section>
					<section type="none" id="sidelem4x8101">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x8104">
							<sec_title>Oral inhalation route</sec_title>
							<para/>
						</section>
						<section type="none" id="sidelem4x8108">
							<sec_title>Powder for oral inhalation (Diskus):</sec_title>
							<para>
								<list id="lidelem4x8112">
									<item>
										<label>•</label>
										<para>Most children &lt;4 years of age do not generate sufficient inspiratory flow to activate dry powder inhalers</para>
									</item>
									<item>
										<label>•</label>
										<para>Give with the Diskus device: to open and prepare mouthpiece, slide device lever to activate the first dose, do not advance the lever &gt;1 time; holding the Diskus mouthpiece level to, but away from, the mouth, exhale; then put the mouthpiece to the lips and breathe in the dose deeply and slowly; remove the Diskus from the mouth, hold breath for at least 10 sec, and then exhale slowly; close the Diskus, which also resets the dose lever for the next scheduled dose</para>
									</item>
									<item>
										<label>•</label>
										<para>Mouth should be rinsed, spit out water</para>
									</item>
									<item>
										<label>•</label>
										<para>Discard device after 1 mo or when counter reads 0 (whichever comes first)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8133">
							<sec_title>HFA aerosol:</sec_title>
							<para>
								<list id="lidelem4x8137">
									<item>
										<label>•</label>
										<para>Shake canister; prime the inhaler before first use with 4 test sprays away from face or with 2 test sprays (away from the face) if it has not been used for more than 4 wk, or after dropping; use spacer if unable to coordinate inhalation/activation</para>
									</item>
									<item>
										<label>•</label>
										<para>Rinse mouth with water after use, spit out water; clean inhaler mouthpiece at least every day; discard inhaler after 120 sprays or when the counter reads 000</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8148">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8151">
					<section type="none" id="sidelem4x8152">
						<sec_title>CNS: </sec_title>
						<para>Fever, headache, nervousness, dizziness, migraines, insomnia, tremors, agitation, anxiety, depression, hyperactivity, irritability</para>
					</section>
					<section type="none" id="sidelem4x8157">
						<sec_title>EENT: </sec_title>
						<para>Pharyngitis, sinusitis, rhinitis, laryngitis, hoarseness, dry eyes, cataracts, nasal discharge, epistaxis, hypersalivation, eye edema dysphonia, conjunctivitis</para>
					</section>
					<section type="none" id="sidelem4x8162">
						<sec_title>GI: </sec_title>
						<para>Diarrhea, abdominal pain, nausea, vomiting, oral candidiasis</para>
					</section>
					<section type="none" id="sidelem4x8167">
						<sec_title>GU: </sec_title>
						<para>UTI</para>
					</section>
					<section type="none" id="sidelem4x8172">
						<sec_title>INTEG: </sec_title>
						<para>Urticaria, dermatitis</para>
					</section>
					<section type="none" id="sidelem4x8177">
						<sec_title>META: </sec_title>
						<para>Hyperglycemia, growth retardation in children, cushingoid features</para>
					</section>
					<section type="none" id="sidelem4x8182">
						<sec_title>MISC: </sec_title>
						<para>Influenza, eosinophilic conditions, <emphasis style="bold">angioedema, Churg–Strauss syndrome, anaphylaxis, adrenal insufficiency (high doses),</emphasis> reduced bone mineral density, HPA axis suppression</para>
					</section>
					<section type="none" id="sidelem4x8190">
						<sec_title>MS: </sec_title>
						<para>Osteoporosis, muscle soreness, joint pain, decreased growth velocity</para>
					</section>
					<section type="none" id="sidelem4x8195">
						<sec_title>RESP: </sec_title>
						<para>Upper respiratory infection, dyspnea, cough, bronchitis, <emphasis style="bold">bronchospasm</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8202">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Fluticasone: half-life 8 hr, peak 1-2 hr; Salmeterol: half-life 5.5 hr, peak 5 min</para>
			</section>
			<section type="interactions" id="sidelem4x8208">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS stimulation—theophylline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> fluticasone levels—CYP3A4 inhibitors (ketoconazole, itraconazole), darunavir, nelfinavir, ritonavir, amprenavir, fosamprenavir, atazanavir, delavirdine, saquinavir, MAOIs, linezolid</para>
				<para>
					<emphasis alert="lifethreat">Increase: tendinitis, tendon rupture—quinolones</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—loop diuretics, thiazides, theophylline</para>
				<section type="none" id="sidelem4x8226">
					<section type="none" id="sidelem4x8227">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8238">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8241">
					<section type="none" id="sidelem4x8242">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x8245">
							<sec_title>Respiratory status:</sec_title>
							<section type="none" id="sidelem4x8254">
								<para>
									<list id="lidelem4x8254">
										<item>
											<label>•</label>
											<para>Withdrawal symptoms from oral corticosteroids: depression, pain in joints, fatigue
<bbw>
													<emphasis alert="lifethreat">Adrenal Insufficiency:</emphasis> nausea, weakness, fatigue, hypotension, hypoglycemia, anorexia; can occur when changing from systemic to inhalation corticosteroids; may be life threatening; adrenal function tests periodically: hypothalamic–pituitary–adrenal axis suppression in long-term treatment</bbw>
</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x8267">
									<item>
										<label>•</label>
										<para>Growth rate in children; blood glucose, serum potassium for all patients</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8272">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8276">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased severity of asthma</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8282">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8287">
								<item>
									<label>•</label>
									<para>To use bronchodilator first, before using inhalation, if taking both; may use spacer or valved chamber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8295">
							<label>•</label>
							<sec_title>
								<route>Not to use for acute asthmatic attack; acute asthma might require oral corticosteroids; may use short-acting B2 agonists for rescue</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8301">
								<item>
									<label>•</label>
									<para>To avoid smoking, smoke-filled rooms, those with URIs, those not immunized against chickenpox or measles</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8306">
								<item>
									<label>•</label>
									<para>To rinse mouth after inhaled product to reduce the risk of oral candidiasis; not to swallow</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="47" status="active">
			<mono_name>fluvastatin (Rx)</mono_name>
			<info>
				<pronunciation>(flu′vah-stay-tin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x83161">Lescol</tradename>
					<tradename id="tnidelem4x83160">Lescol XL</tradename>
				</tradenames>
				<class type="func"> Antilipemic</class>
				<class type="chem"> HMG-CoA reductase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x8326">
				<para>
					<confusion>
						<tradename id="tnidelem4x83260">fluvastatin</tradename>
						<drug type="generic" refid="idelem4x83260">FLUoxetine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8330">
				<sec_title>Action:</sec_title>
				<para>Inhibits HMG-CoA reductase enzyme, which reduces cholesterol synthesis</para>
			</section>
			<section type="uses" id="sidelem4x8335">
				<sec_title>Uses:</sec_title>
				<para>As an adjunct for primary hypercholesterolemia (types Ia, Ib), coronary atherosclerosis in CAD; to reduce the risk for secondary prevention of coronary events in patients with CAD; as an adjunct to diet to reduce LDL, total cholesterol, apo B levels in heterozygous familial hyper-cholesterolemia (LDL-C ≥190 mg/dl) or LDL-C ≥160 mg/dl with history of premature CV disease</para>
			</section>
			<section type="contra" id="sidelem4x8340">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity, active hepatic disease</para>
				<section type="none" id="sidelem4x8345">
					<section type="none" id="sidelem4x8346">
						<sec_title>Precautions: </sec_title>
						<para>Previous hepatic disease, alcoholism, severe acute infections, trauma, hypotension, uncontrolled seizure disorders, severe metabolic disorders, electrolyte imbalance, myopathy, rhabdomyolysis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8351">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8359">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8359">
							<item>
								<label>•</label>
								<para> 20-40 mg/day in <emphasis style="smallcaps">pm</emphasis> initially, usual range 20-80 mg, max 80 mg; may be given in 2 doses (40 mg <emphasis style="smallcaps">am</emphasis>, 40 mg <emphasis style="smallcaps">pm</emphasis>); dosage adjustments may be made at ≥ 4-wk intervals or ext rel 80 mg at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8372">
					<section type="none" id="sidelem4x8373">
						<sec_title>Heterozygous familial hypercholesterolemia</sec_title>
						<section type="none" id="sidelem4x8381">
							<label>•</label>
							<sec_title>Adolescent ≥1 yr postmenarche (10-16 yr)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8381">
									<item>
										<label>•</label>
										<para> 20 mg daily at bedtime, may increase q6wk, max 40 mg bid (cap) or 80 mg (ext rel)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8386">
						<sec_title>Available forms: </sec_title>
						<para>Caps 20, 40 mg; ext rel tab 80 mg</para>
					</section>
					<section type="none" id="sidelem4x8391">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8395">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew ext rel tabs, use at any time of day (tab), in the evening (cap)</para>
								</item>
								<item>
									<label>•</label>
									<para>Bile acid sequestrant should be given at least 2 hr before fluvastatin</para>
								</item>
								<item>
									<label>•</label>
									<para>Give without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature, protected from light</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8416">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8419">
					<section type="none" id="sidelem4x8420">
						<sec_title>CNS: </sec_title>
						<para>Headache, dizziness, insomnia, confusion</para>
					</section>
					<section type="none" id="sidelem4x8425">
						<sec_title>EENT: </sec_title>
						<para>Lens opacities</para>
					</section>
					<section type="none" id="sidelem4x8430">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Abdominal pain, cramps, nausea, constipation, diarrhea, dyspepsia, flatus,</emphasis>
							<emphasis alert="lifethreat">hepatic dysfunction, pancreatitis</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x8438">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Thrombocytopenia, hemolytic anemia, leukopenia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x8444">
						<sec_title>INTEG: </sec_title>
						<para>Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x8449">
						<sec_title>MISC: </sec_title>
						<para>Fatigue, influenza, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x8454">
						<sec_title>MS: </sec_title>
						<para>Myalgia, <emphasis style="bold">myositis, rhabdomyolysis,</emphasis><emphasis style="italic">arthritis, arthralgia</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8463">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak response 3-4 wk, metabolized in liver, &gt;98% protein bound, excreted primarily in feces, enters breast milk, half-life 1.9 hr, steady state 4-5 wk</para>
			</section>
			<section type="interactions" id="sidelem4x8468">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of warfarin, digoxin, phenytoin, monitor closely</para>
				<para>
					<emphasis alert="lifethreat">Increase: myopathy—cycloSPORINE, niacin, colchicine, protease inhibitors, fibric acid derivatives, erythromycin</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of fluvastatin—alcohol, cimetidine, ranitidine, omeprazole, phenytoin, rifampin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions—fluconazole, itraconazole, ketoconazole</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> fluvastatin effect—cholestyramine, colestipol, separate by ≥4 hr</para>
				<section type="none" id="sidelem4x8490">
					<section type="none" id="sidelem4x8491">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> adverse reactions—red yeast rice</para>
					</section>
					<section type="none" id="sidelem4x8498">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, CK</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8509">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8512">
					<section type="none" id="sidelem4x8513">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x8521">
							<label>•</label>
							<sec_title>Hypercholesterolemia</sec_title>
							<para>
								<list id="lidelem4x8521">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypercholesterolemia:</emphasis> diet history: fats, fasting lipid profile (cholesterol, LDL, HDL, TG) before and q4-6wk, then q3-6mo when stable</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8528">
							<label>•</label>
							<sec_title>Hepatotoxicity/pancreatitis<route> monitor hepatic studies before, q12wk after dosage change, then q6mo; AST, ALT, LFTs may be increased</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8531">
								<item>
									<label>•</label>
									<para>Renal studies in patients with compromised renal system: BUN, I&amp;O ratio, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8537">
								<item>
									<para>
										<emphasis alert="nurse">Myopathy, rhabdomyolysis: muscle pain, tenderness; obtain baseline CPK if elevated; if these occur, product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8542">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8546">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in sLDL, VLDL, total cholesterol; increased HDL, decreased triglycerides, slowing of CAD</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8552">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8557">
								<item>
									<label>•</label>
									<para>That blood work will be necessary during treatment; to take product as prescribed; that effect may take ≥4 wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8562">
								<item>
									<label>•</label>
									<para>To report severe GI symptoms, headache, muscle pain, weakness, tenderness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8567">
								<item>
									<label>•</label>
									<para>That previously prescribed regimen will continue: low-cholesterol diet, exercise program, smoking cessation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8575">
							<label>•</label>
							<sec_title>
								<route>To report suspected pregnancy; not to use during pregnancy (X), breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8578">
								<item>
									<label>•</label>
									<para>To take without regard to meals; take immediate release product in the evening; separate by ≥4 hr from bile-acid product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="48" status="active">
			<mono_name>fluvoxaMINE (Rx)</mono_name>
			<info>
				<pronunciation>(flu-vox′a-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x85881">
						<country code="CAN">Luvox</country>
					</tradename>
					<tradename id="tnidelem4x85880">
						<country code="CAN">Riva-Fluvox</country>
					</tradename>
				</tradenames>
				<class type="func"> Antidepressant SSRI (selective serotonin reuptake inhibitor)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x8599">
				<para>
					<confusion>
						<tradename id="tnidelem4x85990">Luvox</tradename>
						<drug type="generic" refid="idelem4x85990">Levoxyl/Lasix/Lovenox</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8606">
				<sec_title>Action:</sec_title>
				<para>Inhibits CNS neuron uptake of serotonin but not of norepinephrine</para>
			</section>
			<section type="uses" id="sidelem4x8612">
				<sec_title>Uses:</sec_title>
				<para>Obsessive-compulsive disorder, social phobia</para>
				<section type="none" id="sidelem4x8617">
					<section type="none" id="sidelem4x8618">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Depression, bulimia nervosa, panic disorder, autism, anxiety, posttraumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8623">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, MAOIs</para>
				<section type="none" id="sidelem4x8628">
					<section type="none" id="sidelem4x8629">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, hepatic/cardiac disease, abrupt discontinuation, dehydration, ECT, hyponatremia, hypovolemia, bipolar disorder, seizure disorder</para>
						<para>
							<bbw>Children &lt;8 yr, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8644">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8647">
					<section type="none" id="sidelem4x8648">
						<sec_title>Obsessive-compulsive disorder (OCD)</sec_title>
						<section type="none" id="sidelem4x8656">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8656">
									<item>
										<label>•</label>
										<para> 50 mg at bedtime, increase by 50 mg at 4-7 day intervals, max 300 mg; doses over 100 mg should be divided;  100 mg at bedtime, may titrate upward by 50 mg/wk, max 300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8666">
							<label>•</label>
							<sec_title>Child 12-17 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8666">
									<item>
										<label>•</label>
										<para> 25 mg at bedtime, increase by 25 mg/day q4-7days, max 300 mg/day; doses over 50 mg should be divided</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8673">
							<label>•</label>
							<sec_title>Child 8-11 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8673">
									<item>
										<label>•</label>
										<para> 25 mg/day at bedtime, may increase q4-7days, max 200 mg/day, divide doses if &gt;50 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8677">
						<sec_title>Social anxiety disorder</sec_title>
						<section type="none" id="sidelem4x8685">
							<label>•</label>
							<sec_title>Adult<route> PO EXT REL CAP</route></sec_title>
							<para>
								<list id="lidelem4x8685">
									<item>
										<label>•</label>
										<para> (Luvox CR) 100 mg at bedtime initially, titrate as needed by 50 mg/wk to 100-300 mg/day;  50 mg at bedtime, titrate as needed by 50 mg q4-7days to 50-300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8695">
							<label>•</label>
							<sec_title>Child/adolescent 12-17 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8695">
									<item>
										<label>•</label>
										<para> 25 mg at bedtime, titrate by 25-50 mg q4-7days, max 300 mg/day; if total daily dose &gt;50 mg, divide equally</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8699">
						<sec_title>Hepatic dose/geriatric</sec_title>
						<section type="none" id="sidelem4x8707">
							<label>•</label>
							<sec_title>Adult<route> PO 25 mg at bedtime, may titrate upward slowly</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8710">
						<sec_title>Bulimia nervosa, depression (unlabeled)</sec_title>
						<section type="none" id="sidelem4x8718">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8718">
									<item>
										<label>•</label>
										<para> 50 mg at bedtime × 4-7 days, titrate by 25-50 mg/dose q4-7days as needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8722">
						<sec_title>Premenstrual dysphoric disorder (unlabeled)</sec_title>
						<section type="none" id="sidelem4x8730">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8730">
									<item>
										<label>•</label>
										<para> 50 mg/day, may titrate to 100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8734">
						<sec_title>Posttraumatic stress disorder (PTSD) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x8742">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8742">
									<item>
										<label>•</label>
										<para> 25-50 mg at bedtime × 4-7 days, then titrate by 25-50 mg/dose q4-7days, range 25-300 mg/day single or divided dose × 3-12 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8746">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 25, 50, 100 mg; ext rel cap 100, 150 mg</para>
					</section>
					<section type="none" id="sidelem4x8751">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8756">
								<item>
									<label>•</label>
									<para>With food, milk for GI symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8761">
								<item>
									<label>•</label>
									<para>Store at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8769">
							<label>•</label>
							<sec_title>Immediate release</sec_title>
							<para>
								<list id="lidelem4x8769">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Immediate release:</emphasis> give at bedtime; doses &gt;100 mg/day (or &gt;50 mg/day in those aged 8-17 yr) in 2 divided doses; if doses are not equal, give larger dose at bedtime</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8776">
							<label>•</label>
							<sec_title>Ext rel</sec_title>
							<para>
								<list id="lidelem4x8776">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ext rel:</emphasis> give at bedtime; do not break, crush, chew ext rel product</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8780">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8783">
					<section type="none" id="sidelem4x8784">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Headache, drowsiness, dizziness, seizures,</emphasis> sleep disorders, insomnia, <emphasis style="bold">suicidal ideation (children/adolescents), neuroleptic malignant syndrome–like reactions,</emphasis><emphasis style="italic">weakness,</emphasis><emphasis style="bold">neuroleptic malignant syndrome, tremors</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8797">
						<sec_title>CV: </sec_title>
						<para>Palpitation, chest pain, syncope, nervousness, agitation</para>
					</section>
					<section type="none" id="sidelem4x8802">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea, anorexia, constipation,</emphasis>
							<emphasis style="bold">hepatotoxicity,</emphasis>
							<emphasis style="italic">vomiting, diarrhea,</emphasis> dry mouth, altered taste</para>
					</section>
					<section type="none" id="sidelem4x8813">
						<sec_title>GU: </sec_title>
						<para>
							<emphasis style="italic">Decreased libido,</emphasis> anorgasmia, urinary frequency, priapism</para>
					</section>
					<section type="none" id="sidelem4x8820">
						<sec_title>INTEG: </sec_title>
						<para>
							<emphasis style="italic">Rash, sweating</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x8826">
						<sec_title>MS: </sec_title>
						<para>
							<emphasis alert="lifethreat">Myalgia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x8832">
						<sec_title>SYST: </sec_title>
						<para>
							<emphasis alert="lifethreat">Neonatal abstinence syndrome</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8838">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Crosses blood-brain barrier, 77% protein binding, metabolism by the liver, terminal half-life 15.6 hr, peak 2-8 hr</para>
			</section>
			<section type="interactions" id="sidelem4x8844">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Fatal reaction—MAOIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, barbiturates, benzodiazepines</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of—ramelteon, thioridazine; do not use together</para>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation, death—pimozide, do not use together</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> fluvoxaMINE, toxicity levels—tricyclics, cloZAPine, alosetron, tiZANidine; do not use together</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> metabolism, decrease effects—smoking</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, neuroleptic malignant syndrome: SSRIs, SNRIs, serotonin-receptor agonists, atypical antipsychotics, tramadol</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—anticoagulants, NSAIDs, salicylates, thrombolytics<list id="lidelem4x8880">
						<item>
							<label>•</label>
							<para>Avoid use with clopidogrel</para>
						</item>
					</list></para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> metabolism, increase action of propranolol, diazepam, lithium, theophylline, carBAMazepine, warfarin</para>
				<section type="none" id="sidelem4x8890">
					<section type="none" id="sidelem4x8891">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS effect—kava, valerian</para>
						<para>
							<emphasis alert="lifethreat">Increase: serotonin syndrome—tryptophan, St. John’s wort; do not use together</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8901">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8904">
					<section type="none" id="sidelem4x8905">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8910">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8918">
							<label>•</label>
							<sec_title>
								<route>suicidal tendencies;</route>
							</sec_title>
							<para>
								<list id="lidelem4x8918">
									<item>
										<label>•</label>
										<para>Mental status: mood, sensorium, affect,  increase in psychiatric symptoms: depression, panic, obsessive-compulsive symptoms</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8923">
								<item>
									<label>•</label>
									<para>Constipation; most likely in geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8928">
								<item>
									<label>•</label>
									<para>Growth rate (children), bone density (post-menopausal females), glucose (diabetes)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8934">
								<item>
									<para>
										<emphasis alert="nurse">For toxicity: nausea, vomiting, diarrhea, syncope, increased pulse, seizures</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8939">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8943">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8949">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8954">
								<item>
									<label>•</label>
									<para>That therapeutic effects may take 2-3 wk; not to discontinue abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8959">
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities requiring alertness because drowsiness, dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8964">
								<item>
									<label>•</label>
									<para>Not to use other CNS depressants, alcohol, barbiturates, benzodiazepines, St. John’s wort, kava</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8969">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is suspected, planned</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8974">
								<item>
									<label>•</label>
									<para>To notify prescriber of allergic reaction</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8979">
								<item>
									<label>•</label>
									<para>To increase bulk in diet if constipation occurs, especially in geriatric patients
<bbw>That suicidal thoughts/behaviors may occur</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8996">
							<label>•</label>
							<sec_title>
								<route>To stop taking MAOIs at least 14 days before starting product</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="49" status="active">
			<mono_name>folic acid (vit B9) (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(foe′lik a′sid)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x90152">
						<country code="CAN">Apo-Folic </country>
					</tradename>
					<tradename id="tnidelem4x90151">
						<country code="CAN">Folvite </country>
					</tradename>
					<tradename id="tnidelem4x90150">
						<country code="CAN">Novo-Folacid</country>
					</tradename>
				</tradenames>
				<class type="func"> Vit B complex group, water-soluble vitamin</class>
				<class type="preg">Pregnancy category <preg cat="A">A</preg></class>
			</info>
			<section type="actions" id="sidelem4x9029">
				<sec_title>Action:</sec_title>
				<para>Needed for erythropoiesis; increases RBC, WBC, platelet formation with megaloblastic anemias</para>
			</section>
			<section type="uses" id="sidelem4x9034">
				<sec_title>Uses:</sec_title>
				<para>Megaloblastic or macrocytic anemia caused by folic acid deficiency; hepatic disease, alcoholism, hemolysis, intestinal obstruction, pregnancy to reduce risk for neural tube defects</para>
				<section type="none" id="sidelem4x9039">
					<section type="none" id="sidelem4x9040">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Reduce risk for heart disease, stroke, methotrexate toxicity prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9045">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x9050">
					<section type="none" id="sidelem4x9051">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="A">A</preg>), anemias other than megaloblastic/macrocytic anemia, vit B<emphasis style="inf">12</emphasis> deficiency anemia, uncorrected pernicious anemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9059">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9062">
					<section type="none" id="sidelem4x9063">
						<sec_title>RDA</sec_title>
						<section type="none" id="sidelem4x9071">
							<label>•</label>
							<sec_title>Adult and child ≥14 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9071">
									<item>
										<label>•</label>
										<para> 400 mcg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9079">
							<label>•</label>
							<sec_title>Adult (pregnant/lactating)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9079">
									<item>
										<label>•</label>
										<para> 600 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9086">
							<label>•</label>
							<sec_title>Child 9-13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9086">
									<item>
										<label>•</label>
										<para> 300 mcg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9093">
							<label>•</label>
							<sec_title>Child 4-8 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9093">
									<item>
										<label>•</label>
										<para> 200 mcg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9100">
							<label>•</label>
							<sec_title>Child 1-3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9100">
									<item>
										<label>•</label>
										<para> 150 mcg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9107">
							<label>•</label>
							<sec_title>Infant 6 mo-1 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9107">
									<item>
										<label>•</label>
										<para> 80 mcg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9114">
							<label>•</label>
							<sec_title>Neonate/infant &lt;6 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9114">
									<item>
										<label>•</label>
										<para> 65 mcg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9118">
						<sec_title>Megaloblastic/macrocytic anemia due to folic acid or nutritional deficiency</sec_title>
						<section type="none" id="sidelem4x9126">
							<label>•</label>
							<sec_title>Pregnant/lactating<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9126">
									<item>
										<label>•</label>
										<para> 800-1000 mcg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9130">
						<sec_title>Therapeutic dose</sec_title>
						<section type="none" id="sidelem4x9138">
							<label>•</label>
							<sec_title>Adult and child<route> PO/IM/SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x9138">
									<item>
										<label>•</label>
										<para> up to 1 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9142">
						<sec_title>Maintenance dose</sec_title>
						<section type="none" id="sidelem4x9150">
							<label>•</label>
							<sec_title>Adult and child &gt;4 yr<route> PO/IM/SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x9150">
									<item>
										<label>•</label>
										<para> 0.4 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9157">
							<label>•</label>
							<sec_title>Pregnant and lactating<route> PO/IM/SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x9157">
									<item>
										<label>•</label>
										<para> 0.8-1 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9164">
							<label>•</label>
							<sec_title>Child &lt;4 yr<route> PO/IM/SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x9164">
									<item>
										<label>•</label>
										<para> up to 0.3 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9171">
							<label>•</label>
							<sec_title>Infant<route> PO/IM/SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x9171">
									<item>
										<label>•</label>
										<para> up to 0.1 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9175">
						<sec_title>Prevention of neural tube defects during pregnancy</sec_title>
						<section type="none" id="sidelem4x9183">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9183">
									<item>
										<label>•</label>
										<para> 0.6 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9187">
						<sec_title>Prevention of megaloblastic anemia during pregnancy</sec_title>
						<section type="none" id="sidelem4x9195">
							<label>•</label>
							<sec_title>Adult<route> PO/IM/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x9195">
									<item>
										<label>•</label>
										<para> up to 1 mg/day during pregnancy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9199">
						<sec_title>Tropical sprue</sec_title>
						<section type="none" id="sidelem4x9207">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9207">
									<item>
										<label>•</label>
										<para> 3-15 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9211">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 0.1, 0.4, 0.8, 1, 5 mg; inj 5, 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x9216">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9219">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x9223">
									<item>
										<label>•</label>
										<para>Do not inject intradermally</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9229">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x9233">
									<item>
										<label>•</label>
										<para>Inject deeply in large muscle mass, aspirate</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9239">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x9243">
									<item>
										<label>•</label>
										<para>Direct undiluted ≤5 mg/1 min or more</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9249">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x9253">
									<item>
										<label>•</label>
										<para>May be added to most IV sol or TPN</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9259">
						<sec_title>Y-site compatibilities: </sec_title>
						<para>Alfentanil, aminophylline, ascorbic acid injection, atracurium, atropine, azaTHIOprine, aztreonam, benztropine, bumetanide, calcium gluconate, ceFAZolin, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, cimetidine, clindamycin, cyanocobalamin, cycloSPORINE, dexamethasone, digoxin, diphenhydrAMINE, DOPamine, enalaprilat, ePHEDrine, EPINEPHrine, epoetin alfa, erythromycin, esmolol, famotidine, fentaNYL, fluconazole, furosemide, ganciclovir, glycopyrrolate, heparin, hydrocortisone, hydrOXYzine, imipenem-cilastatin, indomethacin, insulin (regular), ketorolac, labetalol, lidocaine, LR, magnesium sulfate, mannitol, meperidine, methicillin, methylPREDNISolone, metoclopramide, metoprolol, mezlocillin, midazolam, moxalactam, multiple vitamins injection, naloxone, nitroglycerin, nitroprusside, ondansetron, oxacillin, oxytocin, penicillin G potassium/sodium, PENTobarbital, PHENobarbital, phenylephrine, phytonadione, piperacillin, potassium chloride, procainamide, propranolol, ranitidine, Ringer’s, ritodrine, sodium bicarbonate, succinylcholine, SUFentanil, theophylline, ticarcillin, ticarcillin-clavulanate, TPN, trimetaphan, urokinase, vancomycin, vasopressin</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9264">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9267">
					<section type="none" id="sidelem4x9268">
						<sec_title>CNS: </sec_title>
						<para>Confusion, depression, excitability, irritability</para>
					</section>
					<section type="none" id="sidelem4x9273">
						<sec_title>GI: </sec_title>
						<para>Anorexia, nausea, bitter taste</para>
					</section>
					<section type="none" id="sidelem4x9278">
						<sec_title>INTEG: </sec_title>
						<para>Pruritus, rash, erythema</para>
					</section>
					<section type="none" id="sidelem4x9283">
						<sec_title>RESP: </sec_title>
						<para>
							<emphasis alert="lifethreat">Bronchospasm</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x9289">
						<sec_title>SYST: </sec_title>
						<para>
							<emphasis alert="lifethreat">Anaphylaxis (rare)</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9295">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x9298">
					<section type="none" id="sidelem4x9299">
						<sec_title>PO: </sec_title>
						<para>Peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr, bound to plasma proteins, excreted in breast milk, metabolized by liver, excreted in urine (small amounts)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9310">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> need for folic acid—estrogen, hydantoins, carBAMazepine, glucocorticoids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> folate levels—methotrexate, sulfonamides, sulfaSALAzine, trimethoprim</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> phenytoin levels, fosphenytoin, may increase seizures</para>
			</section>
			<section type="considerations" id="sidelem4x9326">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9329">
					<section type="none" id="sidelem4x9330">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9338">
							<label>•</label>
							<sec_title>Megaloblastic anemia</sec_title>
							<para>
								<list id="lidelem4x9338">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Megaloblastic anemia:</emphasis> fatigue, dyspnea, weakness</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9342">
								<item>
									<label>•</label>
									<para>Hgb, Hct, reticulocyte count</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9347">
								<item>
									<label>•</label>
									<para>Nutritional status: bran, yeast, dried beans, nuts, fruits, fresh vegetables, asparagus</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9352">
								<item>
									<label>•</label>
									<para>Products currently taken: estrogen, carBAMazepine, glucocorticoids, hydantoins; these products may cause increased folic acid use by body and contribute to a deficiency if taking other neurotoxic products</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9357">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9361">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased weight, oriented, well-being; absence of fatigue; increase in reticulocyte count within 5 days of beginning treatment, absence of neural tube defect</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9367">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9371">
								<item>
									<label>•</label>
									<para>To take product exactly as prescribed; that periodic lab work is required</para>
								</item>
								<item>
									<label>•</label>
									<para>To alter nutrition to include high–folic-acid foods: organ meats, vegetables, fruit</para>
								</item>
								<item>
									<label>•</label>
									<para>That urine will turn bright yellow</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of allergic reaction</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid breastfeeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="50" status="active" ha="yes">
			<mono_name> fondaparinux (Rx)</mono_name>
			<info>
				<pronunciation>(fon-dah-pair′ih-nux)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x94040">Arixtra</tradename>
				</tradenames>
				<class type="func"> Anticoagulant, antithrombotic</class>
				<class type="chem"> Synthetic, selective factor Xa inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x9414">
				<para>
					<confusion>
						<tradename id="tnidelem4x94140">Arixtra</tradename>
						<drug type="generic" refid="idelem4x94140">Anti-Xa</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9418">
				<sec_title>Action:</sec_title>
				<para>Inhibits factor Xa; neutralization of factor Xa interrupts blood coagulation and thrombin formation</para>
			</section>
			<section type="uses" id="sidelem4x9423">
				<sec_title>Uses:</sec_title>
				<para>Prevention/treatment of deep venous thrombosis, PE in hip and knee replacement, hip fracture or abdominal surgery</para>
				<section type="none" id="sidelem4x9428">
					<section type="none" id="sidelem4x9429">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Acute coronary syndrome, acute MI, unstable angina</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9434">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product; hemophilia, leukemia with bleeding, peptic ulcer disease, hemorrhagic stroke, surgery, thrombocytopenic purpura, weight &lt;50 kg, severe renal disease (CCr &lt;30 ml/min), active major bleeding, bacterial endocarditis</para>
				<section type="none" id="sidelem4x9439">
					<section type="none" id="sidelem4x9440">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, alcoholism, hepatic disease (severe), blood dyscrasias, heparin-induced thrombocytopenia, uncontrolled severe hypertension, acute nephritis, mild to moderate renal disease</para>
						<para>
							<bbw>Spinal/epidural anesthesia, lumbar puncture</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9455">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9458">
					<section type="none" id="sidelem4x9459">
						<sec_title>Deep venous thrombosis/PE</sec_title>
						<section type="none" id="sidelem4x9467">
							<label>•</label>
							<sec_title>Adult &lt;50 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x9467">
									<item>
										<label>•</label>
										<para> 5 mg/day × ≥5 days until INR 2-3; give warfarin within 72 hr of fondaparinux</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9474">
							<label>•</label>
							<sec_title>Adult 50-100 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x9474">
									<item>
										<label>•</label>
										<para> 7.5 mg/day × ≥5 days until INR 2-3; give warfarin within 72 hr of fondaparinux</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9481">
							<label>•</label>
							<sec_title>Adult &gt;100 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x9481">
									<item>
										<label>•</label>
										<para> 10 mg/day × ≥5 days until INR 2-3; give warfarin within 72 hr of fondaparinux</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9485">
						<sec_title>Prevention of deep venous thrombosis</sec_title>
						<section type="none" id="sidelem4x9493">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x9493">
									<item>
										<label>•</label>
										<para> 2.5 mg/day given 6 hr after surgery; (hemostasis established) continue for 5-9 days; for hip surgery, up to 32 days; for abdominal surgery, up to 24 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9497">
						<sec_title>Coronary artery thrombosis prophylaxis/acute coronary syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9505">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x9505">
									<item>
										<label>•</label>
										<para> 2.5 mg until hospital discharge or ≤8 days with standard treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9510">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x9518">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT CCr 30-50 ml/min, use cautiously; CCr &lt;30 ml/min, do not use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9521">
						<sec_title>Available forms: </sec_title>
						<para>Inj 2.5 mg/0.5 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml, 10 mg/0.8 ml prefilled syringes</para>
					</section>
					<section type="none" id="sidelem4x9526">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9530">
								<item>
									<label>•</label>
									<para>Alone; do not mix with other products or solutions; cannot be used interchangeably (unit to unit) with other anticoagulants</para>
								</item>
								<item>
									<label>•</label>
									<para>Only after screening patient for bleeding disorders</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9541">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x9546">
									<item>
										<label>•</label>
										<para>SUBCUT only; do not give IM; do not give &lt;6 hr after surgery</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9551">
									<item>
										<label>•</label>
										<para>Check for discolored sol or sol with particulate; if present, do not give</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9556">
									<item>
										<label>•</label>
										<para>Administer 6-8 hr after surgery; administer to recumbent patient, rotate inj sites (left/right anterolateral, left/right posterolateral abdominal wall)</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9561">
									<item>
										<label>•</label>
										<para>Wipe surface of inj site with alcohol swab, twist plunger cap and remove, remove rigid needle guard by pulling straight off needle; do not aspirate, do not expel air bubble from surface</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9566">
									<item>
										<label>•</label>
										<para>Insert whole length of needle into skinfold held with thumb and forefinger</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9571">
									<item>
										<label>•</label>
										<para>When product is injected, a soft click may be felt or heard</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9576">
									<item>
										<label>•</label>
										<para>Give at same time each day to maintain steady blood levels; observe inj site</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9581">
									<item>
										<label>•</label>
										<para>Avoid all IM inj that may cause bleeding</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9587">
									<item>
										<para>
											<emphasis alert="nurse">Administer only this product when ordered; not interchangeable with heparin</emphasis>
										</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9592">
									<item>
										<label>•</label>
										<para>Store at 77° F (25° C); do not freeze</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9597">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9600">
					<section type="none" id="sidelem4x9601">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Fever</emphasis>, confusion, headache, dizziness, <emphasis style="italic">insomnia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9610">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea, vomiting,</emphasis> diarrhea, dyspepsia, <emphasis style="italic">constipation,</emphasis> increased AST, ALT</para>
					</section>
					<section type="none" id="sidelem4x9620">
						<sec_title>GU: </sec_title>
						<para>UTI, urinary retention</para>
					</section>
					<section type="none" id="sidelem4x9625">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis style="italic">Anemia,</emphasis> minor bleeding, purpura, hematoma, <emphasis style="bold">thrombocytopenia, major bleeding (intracranial, cerebral, retroperitoneal hemorrhage), postoperative hemorrhage, heparin-induced thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9634">
						<sec_title>INTEG: </sec_title>
						<para>Increased wound drainage, bullous eruption, local reaction—<emphasis style="italic">rash,</emphasis> pruritus, inj-site bleeding</para>
					</section>
					<section type="none" id="sidelem4x9642">
						<sec_title>META: </sec_title>
						<para>Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x9647">
						<sec_title>OTHER: </sec_title>
						<para>Hypotension, pain, <emphasis style="italic">edema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9654">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly, completely absorbed; peak steady state 3 hr; distributed primarily in blood; does not bind to plasma proteins except 94% to ATIII; eliminated unchanged in urine within 72 hr with normal renal function; terminal half-life 17-21 hr</para>
			</section>
			<section type="interactions" id="sidelem4x9659">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—salicylates, NSAIDs, abciximab, eptifibatide, tirofiban, clopidogrel, dipyridamole, quiNIDine, valproic acid</para>
				<section type="none" id="sidelem4x9666">
					<section type="none" id="sidelem4x9667">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bleeding risk—feverfew, garlic, ginger, ginkgo, ginseng, green tea, horse chestnut, kava</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9674">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9677">
					<section type="none" id="sidelem4x9678">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Monitor patients who have received epidural/spinal anesthesia or lumbar puncture for neurological impairment, including spinal hematoma, may lead to permanent disability or paralysis</bbw>
						</para>
						<para>
							<list id="lidelem4x9693">
								<item>
									<label>•</label>
									<para>Blood studies (CBC, anti-Xa, Hgb/Hct, prothrombin time, platelets, occult blood in stools), thrombocytopenia may occur; if platelets &lt;100,000/mm<emphasis style="sup">3</emphasis>, treatment should be discontinued; renal studies: BUN, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9701">
								<item>
									<label>•</label>
									<para>For bleeding: gums, petechiae, ecchymosis, black tarry stools, hematuria; decreased Hct, notify prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9709">
							<label>•</label>
							<sec_title>
								<route>For risk of hemorrhage if coadministering with other products that may cause bleeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9712">
								<item>
									<label>•</label>
									<para>For hypersensitivity: rash, fever, chills; notify prescriber</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9717">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9721">
								<item>
									<label>•</label>
									<para>Therapeutic response: prevention of DVT</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9728">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9732">
								<item>
									<label>•</label>
									<para>To use soft-bristle toothbrush to avoid bleeding gums; to use electric razor</para>
								</item>
								<item>
									<label>•</label>
									<para>To report any signs of bleeding: gums, under skin, urine, stools</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC products containing aspirin, NSAIDs</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="51" status="active">
			<mono_name>formoterol (Rx)</mono_name>
			<info>
				<pronunciation>(for-moh′ter-ahl)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x97532">Foradil Aerolizer</tradename>
					<tradename id="tnidelem4x97531">
						<country code="CAN">Oxeze </country>
					</tradename>
					<tradename id="tnidelem4x97530">Perforomist</tradename>
				</tradenames>
				<class type="func"> Bronchodilator</class>
				<class type="chem"> β-Adrenergic agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x9766">
				<para>
					<confusion>
						<tradename id="tnidelem4x97660">Foradil</tradename>
						<drug type="generic" refid="idelem4x97660">Toradol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9770">
				<sec_title>Action:</sec_title>
				<para>Has β<emphasis style="inf">1</emphasis> and β<emphasis style="inf">2</emphasis> action; relaxes bronchial smooth muscle and dilates the trachea and main bronchi by increasing levels of cAMP, which relaxes smooth muscles; causes increased contractility and heart rate by acting on β-receptors in heart</para>
			</section>
			<section type="uses" id="sidelem4x9781">
				<sec_title>Uses:</sec_title>
				<para>Maintenance, treatment of asthma, COPD; prevention of exercise-induced bronchospasm</para>
			</section>
			<section type="contra" id="sidelem4x9786">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sympathomimetics, monotherapy for asthma, COPD, status asthmaticus</para>
				<section type="none" id="sidelem4x9791">
					<section type="none" id="sidelem4x9792">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), geriatric patients, cardiac disorders, hyperthyroidism, diabetes mellitus, prostatic hypertrophy, hypertension, African descent, aneurysm</para>
						<para>
							<bbw>Asthma-related death</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9807">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9810">
					<section type="none" id="sidelem4x9811">
						<sec_title>Maintenance, treatment of asthma</sec_title>
						<section type="none" id="sidelem4x9819">
							<label>•</label>
							<sec_title>Adult and child ≥5 yr</sec_title>
							<para>
								<list id="lidelem4x9819">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult and child ≥5 yr:</emphasis>
											<emphasis style="smallcaps">am</emphasis> and <emphasis style="smallcaps">pm</emphasis> long-term 1 cap (12 mcg) q12hr using aerolizer inhaler</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9830">
						<sec_title>Maintenance of COPD</sec_title>
						<section type="none" id="sidelem4x9838">
							<label>•</label>
							<sec_title>Adult<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x9838">
									<item>
										<label>•</label>
										<para> 12 mcg q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9842">
						<sec_title>Prevention of exercise-induced bronchospasm</sec_title>
						<section type="none" id="sidelem4x9850">
							<label>•</label>
							<sec_title>Adult and child ≥12 yr<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x9850">
									<item>
										<label>•</label>
										<para> prn occasionally 1 cap (12 mcg) ≥15 min before exercise, do not use additional doses for ≥12 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9854">
						<sec_title>Available form: </sec_title>
						<para>INH powder in cap 12 mcg; nebulizer sol for INH 20 mcg/2 ml</para>
					</section>
					<section type="none" id="sidelem4x9859">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9862">
							<sec_title>Inhalation route</sec_title>
							<section type="none" id="sidelem4x9870">
								<label>•</label>
								<sec_title>
									<route>Place cap in aerolizer inhaler; cap is punctured; do not wash aerolizer inhaler</route>
								</sec_title>
							</section>
							<section type="none" id="sidelem4x9876">
								<label>•</label>
								<sec_title>
									<route>Pull off cover, twist mouthpiece to open, push buttons in; make sure the 4 pins are visible; remove cap from blister pack, place cap in chamber; twist to close, press (a click will be heard), release; patient should exhale, place inhaler in mouth, inhale rapidly</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x9879">
									<item>
										<label>•</label>
										<para>Store at room temperature; protection from heat, moisture</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9884">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9887">
					<section type="none" id="sidelem4x9888">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Tremors, anxiety,</emphasis> insomnia, headache, dizziness, stimulation</para>
					</section>
					<section type="none" id="sidelem4x9895">
						<sec_title>CV: </sec_title>
						<para>Palpitations, tachycardia, hypertension, chest pain</para>
					</section>
					<section type="none" id="sidelem4x9900">
						<sec_title>GI: </sec_title>
						<para>Nausea, vomiting, xerostomia</para>
					</section>
					<section type="none" id="sidelem4x9905">
						<sec_title>RESP: </sec_title>
						<para>Bronchial irritation, dryness of oropharynx, <emphasis style="bold">bronchospasms</emphasis> (overuse), infection, inflammatory reaction (child)</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9913">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 15 min; peak 1-3 hr; duration 12 hr; metabolized in liver, lungs, GI tract; half-life 10 hr</para>
			</section>
			<section type="interactions" id="sidelem4x9918">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: serious dysrhythmias—MAOIs, tricyclics</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—loop/thiazide diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of both products—other sympathomimetics, thyroid hormones</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—class IA/III antiarrhythmics, phenothiazines, pimozide, haloperidol, risperiDONE, sertindole, ziprasidone, amoxapine, arsenic trioxide, chloroquine, clarithromycin, dasatinib, dolasetron, droperidol, erythromycin, halofantrine, halogenated anesthetics, levomethadyl, maprotiline, methadone, some quinolones, ondansetron, paliperidone, palonosetron, pentamidine, probucol, ranolazine, SUNItinib, tricyclics, vorinostat</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action when used with β-blockers</para>
			</section>
			<section type="considerations" id="sidelem4x9942">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9945">
					<section type="none" id="sidelem4x9946">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9954">
							<label>•</label>
							<sec_title>
								<route>be alert for bronchospasm, which may occur with this patient</route>
							</sec_title>
							<para>
								<list id="lidelem4x9954">
									<item>
										<label>•</label>
										<para>Respiratory function: B/P, pulse, lung sounds; note sputum color, character; respiratory function tests before, during treatment, </para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9961">
							<label>•</label>
							<sec_title>Cardiac status<route> hypertension, palpitations, tachycardia, if CV reactions occur, product may need to be discontinued</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x9964">
								<item>
									<label>•</label>
									<para>For paresthesias, coldness of extremities; peripheral blood flow may decrease</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9969">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9973">
								<item>
									<label>•</label>
									<para>Therapeutic response: ease of breathing</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9979">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>Asthma-related death, severe asthma exacerbations; if wheezing worsens and cannot be relieved during an acute asthma attack, immediate medical attention should be sought</bbw>
						</para>
						<para>
							<list id="lidelem4x9993">
								<item>
									<label>•</label>
									<para>To rinse mouth after use</para>
								</item>
								<item>
									<label>•</label>
									<para>About correct use of inhaler/nebulizer (review package insert with patient); to avoid getting aerosol in eyes</para>
								</item>
								<item>
									<label>•</label>
									<para>About all aspects of product; to avoid smoking, smoke-filled rooms, persons with respiratory infections; not to swallow caps</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="52" status="active">
			<mono_name>fosamprenavir (Rx)</mono_name>
			<info>
				<pronunciation>(fos-am-pren′a-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x100190">Lexiva</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Protease inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x10029">
				<sec_title>Action:</sec_title>
				<para>A prodrug of amprenavir; inhibits human immunodeficiency virus (HIV) protease, which prevents maturation of the infectious virus</para>
			</section>
			<section type="uses" id="sidelem4x10034">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 infection in combination with antiretrovirals</para>
			</section>
			<section type="contra" id="sidelem4x10039">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to protease inhibitors</para>
				<section type="none" id="sidelem4x10044">
					<section type="none" id="sidelem4x10045">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, hepatic disease, hemolytic anemia, diabetes, sulfa sensitivity, autoimmune disease with immune reconstitution</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10050">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10053">
					<section type="none" id="sidelem4x10054">
						<sec_title>Therapy-naive patients</sec_title>
						<section type="none" id="sidelem4x10062">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10062">
									<item>
										<label>•</label>
										<para> 1400 mg bid without ritonavir or fosamprenavir 1400 mg/day and with ritonavir 200 mg/day or fosamprenavir 700 mg bid and ritonavir 100 mg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10069">
							<label>•</label>
							<sec_title>Child &gt;2 yr-adolescents</sec_title>
							<para>
								<list id="lidelem4x10069">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child &gt;2 yr-adolescents:</emphasis>&gt;20 kg: PO 18 mg/kg (max: 700 mg) bid plus ritonavir 3 mg/kg (max: 100 mg) bid; 15 kg to &lt;20 kg: 23 mg/kg bid plus ritonavir 3 mg/kg bid; 11 kg to &lt;15 kg: 30 mg/kg/dose bid plus ritonavir 3 mg/kg/dose bid; &lt;11 kg: 45 mg/kg/dose bid plus ritonavir 7 mg/kg/dose bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10073">
						<sec_title>Protease-experienced patients (PI)</sec_title>
						<section type="none" id="sidelem4x10081">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10081">
									<item>
										<label>•</label>
										<para> 700 mg bid and ritonavir 100 mg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10088">
							<label>•</label>
							<sec_title>Child/adolescent ≥20 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10088">
									<item>
										<label>•</label>
										<para> 18 mg/kg bid with ritonavir 3 mg/kg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10095">
							<label>•</label>
							<sec_title>Child/adolescent 15 kg to &lt;20 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10095">
									<item>
										<label>•</label>
										<para> 23 mg/kg bid with ritonavir 3 mg/kg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10102">
							<label>•</label>
							<sec_title>Child/adolescent 11 kg to &lt;15 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10102">
									<item>
										<label>•</label>
										<para> 30 mg/kg bid with ritonavir 3 mg/kg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10109">
							<label>•</label>
							<sec_title>Child/adolescent &lt;11 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10109">
									<item>
										<label>•</label>
										<para> 45 mg/kg bid with ritonavir 7 mg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10117">
							<label>•</label>
							<sec_title>Infant ≥6 mo</sec_title>
							<para>
								<list id="lidelem4x10117">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infant ≥6 mo:</emphasis> 15 kg to &lt;20 kg:  susp 23 mg/kg bid with ritonavir 3 mg/kg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10127">
							<label>•</label>
							<sec_title>Infant ≥6 mo</sec_title>
							<para>
								<list id="lidelem4x10127">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infant ≥6 mo:</emphasis> 11 kg to &lt;15 kg:  susp 30 mg/kg bid with ritonavir 3 mg/kg bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10137">
							<label>•</label>
							<sec_title>Infant ≥6 mo</sec_title>
							<para>
								<list id="lidelem4x10137">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infant ≥6 mo:</emphasis>&lt;11 kg:  susp 45 mg/kg bid with ritonavir 7 mg/kg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10144">
						<sec_title>Combination with efavirenz</sec_title>
						<section type="none" id="sidelem4x10152">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10152">
									<item>
										<label>•</label>
										<para> add another 100 mg/day of ritonavir for a total of 300 mg/day when all 3 products given</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10156">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x10164">
							<label>•</label>
							<sec_title>Adult<route> PO (Child-Pugh 5-6) 700 mg bid without ritonavir (treatment-naive patients) or 700 mg bid with ritonavir 100 mg daily (treatment-naive or experienced patients); (Child-Pugh 7-9) 700 mg bid without ritonavir (treatment-naive patients) or 450 mg bid with ritonavir 100 mg daily (treatment-naive or experienced patients); (Child-Pugh 10-15) 350 mg bid without ritonavir (treatment-naive patients) or 300 mg bid with ritonavir 100 mg daily (treatment-naive or experienced patients)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10167">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 700 mg (equivalent to 600 mg amprenavir); oral susp 50 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x10172">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x10180">
							<label>•</label>
							<sec_title>Tab</sec_title>
							<para>
								<list id="lidelem4x10180">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Tab:</emphasis> without regard to food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10187">
							<label>•</label>
							<sec_title>Oral susp</sec_title>
							<para>
								<list id="lidelem4x10187">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral susp:</emphasis> give without food (adult), with food (pediatric); if vomiting occurs within 30 min of dose, readminister; shake vigorously before dose, use calibrated device</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10191">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10194">
					<section type="none" id="sidelem4x10195">
						<sec_title>CNS: </sec_title>
						<para>Headache, fatigue, depression, oral paresthesia</para>
					</section>
					<section type="none" id="sidelem4x10200">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea, diarrhea, vomiting, abdominal pain</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x10206">
						<sec_title>INTEG: </sec_title>
						<para>Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x10211">
						<sec_title>MISC: </sec_title>
						<para>Redistribution or accumulation of body fat, hyperglycemia, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10218">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Prodrug of amprenavir, peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-4 hr; 90% protein binding; metabolized in liver by CYP3A4; excretion of unchanged product minimal; half-life 7.7 hr</para>
			</section>
			<section type="interactions" id="sidelem4x10229">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> treatment failure—ritonavir with boceprevir or ritonavir with telaprevir, not recommended</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of—warfarin</para>
				<para>
					<emphasis alert="nurse">Serious life-threatening reactions: amiodarone, calcium channel blockers, lidocaine, pimozide, ergots, midazolam, triazolam, flecainide, lovastatin, simvastatin, propafenone</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of—ARIPiprazole, rifbutin, ketoconazole, itraconazole, sildenafil, vardenafil</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—HMG-CoA reductase inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> dose of maraviroc with product if used with ritonavir; do not use maraviroc with unboosted fosamprenavir</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of oral contraceptives, methadone</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> fosamprenavir levels—nevirapine, antacids, efavirenz, saquinavir, ranitidine, carBAMazepine, phenytoin, lopinavir/ritonavir, barbiturates, proton-pump inhibitors, H<emphasis style="inf">2</emphasis>-receptor antagonists, dexamethasone; avoid concurrent use</para>
				<section type="none" id="sidelem4x10268">
					<section type="none" id="sidelem4x10269">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x10273">
								<item>
									<label>•</label>
									<para>Avoid use with St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10279">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum glucose, AST, ALT, triglycerides</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10286">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10289">
					<section type="none" id="sidelem4x10290">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x10298">
							<label>•</label>
							<sec_title>HIV</sec_title>
							<para>
								<list id="lidelem4x10298">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">HIV:</emphasis> monitor CD4+ T cell count, plasma HIV RNA, serum cholesterol, serum lipid profile</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10302">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; monitor hydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10307">
								<item>
									<label>•</label>
									<para>Skin eruptions, rash, urticaria, itching; allergy to sulfonamides; cross-sensitivity may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10314">
								<item>
									<para>
										<emphasis alert="nurse">Stevens-Johnson syndrome; skin reactions, report immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10322">
							<label>•</label>
							<sec_title>Immune reconstitution syndrome<route> may occur with combination antiretroviral therapy, autoimmune disease may also develop, up to months after treatment starts</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10325">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10330">
								<item>
									<label>•</label>
									<para>To avoid taking with other medications unless directed by provider</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10335">
								<item>
									<label>•</label>
									<para>That product does not cure but does manage symptoms; that product does not prevent transmission of HIV to others</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10343">
							<label>•</label>
							<sec_title>
								<route>To use a nonhormonal form of birth control while taking this product</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x10346">
								<item>
									<label>•</label>
									<para>That if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10351">
								<item>
									<label>•</label>
									<para>Not to alter dose or stop therapy without talking to physician</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10356">
								<item>
									<label>•</label>
									<para>To advise physician if patient has sulfa allergy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10361">
								<item>
									<label>•</label>
									<para>To report all medications, including herbal supplements, to physician</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10366">
								<item>
									<label>•</label>
									<para>That patients receiving phosphodiesterase type 5 inhibitors may be at increased risk for PDE5 inhibitor adverse effects</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="53" status="active">
			<mono_name>foscarnet (Rx)</mono_name>
			<info>
				<pronunciation>(foss-kar′net)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x103760">Foscavir</tradename>
				</tradenames>
				<class type="func"> Antiviral</class>
				<class type="chem"> Inorganic pyrophosphate organic analog</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x10386">
				<sec_title>Action:</sec_title>
				<para>Antiviral activity is produced by selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases and reverse transcriptases at concentrations that do not affect cellular DNA polymerases</para>
			</section>
			<section type="uses" id="sidelem4x10391">
				<sec_title>Uses:</sec_title>
				<para>Treatment of CMV retinitis, HSV infections; used with ganciclovir for relapsing patients</para>
			</section>
			<section type="contra" id="sidelem4x10396">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, CCr &lt;0.4 ml/min/kg</para>
				<section type="none" id="sidelem4x10401">
					<section type="none" id="sidelem4x10402">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, seizure disorders, severe anemia</para>
						<para>
							<bbw>Renal disease, electrolyte/mineral imbalances</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10417">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10420">
					<section type="none" id="sidelem4x10421">
						<sec_title>Acyclovir-resistant mucocutaneous herpes simplex virus infection (herpes labialis, herpes febrilis, herpes genitalis) in HIV-infected patients</sec_title>
						<section type="none" id="sidelem4x10429">
							<label>•</label>
							<sec_title>Adult/adolescent (unlabeled)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x10429">
									<item>
										<label>•</label>
										<para> 40 mg/kg every 8-12 hr × 2-3 wk or until lesions are healed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10433">
						<sec_title>Cytomegalovirus (CMV) encephalitis (unlabeled); CMV neurological disease (unlabeled) (including encephalitis) in HIV-infected patients</sec_title>
						<section type="none" id="sidelem4x10441">
							<label>•</label>
							<sec_title>Adult/adolescent<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x10441">
									<item>
										<label>•</label>
										<para> 90 mg/kg every 12 hr or 60 mg/kg every 8 hr × 3 wk (or until symptomatic improvement) with ganciclovir 5 mg/kg IV every 12 hr × 2-3 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10445">
						<sec_title>Encephalitis (unlabeled) caused by human herpesvirus 6 (HHV-6) in immunocompromised patients</sec_title>
						<section type="none" id="sidelem4x10453">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x10453">
									<item>
										<label>•</label>
										<para> 60 mg/kg every 8 hr or 90 mg/kg every 12 hr alone or in combination with ganciclovir 5 mg/kg IV every 12 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10457">
						<sec_title>CMV retinitis or disseminated disease (unlabeled) in HIV-infected patients, recurrent or relapsed CMV retinitis in HIV-infected patients</sec_title>
						<section type="none" id="sidelem4x10465">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x10465">
									<item>
										<label>•</label>
										<para> Induction with 90 mg/kg every 12 hr or 60 mg/kg IV every 8 hr × 14-21 days, depending upon the clinical response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10470">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x10478">
							<label>•</label>
							<sec_title>
								<route>HSV induction dosage equivalent to 80 mg/kg/day (40 mg/kg IV every 12 hr)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x10484">
							<label>•</label>
							<sec_title>Adult<route> IV CCr &gt;1.4 ml/min/kg</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10487">
						<sec_title>HSV induction dosage equivalent to 120 mg/kg/day (40 mg/kg IV every 8 hr)</sec_title>
						<section type="none" id="sidelem4x10495">
							<label>•</label>
							<sec_title>Adult<route> IV CCr &gt;1.4 ml/min/kg</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10498">
						<sec_title>CMV induction dosage equivalent to 180 mg/kg/day (60 mg/kg every 8 hr)</sec_title>
						<section type="none" id="sidelem4x10506">
							<label>•</label>
							<sec_title>Adult<route> IV CCr &gt;1.4 ml/min/kg</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10509">
						<sec_title>CMV induction dosage equivalent to 180 mg/kg/day (90 mg/kg IV every 12 hr)</sec_title>
						<section type="none" id="sidelem4x10517">
							<label>•</label>
							<sec_title>Adult<route> IV CCr &gt;1.4 ml/min/kg</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10520">
						<sec_title>Available forms: </sec_title>
						<para>Inj 6000 mg/250 ml, 12,000 mg/500 ml (24 mg/ml)</para>
					</section>
					<section type="none" id="sidelem4x10525">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10529">
								<item>
									<label>•</label>
									<para>Increased fluids before and during product administration to induce diuresis, minimize renal toxicity</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10535">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x10539">
									<item>
										<label>•</label>
										<para>Using infusion device at no more than 1 mg/kg/min; do not give by rapid or bolus IV; give by CVL or peripheral vein; standard 24 mg/ml sol may be used without dilution if using by CVL; dilute the 24 mg/ml sol to 12 mg/ml with D<emphasis style="inf">5</emphasis>W or NS if using peripheral vein</para>
									</item>
									<item>
										<label>•</label>
										<para>Manufacturer recommends product not be given with other medications in syringe or admixed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10553">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10556">
					<section type="none" id="sidelem4x10557">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Fever</emphasis>, dizziness, <emphasis style="italic">headache</emphasis>, <emphasis style="bold">seizures,</emphasis><emphasis style="italic">fatigue</emphasis>, neuropathy, asthenia, encephalopathy, malaise, meningitis, <emphasis style="italic">paresthesia</emphasis>, depression, <emphasis style="italic">confusion, anxiety</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10577">
						<sec_title>CV: </sec_title>
						<para>ECG abnormalities, 1st-degree AV block, nonspecific ST-T segment changes, cerebrovascular disorder, <emphasis style="bold">cardiomyopathy, cardiac arrest, atrial fibrillation, CHF, sinus tachycardia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10584">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea, vomiting, diarrhea, anorexia,</emphasis> abdominal pain, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10593">
						<sec_title>GU: </sec_title>
						<para>
							<emphasis style="bold">Acute renal failure,</emphasis> decreased CCr, increased serum creatinine, azotemia, diabetes insipidus, <emphasis style="bold">renal tubular disorders</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10602">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis style="italic">Anemia</emphasis>, <emphasis style="bold">granulocytopenia, leukopenia, thrombocytopenia, thrombosis,</emphasis> neutropenia, lymphadenopathy</para>
					</section>
					<section type="none" id="sidelem4x10612">
						<sec_title>INTEG: </sec_title>
						<para>
							<emphasis style="italic">Rash</emphasis>, sweating, pruritus, skin discoloration</para>
					</section>
					<section type="none" id="sidelem4x10619">
						<sec_title>RESP: </sec_title>
						<para>
							<emphasis style="italic">Coughing, dyspnea,</emphasis> pneumonia, <emphasis style="bold">pulmonary infiltration, pneumothorax, hemoptysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10628">
						<sec_title>SYST: </sec_title>
						<para>
							<emphasis style="italic">Hypokalemia, hypocalcemia, hypomagnesemia;</emphasis> hypophosphatemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10635">
				<sec_title>Pharmacokinetics</sec_title>
				<para>14%-17% protein bound, half-life 18-88 hr in normal renal function, 79%-92% excreted via kidneys</para>
			</section>
			<section type="interactions" id="sidelem4x10640">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> nephrotoxicity—acyclovir, cidofovir, CISplatin, gold compounds, penicillamine, tacrolimus, tenofovir, vancomycin, aminoglycosides, amphotericin B, NSAIDs, lithium, cycloSPORINE</bbw>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypocalcemia—pentamidine</para>
			</section>
			<section type="considerations" id="sidelem4x10659">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10662">
					<section type="none" id="sidelem4x10663">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Renal tubular disorders:</emphasis> I&amp;O ratio, urine pH, serum creatinine at baseline, 3×/wk during initial therapy then 2×/wk thereafter; CCr at baseline, throughout treatment; if CCr &lt;0.4 ml/min/kg, discontinue</bbw>
						</para>
						<para>
							<list id="lidelem4x10681">
								<item>
									<label>•</label>
									<para>Blood counts q2wk; watch for decreasing granulocytes, Hgb; if low, therapy may have to be discontinued and restarted after hematologic recovery; blood transfusions may be required</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10686">
								<item>
									<label>•</label>
									<para>Lesions in HSV</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10691">
								<item>
									<label>•</label>
									<para>Electrolytes and minerals (calcium, phosphate, magnesium, potassium); watch closely for tetany during 1st administration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10696">
								<item>
									<label>•</label>
									<para>GI symptoms: nausea, vomiting, diarrhea; severe symptoms may necessitate discontinuing product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10702">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias (anemia, granulocytopenia): bruising, fatigue, bleeding, poor healing</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10710">
							<label>•</label>
							<sec_title>Allergic reactions</sec_title>
							<para>
								<list id="lidelem4x10710">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reactions:</emphasis> flushing, rash, urticaria, pruritus</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10714">
							<sec_title>CMV retinitis</sec_title>
							<para>
								<list id="lidelem4x10718">
									<item>
										<label>•</label>
										<para>Culture should be performed before treatment (blood, urine, throat); a negative culture does not rule out CMV</para>
									</item>
									<item>
										<label>•</label>
										<para>Ophthalmic exam should confirm diagnosis</para>
									</item>
									<item>
										<label>•</label>
										<para>Close monitoring during therapy for tingling, numbness, paresthesias; if these occur, stop infusion, obtain lab sample for electrolytes</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10734">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10738">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in CMV retinitis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10744">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10748">
								<item>
									<label>•</label>
									<para>To call prescriber if sore throat, swollen lymph nodes, malaise, fever occur, since other infections may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To report perioral tingling, numbness in extremities, and paresthesias</para>
								</item>
								<item>
									<label>•</label>
									<para>That serious product interactions may occur if OTC products are ingested; check first with prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That product is not a cure but will control symptoms</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="54" status="active">
			<mono_name>fosinopril (Rx)</mono_name>
			<info>
				<pronunciation>(foss′in-oh-pril)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x107740">Monopril</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin-converting enzyme (ACE) inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x10784">
				<para>
					<confusion>
						<tradename id="tnidelem4x107840">Monopril</tradename>
						<drug type="generic" refid="idelem4x107840">minoxidil//Monurol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10788">
				<sec_title>Action:</sec_title>
				<para>Selectively suppresses renin-angiotensin-aldosterone system; inhibits ACE; prevents conversion of angiotensin I to angiotensin II; results in dilation of arterial, venous vessels</para>
			</section>
			<section type="uses" id="sidelem4x10793">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination with thiazide diuretics, systolic CHF</para>
				<section type="none" id="sidelem4x10798">
					<section type="none" id="sidelem4x10799">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Proteinuria in nondiabetic nephropathy</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10804">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, children, hypersensitivity to ACE inhibitors, history of ACE-inhibitor–induced angioedema</para>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x10819">
					<section type="none" id="sidelem4x10820">
						<sec_title>Precautions: </sec_title>
						<para>Geriatric patients, impaired hepatic function, hypovolemia, blood dyscrasias, CHF, COPD, asthma, angioedema, hyperkalemia, renal artery stenosis, renal disease, aortic stenosis, autoimmune disorders, collagen vascular disease, febrile illness</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10825">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10828">
					<section type="none" id="sidelem4x10829">
						<sec_title>CHF</sec_title>
						<section type="none" id="sidelem4x10837">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10837">
									<item>
										<label>•</label>
										<para> 5-10 mg/day, then up to 40 mg/day increased over several wk; use lower dose for those diuresed before fosinopril</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10841">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x10849">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10849">
									<item>
										<label>•</label>
										<para> 10 mg/day initially, then 20-40 mg/day divided bid or daily, max 80 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10853">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 10, 20, 40 mg</para>
					</section>
					<section type="none" id="sidelem4x10859">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10863">
								<item>
									<label>•</label>
									<para>May be taken without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at ≤86° F (30° C)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10874">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10877">
					<section type="none" id="sidelem4x10878">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Headache, dizziness,</emphasis> fatigue, syncope</para>
					</section>
					<section type="none" id="sidelem4x10885">
						<sec_title>CV: </sec_title>
						<para>
							<emphasis style="italic">Hypotension,</emphasis> orthostatic hypotension, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x10892">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea,</emphasis> constipation, <emphasis style="italic">vomiting,</emphasis> diarrhea, <emphasis style="bold">hepatotoxicity, cholestatic jaundice, fulminant hepatic necrosis, hepatic failure, death</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10904">
						<sec_title>GU: </sec_title>
						<para>Increased BUN, creatinine, azotemia, <emphasis style="bold">renal artery stenosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10911">
						<sec_title>HEMA: </sec_title>
						<para>Decreased Hct, Hgb; <emphasis style="bold">eosinophilia, leukopenia, neutropenia, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10918">
						<sec_title>META: </sec_title>
						<para>
							<emphasis style="italic">Hyperkalemia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x10924">
						<sec_title>RESP: </sec_title>
						<para>
							<emphasis style="italic">Cough</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x10930">
						<sec_title>SYST: </sec_title>
						<para>
							<emphasis alert="lifethreat">Anaphylaxis, angioedema</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10936">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 3 hr, serum protein binding 99%, half-life 11.5-14 hr, metabolized by liver (metabolites excreted in urine, feces)</para>
			</section>
			<section type="interactions" id="sidelem4x10941">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia risk—potassium-sparing diuretics, potassium supplements</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—diuretics, other antihypertensives, ganglionic blockers, adrenergic blockers, nitrates, acute alcohol ingestion</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—vasodilators, hydrALAZINE, prazosin, potassium-sparing diuretics, sympathomimetics, digoxin, lithium, NSAIDs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—antacids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—salicylates</para>
				<section type="none" id="sidelem4x10964">
					<section type="none" id="sidelem4x10965">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
					</section>
					<section type="none" id="sidelem4x10976">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, alk phos, glucose, bilirubin, uric acid</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine acetone</para>
						<para>
							<emphasis style="bold">Positive:</emphasis> ANA titer</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10991">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10994">
					<section type="none" id="sidelem4x10995">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11003">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x11003">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P, orthostatic hypotension, syncope</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11010">
							<label>•</label>
							<sec_title>Collagen vascular disease<route> neutrophils, decreased platelets; obtain WBC with differential baseline and monthly × 6 mo, then q2-3mo × 1 yr; if neutrophils &lt;1000/mm</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11021">
							<label>•</label>
							<sec_title>Pregnancy</sec_title>
							<para>
								<list id="lidelem4x11021">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pregnancy:</emphasis> identify pregnancy before starting therapy, pregnancy (D)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11025">
								<item>
									<label>•</label>
									<para>Renal studies: protein, BUN, creatinine; increased levels may indicate nephrotic syndrome</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11030">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic studies before therapy begins</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11035">
								<item>
									<label>•</label>
									<para>Potassium levels, although hyperkalemia rarely occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11043">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x11043">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> edema in feet, legs daily; weigh daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11050">
							<label>•</label>
							<sec_title>Allergic reactions</sec_title>
							<para>
								<list id="lidelem4x11050">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reactions:</emphasis> rash, fever, pruritus, urticaria; product should be discontinued if antihistamines fail to help</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11054">
								<item>
									<label>•</label>
									<para>Supine position for severe hypotension</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11059">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11063">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11069">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11073">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly; to take at same time of day</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use OTC products (cough, cold, allergy) unless directed by prescriber; not to use salt substitutes containing potassium without consulting prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>About the importance of complying with dosage schedule, even if feeling better</para>
								</item>
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of mouth sores, sore throat, fever, swelling of hands or feet, irregular heartbeat, chest pain, nonproductive cough</para>
								</item>
								<item>
									<label>•</label>
									<para>To report excessive perspiration, dehydration, vomiting, diarrhea; may lead to fall in B/P</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting, light-headedness during first few days of therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may cause skin rash or impaired perspiration</para>
								</item>
								<item>
									<label>•</label>
									<para>How to take B/P; normal readings for age group
<bbw>To notify prescriber if pregnancy is planned or suspected, pregnancy (D), to use contraception during treatment</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="55" status="active">
			<mono_name>fosphenytoin (Rx)</mono_name>
			<info>
				<pronunciation>(foss-fen′i-toy-in)</pronunciation>
				<class type="func"> Anticonvulsant</class>
				<class type="chem"> Hydantoin, phosphate phenytoin ester</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x11147">
				<sec_title>Action:</sec_title>
				<para>Inhibits spread of seizure activity in motor cortex by altering ion transport; increases AV conduction, prodrug of phenytoin</para>
			</section>
			<section type="uses" id="sidelem4x11152">
				<sec_title>Uses:</sec_title>
				<para>Generalized tonic-clonic seizures, status epilepticus, partial seizures</para>
			</section>
			<section type="contra" id="sidelem4x11157">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity, bradycardia, SA and AV block, Stokes-Adams syndrome</para>
				<section type="none" id="sidelem4x11162">
					<section type="none" id="sidelem4x11163">
						<sec_title>Precautions: </sec_title>
						<para>Breastfeeding, allergies, renal/hepatic disease, myocardial insufficiency, hypoalbuminemia, hypothyroidism, Asian patients positive for HLA-B 1502, abrupt discontinuation, agranulocytosis, alcoholism, carBAMazepine/barbiturate hypersensitivity, bone marrow suppression, CAD, geriatric patients, hemolytic anemia, hyponatremia, methemoglobinemia, myasthenia gravis, psychosis, suicidal ideation</para>
						<para>
							<bbw>Rapid IV infusion</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11178">
				<sec_title>Dosage and routes</sec_title>
				<para>
					<emphasis alert="lifethreat">All doses in PE (phenytoin sodium equivalent)</emphasis>
				</para>
				<section type="none" id="sidelem4x11184">
					<section type="none" id="sidelem4x11185">
						<sec_title>Status epilepticus</sec_title>
						<section type="none" id="sidelem4x11193">
							<label>•</label>
							<sec_title>Adult and adolescent<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11193">
									<item>
										<label>•</label>
										<para> 15-20 mg PE/kg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11200">
							<label>•</label>
							<sec_title>Child &lt;12 yr (unlabeled)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11200">
									<item>
										<label>•</label>
										<para> 15-20 mg PE/kg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11204">
						<sec_title>Nonemergency/maintenance dosing</sec_title>
						<section type="none" id="sidelem4x11212">
							<label>•</label>
							<sec_title>Adult and adolescent &gt;16 yr<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x11212">
									<item>
										<label>•</label>
										<para> 10-20 mg PE/kg; 4-6 mg PE/kg/day (maintenance); start maintenance 12 hr after loading dose; give in 2-3 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11216">
						<sec_title>Available forms: </sec_title>
						<para>Inj 150 mg (100 mg phenytoin equiv), 750 mg (500 mg phenytoin equiv), 50-mg/ml vials</para>
					</section>
					<section type="none" id="sidelem4x11221">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x11224">
							<sec_title>Injectable routes</sec_title>
							<para>
								<list id="lidelem4x11228">
									<item>
										<label>•</label>
										<para>Give IM/IV; the dosage, concentration, and infusion rate of fosphenytoin should always be expressed, prescribed, and dispensed in phenytoin sodium equivalents (PE); exercise extreme caution when preparing and administering fosphenytoin; the concentration and dosage should be carefully confirmed; fatal overdoses have occurred in children when the per ml concentration of the product (50 mg PE/mL) was misinterpreted as the total amount of drug in the vial</para>
									</item>
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter and discoloration before use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11239">
							<sec_title>IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x11244">
									<item>
										<label>•</label>
										<para>Before infusion, dilute in 5% dextrose or 0.9% saline solution to a concentration ranging from 1.5 to 25 mg PE/ml</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x11249">
									<item>
										<label>•</label>
										<para>Because of the risk of hypotension, do not exceed recommended infusion rates; continuous monitoring of ECG, B/P, and respiratory function is recommended, especially throughout the period where phenytoin concentrations peak (about 10-20 min after the end of the infusion)</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x11254">
									<item>
										<label>•</label>
										<para>Loading doses should always be followed by maintenance doses of oral or parenteral phenytoin or parenteral fosphenytoin</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x11262">
								<label>•</label>
								<sec_title>Adult<route> IV</route></sec_title>
								<para>
									<list id="lidelem4x11262">
										<item>
											<label>•</label>
											<para> Infuse at a max rate of 150 mg PE/min</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x11269">
								<label>•</label>
								<sec_title>Elderly or debilitated adults<route> IV</route></sec_title>
								<para>
									<list id="lidelem4x11269">
										<item>
											<label>•</label>
											<para> Infuse at a max 3 mg PE/kg/min or 150 mg PE/min, whichever is less</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x11276">
								<label>•</label>
								<sec_title>Child<route> IV</route></sec_title>
								<para>
									<list id="lidelem4x11276">
										<item>
											<label>•</label>
											<para> Infuse at a rate of 0.5-3 mg PE/kg/min or max 150 mg PE/min, whichever is less</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x11283">
								<label>•</label>
								<sec_title>Infant/neonate<route> IV</route></sec_title>
								<para>
									<list id="lidelem4x11283">
										<item>
											<label>•</label>
											<para> Infuse at a rate max 0.5-3 mg PE/kg/min</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Aminocaproic acid, amphotericin B lipid complex, amphotericin B liposome, anidulafungin, atenolol, bivalirudin, bleomycin, CARBOplatin, CISplatin, cyclophosphamide, cytarabine, DACTINomycin, DAPTOmycin, dexmedetomidine, diltiazem, DOCEtaxel, doxacurium, eptifibatide, ertapenem, etoposide, fludarabine, fluorouracil, gatifloxacin, gemcitabine, gemtuzumab, granisetron, ifosfamide, levofloxacin, linezolid, LORazepam, mechlorethamine, meperidine, methotrexate, metroNIDAZOLE, nesiritide, octreotide, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pantoprazole, PEMEtrexed, PHENobarbital, piperacillin-tazobactam, rocuronium, sodium acetate, tacrolimus, teniposide, thiotepa, tigecycline, tirofiban, vinCRIStine, vinorelbine, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11292">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11295">
					<section type="none" id="sidelem4x11296">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Drowsiness,</emphasis> dizziness, insomnia, paresthesias, depression, <emphasis style="bold">suicidal tendencies,</emphasis> aggression, headache, confusion, paresthesia, emotional liability, syncope, cerebral edema</para>
					</section>
					<section type="none" id="sidelem4x11306">
						<sec_title>CV: </sec_title>
						<para>Hypo/hypertension, <emphasis style="bold">CHF, shock, dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11313">
						<sec_title>EENT: </sec_title>
						<para>Nystagmus, diplopia, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x11318">
						<sec_title>GI: </sec_title>
						<para>Nausea, vomiting, diarrhea, constipation, anorexia, weight loss, hepatitis, jaundice, gingival hyperplasia</para>
					</section>
					<section type="none" id="sidelem4x11323">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Agranulocytosis, leukopenia, aplastic anemia, thrombocytopenia, megaloblastic anemia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x11329">
						<sec_title>INTEG: </sec_title>
						<para>Rash, lupus erythematosus, <emphasis style="bold">Stevens-Johnson syndrome,</emphasis> hirsutism, hypersensitivity, pruritus</para>
					</section>
					<section type="none" id="sidelem4x11337">
						<sec_title>RESP: </sec_title>
						<para>
							<emphasis alert="lifethreat">Bronchospasm, cough</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x11343">
						<sec_title>SYST: </sec_title>
						<para>Hyperglycemia, hypokalemia, SJS/TEN Asian patients positive for HLA-B 1502; <emphasis style="bold">drug reaction with eosinophilia and systemic symptoms (DRESS), purple glove syndrome, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11350">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted by kidneys, protein binding 95%-99%, rapidly converted to phenytoin</para>
			</section>
			<section type="interactions" id="sidelem4x11355">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> fosphenytoin level—cimetidine, amiodarone, chloramphenicol, estrogens, H<emphasis style="inf">2</emphasis> antagonists, phenothiazines, salicylates, sulfonamides, tricyclics, CYP1A2 inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> fosphenytoin effects—alcohol (chronic use), antihistamines, antacids, traMADol, antineoplastics, rifampin, folic acid, carBAMazepine, theophylline, CYP1A2 inducers</para>
				<para>
					<emphasis alert="lifethreat">Decrease: virologic response, resistance—delavirdine, do not use concurrently</emphasis>
				</para>
				<section type="none" id="sidelem4x11372">
					<section type="none" id="sidelem4x11373">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> anticonvulsant effect—ginkgo</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> anticonvulsant effect—ginseng, valerian</para>
					</section>
					<section type="none" id="sidelem4x11384">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> glucose, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> dexamethasone, metyrapone test serum, PBI, urinary steroids, potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11395">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11398">
					<section type="none" id="sidelem4x11399">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x11404">
								<item>
									<label>•</label>
									<para>Drug level: target level 10-20 mcg/ml, toxic level 30-50 mcg/ml, wait &gt;2 hr after dose before testing, 4 hr after IM dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11409">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, platelets q2wk until stabilized, then monthly × 12 mo, then q3mo; serum calcium, albumin, phosphorus, potassium</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11415">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: mood, sensorium, affect, memory (long, short), suicidal thoughts/behaviors</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11423">
							<label>•</label>
							<sec_title>Serious skin reactions<route> usually occurring within 28 days of treatment; if a rash develops, patient should be evaluated for DRESS</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11429">
							<label>•</label>
							<sec_title>
								<route>Seizure activity including type, location, duration, character; provide seizure precaution</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x11432">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, BUN, urine creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11437">
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST, bilirubin, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11442">
								<item>
									<label>•</label>
									<para>Allergic reaction: red, raised rash; product should be discontinued</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11451">
							<label>•</label>
							<sec_title>Toxicity/bone marrow depression<route> nausea, vomiting, ataxia, diplopia, cardiovascular collapse, slurred speech, confusion</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x11454">
								<item>
									<label>•</label>
									<para>Respiratory depression: rate, depth, character of respirations</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11460">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias: fever, sore throat, bruising, rash, jaundice</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11465">
								<item>
									<label>•</label>
									<para>Continuous monitoring of ECG, B/P, respiratory function</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11473">
							<label>•</label>
							<sec_title>
								<route>Rash; discontinue as soon as rash develops, serious adverse reactions such as Stevens-Johnson syndrome can occur</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11476">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11480">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in severity of seizures</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11486">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11491">
								<item>
									<label>•</label>
									<para>About the reason for, expected outcomes of treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11496">
								<item>
									<label>•</label>
									<para>Not to use machinery or engage in hazardous activity, since drowsiness, dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11501">
								<item>
									<label>•</label>
									<para>To carry emergency ID denoting product use, name of prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11509">
							<label>•</label>
							<sec_title>
								<route>depression, suicidal thought</route>
							</sec_title>
							<para>
								<list id="lidelem4x11509">
									<item>
										<label>•</label>
										<para>To notify prescriber of rash, bleeding, bruising, slurred speech, jaundice of skin or eyes, joint pain, nausea, vomiting, severe headaches, </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11513">
								<item>
									<label>•</label>
									<para>To keep all medical appointments, including those for lab work, physical assessment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11518">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned, suspected</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11523">
								<item>
									<label>•</label>
									<para>To use contraception while using this product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="56" status="active">
			<mono_name>frovatriptan (Rx)</mono_name>
			<info>
				<pronunciation>(froh-vah-trip′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x115330">Frova</tradename>
				</tradenames>
				<class type="func"> Antimigraine agent</class>
				<class type="chem"> 5-HT-Receptor agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x11546">
				<sec_title>Action:</sec_title>
				<para>Binds selectively to the vascular 5-HT<emphasis style="inf">1B</emphasis>, 5-HT<emphasis style="inf">1D</emphasis> receptor subtypes; exerts antimigraine effect; binds to benzodiazepine receptor sites, causes vasoconstriction in cranium</para>
			</section>
			<section type="uses" id="sidelem4x11558">
				<sec_title>Uses:</sec_title>
				<para>Acute treatment of migraine with/without aura</para>
			</section>
			<section type="contra" id="sidelem4x11563">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, angina pectoris, history of MI, documented silent ischemia, Prinzmetal’s angina, ischemic heart disease; concurrent ergotamine-containing preparations; uncontrolled hypertension; basilar or hemiplegic migraine; ischemic bowel disease; peripheral vascular disease, severe hepatic disease, prophylactic migraine treatment</para>
				<section type="none" id="sidelem4x11568">
					<section type="none" id="sidelem4x11569">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, postmenopausal women, men &gt;40 yr, risk factors for CAD, hypercholesterolemia, obesity, diabetes, impaired hepatic function, seizure disorder</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11574">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11582">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x11582">
							<item>
								<label>•</label>
								<para> 2.5 mg; a 2nd dose may be taken after ≥2 hr; max 3 tabs (7.5 mg/day)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11586">
					<section type="none" id="sidelem4x11587">
						<sec_title>Available form: </sec_title>
						<para>Tabs 2.5 mg</para>
					</section>
					<section type="none" id="sidelem4x11592">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11596">
								<item>
									<label>•</label>
									<para>Swallow tabs whole; do not break, crush, or chew</para>
								</item>
								<item>
									<label>•</label>
									<para>With fluids</para>
								</item>
								<item>
									<label>•</label>
									<para>2 days/wk or less; rebound headache may occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11612">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11615">
					<section type="none" id="sidelem4x11616">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Hot/cold sensation</emphasis>, paresthesia, <emphasis style="italic">dizziness,</emphasis> headache, fatigue, insomnia, anxiety, somnolence, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11628">
						<sec_title>CV: </sec_title>
						<para>
							<emphasis style="italic">Flushing</emphasis>, chest pain, palpitation</para>
					</section>
					<section type="none" id="sidelem4x11635">
						<sec_title>GI: </sec_title>
						<para>Dry mouth, dyspepsia, abdominal pain, diarrhea, vomiting, nausea</para>
					</section>
					<section type="none" id="sidelem4x11640">
						<sec_title>MS: </sec_title>
						<para>Skeletal pain</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11645">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset of pain relief 2-3 hr, terminal half-life 25-29 hr, protein binding 15%, metabolized liver by CYP1A2</para>
			</section>
			<section type="interactions" id="sidelem4x11650">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> frovatriptan levels—CYP1A2 inhibitors (cimetidine, ciprofloxacin, erythromycin), estrogen, propranolol, oral contraceptives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—SSRIs, other serotonin agonists (dextromethorphan, MAOIs, antidepressants)</para>
			</section>
			<section type="considerations" id="sidelem4x11661">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11664">
					<section type="none" id="sidelem4x11665">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11673">
							<label>•</label>
							<sec_title>Migraine symptoms</sec_title>
							<para>
								<list id="lidelem4x11673">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Migraine symptoms:</emphasis> aura, unable to view light; ingestion of tyramine-containing foods (pickled products, beer, wine, aged cheese), food additives, preservatives, colorings, artificial sweeteners, chocolate, caffeine, which may precipitate these types of headaches</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11677">
								<item>
									<label>•</label>
									<para>B/P; signs, symptoms of coronary vasospasms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11682">
								<item>
									<label>•</label>
									<para>For stress level, activity, recreation, coping mechanisms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11687">
								<item>
									<label>•</label>
									<para>Quiet, calm environment with decreased stimulation from noise, bright light, excessive talking</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11692">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11696">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in frequency, severity of migraine</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11702">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11706">
								<item>
									<label>•</label>
									<para>To report any side effects to prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To use contraception while taking product; to inform prescriber if pregnant or planning to become pregnant</para>
								</item>
								<item>
									<label>•</label>
									<para>To consult prescriber if breastfeeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="57" status="active" ha="yes">
			<mono_name> fulvestrant (Rx)</mono_name>
			<info>
				<pronunciation>(full-vess′trant)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x117290">Faslodex</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> Estrogen-receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x11739">
				<sec_title>Action:</sec_title>
				<para>Inhibits cell division by competitive binding to cytoplasmic estrogen receptors, downregulates estrogen receptors</para>
			</section>
			<section type="uses" id="sidelem4x11744">
				<sec_title>Uses:</sec_title>
				<para>Advanced breast carcinoma in estrogen-receptor–positive patients (usually postmenopausal)</para>
				<section type="none" id="sidelem4x11749">
					<section type="none" id="sidelem4x11750">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Loading dose for metastatic breast cancer</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11756">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, children, hypersensitivity</para>
				<section type="none" id="sidelem4x11761">
					<section type="none" id="sidelem4x11762">
						<sec_title>Precautions: </sec_title>
						<para>Hepatic disease, jaundice, thrombocytopenia, biliary tract disease, coagulopathy</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11767">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11775">
					<label>•</label>
					<sec_title>Adult<route> IM</route></sec_title>
					<para>
						<list id="lidelem4x11775">
							<item>
								<label>•</label>
								<para> 500 mg as 2-, 5-ml injections on days 1, 15, 29 and monthly thereafter</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11779">
					<section type="none" id="sidelem4x11780">
						<sec_title>Available forms: </sec_title>
						<para>Inj 50 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x11785">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x11788">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x11792">
									<item>
										<label>•</label>
										<para>IM 5 ml give one inj in each buttock slowly, over 1-2 min</para>
									</item>
									<item>
										<label>•</label>
										<para>Antiemetic 30-60 min before product to prevent vomiting prn</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in refrigerator; protect from light</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11808">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11811">
					<section type="none" id="sidelem4x11812">
						<sec_title>CNS: </sec_title>
						<para>
							<emphasis style="italic">Headache,</emphasis> depression, dizziness, insomnia, paresthesia, anxiety</para>
					</section>
					<section type="none" id="sidelem4x11819">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea, vomiting,</emphasis> anorexia, constipation, diarrhea, abdominal pain, <emphasis style="bold">hepatitis, hepatic failure, hyperbilirubinemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11828">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Anemia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x11834">
						<sec_title>INTEG: </sec_title>
						<para>
							<emphasis style="italic">Rash,</emphasis> sweating, <emphasis style="italic">hot flashes,</emphasis> inj-site pain</para>
					</section>
					<section type="none" id="sidelem4x11844">
						<sec_title>MS: </sec_title>
						<para>Bone pain, arthritis, back pain</para>
					</section>
					<section type="none" id="sidelem4x11849">
						<sec_title>RESP: </sec_title>
						<para>Pharyngitis, dyspnea, cough</para>
					</section>
					<section type="none" id="sidelem4x11854">
						<sec_title>SYST: </sec_title>
						<para>
							<emphasis alert="lifethreat">Angioedema</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11860">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 40 days, metabolized by CYP3A4, excretion in feces 90%</para>
			</section>
			<section type="interactions" id="sidelem4x11865">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> Bleeding—anticoagulants, do not use concurrently</para>
				<section type="none" id="sidelem4x11872">
					<section type="none" id="sidelem4x11873">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11880">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11883">
					<section type="none" id="sidelem4x11884">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x11888">
								<item>
									<label>•</label>
									<para>For anticoagulant use</para>
								</item>
								<item>
									<label>•</label>
									<para>For side effects; report to prescriber</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11899">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11903">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11909">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11914">
								<item>
									<label>•</label>
									<para>To report any complaints, side effects to prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11919">
								<item>
									<label>•</label>
									<para>To report vaginal bleeding immediately</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11924">
								<item>
									<label>•</label>
									<para>That tumor flare (increase in size of tumor, increased bone pain) may occur, will subside rapidly; that analgesics may be taken for pain</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11932">
							<label>•</label>
							<sec_title>
								<route>That premenopausal women must use mechanical birth control because ovulation may be induced; not to breastfeed</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x11938">
							<label>•</label>
							<sec_title>
								<route>To use contraception to prevent pregnancy; pregnancy category (D)</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="58" status="active">
			<mono_name>furosemide (Rx)</mono_name>
			<info>
				<pronunciation>(fur-oh′se-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x119460">Lasix</tradename>
				</tradenames>
				<class type="func"> Loop diuretic</class>
				<class type="chem"> Sulfonamide derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x11956">
				<para>
					<confusion>
						<tradename id="tnidelem4x119560">furosemide</tradename>
						<drug type="generic" refid="idelem4x119560">torsemide</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x11963">
				<sec_title>Action:</sec_title>
				<para>Inhibits reabsorption of sodium and chloride at proximal and distal tubule and in the loop of Henle</para>
			</section>
			<section type="uses" id="sidelem4x11968">
				<sec_title>Uses:</sec_title>
				<para>Pulmonary edema; edema with CHF, hepatic disease, nephrotic syndrome, ascites, hypertension</para>
				<section type="none" id="sidelem4x11973">
					<section type="none" id="sidelem4x11974">
						<sec_title>Unlabeled uses: </sec_title>
						<para>Hypercalcemia with malignancy, hypertensive emergency/urgency, pulmonary edema or prevention of hemodynamic effects associated with blood product transfusion, ascites</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11979">
				<sec_title>Contraindications:</sec_title>
				<para>Anuria</para>
				<section type="none" id="sidelem4x11984">
					<section type="none" id="sidelem4x11985">
						<sec_title>Precautions: </sec_title>
						<para>Pregnancy (<preg cat="C">C</preg>), breastfeeding, diabetes mellitus, dehydration, severe renal disease, cirrhosis, ascites, hypersensitivity to sulfonamides/thiazides, infants, hypovolemia, electrolyte depletion, hypersensitivity</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11990">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11993">
					<section type="none" id="sidelem4x11994">
						<sec_title>Edema</sec_title>
						<section type="none" id="sidelem4x12002">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12002">
									<item>
										<label>•</label>
										<para> 20-80 mg/day in <emphasis style="smallcaps">am</emphasis>; may give another dose after 6 hr up to 600 mg/day;  20-40 mg; increase by 20 mg q2hr until desired response</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12015">
							<label>•</label>
							<sec_title>Child<route> PO/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x12015">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg; may increase by 1-2 mg/kg q6-8hr up to 6 mg/kg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12019">
						<sec_title>Antihypercalcemia</sec_title>
						<section type="none" id="sidelem4x12027">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x12027">
									<item>
										<label>•</label>
										<para> 80-100 mg q1-4hr or  120 mg/day or divided bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12037">
							<label>•</label>
							<sec_title>Child<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x12037">
									<item>
										<label>•</label>
										<para> 25-50 mg, repeat q4hr if needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12041">
						<sec_title>Acute/chronic renal failure</sec_title>
						<section type="none" id="sidelem4x12049">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12049">
									<item>
										<label>•</label>
										<para> 80 mg/day, increase by 80-120 mg/day to desired response;  100-200 mg, max 600-800 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12056">
						<sec_title>Hypertensive emergency/urgency (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12064">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12064">
									<item>
										<label>•</label>
										<para> 40-80 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12068">
						<sec_title>Pulmonary edema/prevention of adverse hemodynamic effects associated with blood product transfusion (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12076">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12076">
									<item>
										<label>•</label>
										<para> 40 mg injected slowly, then 80 mg injected slowly after 2 hr if needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12083">
							<label>•</label>
							<sec_title>Child<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x12083">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg q6-12hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12090">
							<label>•</label>
							<sec_title>Premature neonate &gt;32 wk postconceptional age<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x12090">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg q12-24hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12097">
							<label>•</label>
							<sec_title>Premature neonate ≤32 wk postconceptional age<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x12097">
									<item>
										<label>•</label>
										<para> max 1 mg/kg, give no more frequently than q24hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12101">
						<sec_title>Available forms: </sec_title>
						<para>Tabs 20, 40, 80 mg; oral sol 8 mg/ml, 10 mg/ml; inj 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x12106">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12110">
								<item>
									<label>•</label>
									<para>In <emphasis style="smallcaps">am</emphasis> to avoid interference with sleep if using product as diuretic</para>
								</item>
								<item>
									<label>•</label>
									<para>Potassium replacement if potassium &lt;3 mg/dl</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12124">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x12128">
									<item>
										<label>•</label>
										<para>PO with food if nausea occurs; absorption may be decreased slightly; tabs may be crushed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12134">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x12138">
									<item>
										<label>•</label>
										<para>Undiluted; may be given through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock; give ≤20 mg/min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12147">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x12151">
									<item>
										<label>•</label>
										<para>May be added to NS or D<emphasis style="inf">5</emphasis>W; if large doses required and given as IV infusion, max 4 mg/min; use infusion pump</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, alprostadil, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B cholesteryl/lipid complex/liposome, anidulafungin, argatroban, ascorbic acid, atenolol, atropine, azaTHIOprine, aztreonam, bivalirudin, bleomycin, bumetanide, calcium chloride/gluconate, CARBOplatin, cefamandole, ceFAZolin, cefepime, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, ceftobiprole, cefTRIAXone, cefuroxime, chloramphenicol, CISplatin, cladribine, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, DOCEtaxel, doripenem, doxacurium, DOXOrubicin liposome, enalaprilat, ePHEDrine, EPINEPHrine, etoposide, fentaNYL, fludarabine, fluorouracil, folic acid, foscarnet, gallium nitrate, ganciclovir, granisetron, heparin, hydrocortisone, HYDROmorphone, ifosfamide, imipenem-cilastatin, indomethacin, insulin (regular), isosorbide, kanamycin, leucovorin, lidocaine, linezolid, LORazepam, LR, mannitol, mechlorethamine, melphalan, meropenem, methicillin, methotrexate, methylPREDNISolone, metoprolol, metroNIDAZOLE, mezlocillin, micafungin, miconazole, mitoMYcin, moxalactam, multiple vitamin injection, nafcillin, naloxone, nitroprusside, octreotide, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pantoprazole, PEMEtrexed, penicillin G, PENTobarbital, PHENobarbital, phytonadione, piperacillin, piperacillin-tazobactam, potassium chloride, procainamide, propofol, propranolol, ranitidine, remifentanil, Ringer’s, ritodrine, sargramostim, sodium acetate/bicarbonate, succinylcholine, SUFentanil, temocillin, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA, tobramycin, urokinase, vit B/C, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12166">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12169">
					<section type="none" id="sidelem4x12170">
						<sec_title>CNS: </sec_title>
						<para>Headache, fatigue, weakness, vertigo, paresthesias</para>
					</section>
					<section type="none" id="sidelem4x12175">
						<sec_title>CV: </sec_title>
						<para>Orthostatic hypotension, chest pain, ECG changes, <emphasis style="bold">circulatory collapse</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12182">
						<sec_title>EENT: </sec_title>
						<para>Loss of hearing, ear pain, tinnitus, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x12187">
						<sec_title>ELECT: </sec_title>
						<para>
							<emphasis style="italic">Hypokalemia, hypochloremic alkalosis, hypomagnesemia, hyperuricemia, hypocalcemia, hyponatremia,</emphasis> metabolic alkalosis</para>
					</section>
					<section type="none" id="sidelem4x12194">
						<sec_title>ENDO: </sec_title>
						<para>
							<emphasis style="italic">Hyperglycemia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x12200">
						<sec_title>GI: </sec_title>
						<para>
							<emphasis style="italic">Nausea,</emphasis> diarrhea, dry mouth, vomiting, anorexia, cramps, oral, gastric irritations, pancreatitis</para>
					</section>
					<section type="none" id="sidelem4x12207">
						<sec_title>GU: </sec_title>
						<para>
							<emphasis style="italic">Polyuria,</emphasis>
							<emphasis style="bold">renal failure,</emphasis> glycosuria, bladder spasms</para>
					</section>
					<section type="none" id="sidelem4x12216">
						<sec_title>HEMA: </sec_title>
						<para>
							<emphasis alert="lifethreat">Thrombocytopenia, agranulocytosis, leukopenia, neutropenia, anemia</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x12222">
						<sec_title>INTEG: </sec_title>
						<para>
							<emphasis style="italic">Rash, pruritus,</emphasis> purpura, <emphasis style="bold">Stevens-Johnson syndrome,</emphasis> sweating, photosensitivity, urticaria</para>
					</section>
					<section type="none" id="sidelem4x12232">
						<sec_title>MS: </sec_title>
						<para>Cramps, stiffness</para>
					</section>
					<section type="none" id="sidelem4x12237">
						<sec_title>SYST: </sec_title>
						<para>
							<emphasis alert="lifethreat">Toxic epidermal necrolysis</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12243">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x12246">
					<section type="none" id="sidelem4x12247">
						<sec_title>PO: </sec_title>
						<para>Onset 1 hr, peak 1-2 hr, duration 6-8 hr, absorbed 70%</para>
					</section>
					<section type="none" id="sidelem4x12252">
						<sec_title>IV: </sec_title>
						<para>Onset 5 min; peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; duration 2 hr (metabolized by the liver 30%); excreted in urine, some as unchanged product, and feces; crosses placenta; excreted in breast milk; half-life <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x12269">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—lithium, nondepolarizing skeletal muscle relaxants, digoxin, salicylates, aminoglycosides, cisplatin</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotensive action of antihypertensives, nitrates</para>
				<para>
					<emphasis alert="lifethreat">Increase: ototoxicity—aminoglycosides, CISplatin, vancomycin</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of anticoagulants, salicylates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> furosemide effect—probenecid</para>
				<section type="none" id="sidelem4x12290">
					<section type="none" id="sidelem4x12291">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Interference:</emphasis> GTT</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> LDL</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12302">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12305">
					<section type="none" id="sidelem4x12306">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x12314">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x12314">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> weight, I&amp;O daily to determine fluid loss; effect of product may be decreased if used daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12322">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x12322">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P lying, standing; postural hypotension may occur</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12326">
								<item>
									<label>•</label>
									<para>Metabolic alkalosis: drowsiness, restlessness</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12334">
							<label>•</label>
							<sec_title>Hypokalemia</sec_title>
							<para>
								<list id="lidelem4x12334">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypokalemia:</emphasis> postural hypotension, malaise, fatigue, tachycardia, leg cramps, weakness</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12338">
								<item>
									<label>•</label>
									<para>Rashes, temperature elevation daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12343">
								<item>
									<label>•</label>
									<para>Confusion, especially in geriatric patients; take safety precautions if needed</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12351">
							<label>•</label>
							<sec_title>
								<route>Hearing,</route>
							</sec_title>
							<para>
								<list id="lidelem4x12351">
									<item>
										<label>•</label>
										<para> including tinnitus and hearing loss, when giving high doses for extended periods or rapid infusion</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12355">
								<item>
									<label>•</label>
									<para>Rate, depth, rhythm of respiration, effect of exertion, lung sounds</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12360">
								<item>
									<label>•</label>
									<para>Electrolytes (potassium, sodium, chloride); include BUN, blood glucose, CBC, serum creatinine, blood pH, ABGs, uric acid</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12365">
								<item>
									<label>•</label>
									<para>Glucose in urine if patient diabetic</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12370">
								<item>
									<label>•</label>
									<para>Allergies to sulfonamides, thiazides</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12375">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12379">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in edema of feet, legs, sacral area (CHF); increase urine output, decreased B/P; decreased calcium levels (hypercalcemia)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12385">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12389">
								<item>
									<label>•</label>
									<para>To discuss the need for a high-potassium diet or potassium replacement with prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To rise slowly from lying or sitting position because orthostatic hypotension may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To recognize adverse reactions that may occur: muscle cramps, weakness, nausea, dizziness</para>
								</item>
								<item>
									<label>•</label>
									<para>About the entire treatment regimen, including exercise, diet, stress relief for hypertension</para>
								</item>
								<item>
									<label>•</label>
									<para>To take with food or milk for GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>To use sunscreen or protective clothing to prevent photosensitivity</para>
								</item>
								<item>
									<label>•</label>
									<para>To take early in the day to prevent sleeplessness</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications unless directed by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>